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ABBREVIATIONS
ANS 1-anilinonaphtalene-8-sulfonic acid
AOFA anthroyloxy-labeled fatty acid
2-AP 2-(9-anthroyloxy)palmitic acid
12-AS 12-anthroyloxy stearate
BSA bovine serum albumin
cDNA complementary deoxyribonucleic acid
CRABP cellular retinoic acid-binding protein
CRBP cellular retinol-binding protein
[D]
50
concentration of denaturant giving 50% unfolding
DAUDA (11-((5-dimethylaminonaphtalene-1-sulfonyl)amino)undecanoic
acid
DHA docosahexaenoic acid
DMEM Dulbecco’s modified Eagles medium
ELISA enzyme-linked immunosorbent assay
FA fatty acid(s)
FAAR fatty acid-activated receptor
FABP fatty acid-binding protein
FABP
PM
plasma membrane-associated  FABP
FAT fatty acid translocase
FATP fatty acid-transport protein
FRAP fluorescence recovery after photobleaching
I-LBP ileal lipid-binding protein
IPTG isopropyl β-D-thiogalactopyranoside
Kd dissociation constant
kDa kilodalton(s)
MDCK Madin Darby canine kidney
MDGI mammary-derived growth inhibitor
NBD-stearate 12-N-methyl-(7-nitrobenzo-2-oxa-1,3-diazol)aminostearate
NIDDM non-insulin-dependent diabetes mellitus
NMR nuclear magnetic resonance
PAGE polyacrylamide gel electrophoresis
PBS phosphate-buffered saline
PPAR peroxisome proliferator-activated receptor
SDS sodium dodecyl sulphate
TG triacylglycerols
TLC                         thin layer chromatography
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INTRODUCTION
1.1. Significance of lipid-binding proteins
The uptake and biosynthesis of both water-soluble and insoluble metabolites is essential
for every living cell. The solubility and the translocation of hydrophobic ligands is facilitated in
intra- and extracellular fluids by lipid-binding proteins. Many proteins are capable of associating
with lipids. Lipid-binding molecules belong to several unrelated families of proteins which are
being increasingly characterized and defined. Examples of these include integral and peripheral
membrane proteins, the apolipoproteins of the serum, albumin (Spector, 1986), acyl-CoA-binding
protein (Knudsen, 1990; Gossett et al., 1996), glycolipid-binding proteins, fatty acid-binding
proteins (FABPs), phospholipid-binding proteins (Wirtz, 1997), retinoid-binding proteins (Noy,
2000), lipocalins (Flower, 1996), and membrane-associated proteins that translocate lipids
intracellularly (Abumrad et al., 1999).
The structure of three families of proteins which bind fatty acids (FA) has been described
(Spector, 1986; Veerkamp et al., 1991; Flower, 1996). Many of the proteins of these families bind
FA as their main ligand, but also other proteins with quite different structures have affinity for FA
(e.g. fetuin, adipose differentiation related protein, heat-shock protein, caveolin 1, plasma
membrane FABP, fatty acid translocase (FAT), fatty acid transport protein (FATP), glutathione S-
transferase, sterol-carrier protein-2) (Veerkamp et al., 1991; Veerkamp and Maatman, 1995;
Abumrad et al., 1999). Together with lipocalins and avidins, the FABPs form part of the superfamily
of the calycins with a β-barrel structure (Flower, 1996).
The family of FABPs is the main subject of this introduction. For almost three decades the
presence of cytoplasmic proteins that associate noncovalently with hydrophobic ligands such
as FA or retinoids has been appreciated (Ockner et al., 1972). Although molecular cloning and
structural studies have increased our knowledge of the evolutionary and cellular diversity of
FABPs, the evidence of their physiological role has been equivocal for many years. Only recently,
studies on knockout mice provided direct proof of the importance of FABPs in the uptake and
transport of long-chain FA and their interaction with other transport systems and enzymes.
Numerous reviews on structural and functional aspects of the FABP family have appeared
over the last 10-15 years (overviewed in Stewart, 2000). We will focus mainly on recent data
on the structure of FABPs, their role in FA uptake and transport and their involvement in the
modulation of several cellular processes including signal transduction, gene expression, growth
and differentiation.
1.2. Family of FABPs
The family of FABPs involves on structural basis also the retinoid-binding proteins (Noy, 2000).
These comprise 3 types of cellular retinol-binding protein (CRBP) and 2 types of cellular retinoic
acid-binding protein (CRABP) which will not be discussed here. The intracellular or cytoplasmic
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FABPs form a group of at least nine distinct protein types. They are 14-15 kDa proteins of 126-134
amino acids, and are named after the first tissue of isolation or identification (Table 1). Some
tissues contain more types, either in different cell types (brain, kidney, stomach) or in the same
cell type (enterocyte). Heart (H-)FABP is the most widely distributed FABP. It is found in heart,
skeletal and smooth muscle, mammary epithelial cells, aorta, distal tubules of the kidney, lung,
brain, placenta and ovary.
The indication of an FABP type in a tissue does not mean its presence in all cell types of that tissue; the
FABP type may be limited to specific cells or may be present at certain developmental stages.
The members of the FABP family show an amino acid sequence similarity of 22-73 % (Fig. 1),
but their three-dimensional structures remain highly conserved (see paragraph 1.4). On basis
of amino acid sequence the family can be divided in three groups: one group containing H-
FABP, brain (B-)FABP, myelin (M-)FABP, adipocyte (A-)FABP and epidermal (E-)FABP, a group
containing ileal lipid-binding protein (I-LBP or IL-FABP) and liver (L-)FABP, and intestinal (I-)FABP. I-
LBP and L-FABP have a four residue gap in the C-terminal part that is conserved in the other
FABP types. This feature is probably related to their different binding characteristics. L-FABP and
I-LBP bind more bulky, hydrophobic ligands as lysophospholipids, prostaglandins, bile acids,
eicosanoids and some drugs (Veerkamp et al., 1993; Maatman et al., 1994; Thumser et al.,
1996). Unlike L-FABP which can bind two FA simultaneously, I-LBP has no affinity for FA
(Zimmerman et al., 2001). I-FABP differs from both groups of FABP types in the conformation of
its bound ligand (bent instead of U-shaped) (Banaszak et al., 1994; Thompson et al., 1997).
Chapter 1
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Figure 1.
Aligment of amino acid sequences of the members of the FABP family.
All sequences are for human proteins. Positions of well-conserved amino acids (identical residues present
in at least 5 molecules) are in bold.
The latest FABP members identified are B-FABP and E-FABP. The human B-FABP cDNA se-
quence shows 67% homology with H-FABP, whereas E-FABP is 48% homologous with H-FABP.
B-FABP is exclusively expressed in the central nervous system where its main function is possibly
the binding and transport of polyunsaturated fatty acids, like docosahexaenoic acid (DHA).
These FA are essential during the early postnatal development when cellular differentiation,
active synaptogenesis and photoreceptor membrane biogenesis take place (Neuringer et al.,
1988; Green et al., 1999; Veerkamp and Zimmerman, 2001). B-FABP is mainly expressed in the
radial glia and its expression appeared to be strictly correlated with the differentiation and
migration of neurons from these cells (Feng et al., 1994). E-FABP, also known as psoriasis-
associated (PA-)FABP (Madsen et al., 1992), keratinocyte FABP (Krieg et al., 1993) or DA11 (De
Léon et al., 1996) was first recognized as a psoriasis-associated FABP, one of the gene products
highly upregulated in expression in human psoriatic skin. Later the same protein was identified
in many other normal tissues such as adipocytes, tongue epithelia, lens, retina, testis, lung and
mammary gland (Wen et al., 1995; Jaworski and Wistow, 1996; Masouyé et al., 1997). The
presence of one or more disulfide bridges is a unique feature of E-FABP that may be physiologically
relevant (Hohoff et al., 1999; Odani et al., 2000). Structural features of FABPs will be further
discussed in paragraph 1.4.
Phylogenetic analyses have shed light on the molecular relationships between the members
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of the FABP family and their evolution (reviewed in Santomé et al., 1998). FABPs from the same
mammalian tissue of different species show greater amino acid similarity and identity than
observed between FABPs isolated from different tissues from the same species (Veerkamp et
al., 1993, 1995; Börchers and Spener, 1994). Molecular information supports the hypothesis that
FABPs have developed distinct binding sites in order to perform specific functions within the
different tissues they are expressed in.
Analysis of the evolutionary relationship of 51 FABP molecules of various species agrees
with the hypothesis that gene duplication leading to mammalian liver and heart FABPs occurred
before the vertebrate-invertebrate differentiation (Schleicher et al., 1995). The presence of an
FABP in an invertebrate tissue, the flight muscle of the desert locust Schistocerca gregaria was
shown for the first time in 1990 (Haunerland and Chisholm) and, like that of Locusta migratoria
(Maatman et al., 1994), it showed similarity with mammalian H-FABP (Haunerland, 1994). Later,
FABPs were also detected in Schistosoma mansoni (Moser et al., 1991), Fasciola hepatica
(Rodriguez-Pérez et al., 1992), Manduca sexta (Smith et al., 1992), Schistosoma japonicum (Becker
et al., 1994) and Ascaris suum (Mei et al., 1997). All invertebrate FABP types resemble H-FABP,
except FABP from Manduca sexta, which resembles L-FABP (Smith et al., 1992). Primitive fish
(shark, lamprey) express H-FABP in their livers (Medzihradszky et al., 1992; Baba et al. 1999a),
whereas some bony fish can produce L-FABP and H-FABP in the liver (Schleicher et al., 1995).
The transition from H-FABP, to H-FABP plus L-FABP, to L-FABP moving from lower pisciformes, to
teleosts, to higher vertebrates suggests the divergence of liver function in lower vertebrates and
is consistent with the cartilaginous/bony fish boundary and the finding of a mammalian type L-
FABP in the liver of an amphibian (Rana catesbeiana) (Baba et al., 1999b).
For a long time, the L-FABP type had been reported only for mammals but in 1994, the
sequence of a basic (pI 9.0) FABP from chicken (Gallus domesticus) liver was reported (Ceciliani
et al., 1994). This protein was called liver basic (Lb-)FABP and showed the highest amino acid
identity with rat and pig ileal FABPs (42 and 43%, respectively), and with rat L-FABP (39%) while
mammalian L-FABPs have 79-90% identity with one another. Later, this non-mammalian FABP
was found in the livers of several species, namely catfish (Rhamdia sapo) (Di Pietro et al., 1996,
1997), toad (Bufo arenarum) (Schleicher and Santomé, 1996), iguana (Anolis pulchellus), and
axolotl (Ambistoma mexicanum) (Di Pietro et al., 1999). Axolotl is the first nonmammalian species
clearly proven to express both L-FABP and Lb-FABP in liver. The ligand-binding characteristics,
ligand-conformation-dependent stoichiometry and specificity of axolotl Lb-FABP do not resemble
those of other FABP types. These findings indicate that the two liver FABP types diverged before
the fish-tetrapod split, and that they may have distinct functional properties (Di Pietro et al.,
1999).
Analysis of the evolution of FABPs resulted in a phylogenetic tree with four branches: the I-
FABPs, the L-FABPs/IL-FABPs, the Manduca sexta FABPs and a complex branch including the
rest of the family members (A-FABP, M-FABP, H-FABP, B-FABP, E-FABP and the CRBPs) (Santomé
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et al., 1998). The divergence from a common progenitor into four branches took place before
the vertebrate/invertebrate split – approximately 600 million years ago.
1.3. Gene structure and regulation of expression.
Screening of genomic libraries with specific cDNAs revealed the genes of seven FABP types
up to now (Fig. 2). The overall organisation of the genes is identical: four exons and three
introns for all members of the FABP family: FABPs, CRBPs and CRABPs. The exon/intron positions
are similar in all genes, but the intron-length is variable. Especially the CRBP encoding genes
have relatively large introns (not shown). Several cis-acting elements in the 5’ promoter region
and various trans-acting nuclear factors that may influence transcription have been identified.
Figure 2.
Comparison of the structures of the genes for FABPs.
E, exon; l, intron; UTR, untranslated regions of exon 1 and exon 4, respectively. The numbers in the boxes
indicate the number of amino acids encoded within each exon. The intron lengths are in kilobase pairs,
the exon lengths in base pairs. The origin of the gene structures is given in the text.
The structure and regulation of most FABP genes have been reviewed by Veerkamp and
Maatman (1995) and Bernlohr et al. (1997). The structure of the H-FABP gene was elucidated for
mouse (Treuner et al., 1994), rat (Zhang et al., 1999), man (Phelan et al., 1996) and pig (Gerbens
et al., 1997). The human M-FABP gene was described by Hayasaka et al. (1993), the mouse M-
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FABP gene by Narayanan et al. (1991), the human I-FABP gene by Sweetser et al. (1987), the rat
L-FABP gene by Sweetser et al. (1986), the murine A-FABP gene by Hunt et al. (1986), and the
murine E-FABP gene by Hertzel and Bernlohr (1998) and Bleck et al. (1998). The I-LBP gene was
elucidated for mouse (Crossman et al., 1994) and rabbit (Stengelin et al., 1996). The structure of
the B-FABP gene has not been described yet. Recently, a concise promoter region of the H-FABP
gene was found which dictates tissue-appropriate expression (Qian et al., 1999). A bile acid-
responsive element was identified in the I-LBP gene (Grober et al., 1999) and a repeated heptad
sequence with suppressor and activator functions in the L-FABP gene (Simon et al., 1997).
Chromosomal mapping of the FABP genes (FABP1-9) shows a dispersed pattern of loci along
the genomes (Table 2). Within the different species the genes are located on different but
comparable chromosomes. Synteny exists between the regions where the H-FABP encoding
genes are located (Peeters et al., 1991; Troxler et al., 1993; Treuner et al., 1994; Gerbens et al.,
1997). The A-FABP and I-LBP encoding genes (FABP4 and FABP6) are also located in chromosomal
segments with a syntenic origin (Heuckeroth et al., 1987; Birkenmeier et al., 1994; Oelkers and
Dawson, 1995; Prinsen et al., 1997). The human and mouse A-FABP, M-FABP and E-FABP genes
are mapped on the same chromosome, A-FABP and M-FABP even in the same subregion (8q21.3-
q22.1) (Hayasaka et al., 1993; Prinsen et al., 1997).
All human and mouse gene locations have been retrieved from the human genome database (GDB) and
mouse genome database (MGD), respectively. The pig gene assignments are described by Gerbens et
al. [32,292].
Polymorphisms of the FABP genes were detected in man, cattle, pig and mouse (Table 3).
One of the polymorphisms appeared to cause a structural and physiological defect. Substitution
of Thr-54 by Ala in exon 2 of the human I-FABP (FABP2) gene in the Pima Indian population
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appeared to be associated with increase in body mass index, percent body fat and non-insulin-
dependent diabetes mellitus (NIDDM) (Baier et al., 1995). The threonine-containing protein had
a twofold greater affinity for long-chain FA and the Thr/Thr and Thr/Ala individuals had increased
fat oxidation rates in vivo and showed insulin resistance compared to Ala/Ala individuals (Baier
et al., 1995; Pratley et al., 2000). Caco-2 cells transfected with Thr-54 I-FABP encoding cDNA
showed higher long-chain FA transport and triacylglycerol secretion than cells expressing Ala-
54 I-FABP cDNA (Baier et al., 1996). In general, this polymorphism was shown to exert an effect
on energy metabolism (reviewed by Hegele, 1998). In Canadian Oji Cree indians the Ala54Thr
substitution was associated with differences in body mass index, percent body fat and fasting
plasma concentrations of triacylglycerols (Hegele et al., 1996). In both Pima and Oji Cree indians,
no association of the Thr allele with NIDDM was found (Baier et al., 1996). In the Finnish population,
the Thr-encoding allele of the FABP2 gene is associated with increased postprandial lipemia,
which is associated with postprandial insulin response (Ågren et al., 1998). The relative amounts
of individual FA introduced to chylomicron triacylglycerols were however not changed (Ågren et
al. 2001). Although in male Japanese subjects the Thr-54 allele was associated with intra-
abdominal fat thickness and insulin resistance (Yamada et al., 1997), no such association was
observed in a group of Japanese NIDDM patients (Ito et al., 1999). In Korean men, codon 54
polymorphism is associated with increased fat oxidation and hyperinsulinemia, but these effects
are not mediated by an increase in the intestinal FA absorption (Kim et al., 2001). Finally, also in
the Caucasian population the Ala54Thr polymorphism at the FABP2 locus is a risk factor for
insulin resistance (Chiu et al., 2001). In conclusion, ethnic differences may partly account for the
disparate findings on the Ala54Thr polymorphism.
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Two isoforms of bovine H-FABP were reported, with Asp or Asn on position 98 (Unterberg et
al., 1990). The heterogeneity was caused by distinct mRNA species (Bartetzko et al, 1993), but it
is not clear yet whether this is due to different genes, alternative splicing or RNA editing. Phelan
et al. (1996) reported a Lys53Arg substitution in human H-FABP which had a low frequency in a
Swedish population and showed no association with breast cancer incidence.
Contrasting data exist on the presence of isoforms of L-FABP. On one hand it was suggested
that L-FABP does not exist as isoforms but that the two fractions of rat L-FABP isolated after
proteolytic cleavage represent native conformers (Murphy et al., 1999). On the other hand two
isoforms differing both in structure and ligand binding were detected by circular dichroism,
time-resolved fluorescence spectroscopy and binding/displacement of fluorescent ligands (Frolov
et al., 1997; Di Pietro and Santomé, 2000). The two isoforms (I and II) have a different residue
105, Asn in the former and Asp in the latter (Di Pietro and Santomé, 2000). Isoform II has probably
a more open conformation than isoform I, thus allowing the binding of a greater variety of
ligands. These characteristics suggest that rat L-FABP isoforms may accomplish different
functions, similar to the distinct L-FABP types in non-mammalian species (Di Pietro and Santomé,
2000). Three charged isoforms of rat L-FABP were attributed to modifications or mutations of
Cys-69 (Thumser and Wilton, 1997). Besides single amino acid substitutions, the different isoforms
of L-FABP may also be explained by bound ligands, protein conformation or post-translational
S-thiolation and/or acetylation (reviewed by Jolly et al., 1998).
1.4. Structure of FABPs
Crystallography (Sacchettini et al., 1989; Zanotti et al., 1992; Xu et al., 1992; Cowan et al.,
1993; Thompson et al., 1997; Hohoff et al., 1999; Balendiran et al., 2000) and/or NMR (Lassen et
al., 1995; Hodsdon et al., 1996; Lücke et al., 1996, 2000, 2001) studies revealed the tertiary
structure of I-FABP, H-FABP, A-FABP, M-FABP, L-FABP, E-FABP, B-FABP and I-LBP. Fig. 3 shows the
structure of H-FABP, I-FABP and L-FABP. Structural properties of H-FABP, A-FABP and L-FABP have
been reviewed recently (Zanotti, 1999; Reese-Wagoner et al., 1999; Thompson et al., 1999). All
FABP types show similar structural features. They are composed of 10 antiparallel β-strands
(βA-βJ) that form a β-barrel. The bound ligand is found within the barrel in a central internal
water-filled cavity. The interior of the cavity is determined by the side-chains of both hydrophobic
and polar amino acids, and is variable between the different FABP types. These buried amino
acids probably determine the volume of the cavity and the binding specificity. Internal water
molecules within the cavity are assumed to contribute to the protein stability. Certain internal
water molecules are well ordened and highly conserved in homologous proteins. In FABPs
these water molecules function in the displacement of FA and maintain the electrostatic
interactions inside the binding cavity. Holo H-FABP contains at least 13 ordered water molecules
(Young et al., 1994). Recently it was reported that I-FABP has a cluster of internal water molecules
located within its FA binding cavity (~ 20 in the apo and 6-8 in the holo form), and a single
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“structural” internal water molecule (w135) located in a pocket close to the external surface
(Likic et al., 2000). The latter water molecule is present in the wedge formed by the loop between
βD and βE and the peptide group of Trp-82 and forms three H-bonds with the protein backbone.
Figure 3.
Graphical representation of the three-dimensional backbone structures of FABPs.
Panels show H-FABP , I-FABP and L-FABP with a bound oleate molecule. Oleic acid is represented as a
space-filling model. Figures were produced using GRASP (C. Lücke, Frankfurt, Germany)
The overall tertiary structures of M-FABP, I-FABP, A-FABP and H-FABP types are very similar
(Fig. 3; Banaszak et al., 1994). The apo- and holo-structure are comparable for I-FABP and A-
FABP based on their X-ray diffraction analysis (Sacchettini et al., 1989, Xu et al., 1992). The FA is
bound in a bent conformation in I-FABP. The three-dimensional structure of human H-FABP with
bound FA was resolved and refined by X-ray diffraction to 2.1 Å resolution (Zanotti et al., 1992).
The FA appeared to bind in a U-shaped conformation. The carboxylate group of the FA binds
within the protein cavity and interacts with the side chains of Tyr-128 and Arg-126 and several
ordered water molecules. In this network of hydrogen bonds, Arg-106 and Thr-40 are indirectly
involved in FA binding. The inner cavity of H-FABP is connected to the external solvent through a
small opening, formed by side chains of Val-25, Thr-29, Phe-57, Lys-58, Ala-75 and Asp-76. A
positive charge on the edge of the opening (Lys-58) has been postulated to be the driving force
that attracts the negatively charged FA (Young et al., 1994). A second gap is present between
strands βD and βE. It is thought that internal solvent molecules could exit the protein via this
second gap when a FA ligand enters the portal. However, this area does not represent a real
opening, since the space is filled with solvent molecules. Dynamic simulation led to the hypothesis
that this region could undergo a zip-like movement to widen the first, small aperture (Woolf,
1998; Woolf and Tychko, 1998). This movement would not disrupt the hydrogen bonding network
of the barrel.
Although high resolution X-ray studies on complexes of H-FABP with oleate, elaidate and
stearate showed that these FA are bound in a similar fashion (Young et al., 1994), the recently
published solution structure of human H-FABP (Lücke et al., 2001) suggests a selected-fit
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mechanism in FA binding, depending on the chain-length of the ligand. This behaviour appears
to be especially pronounced in H-FABP, possibly due to its more rigid backbone structure
compared with other FABP types.
The structure of M-FABP (P2) has been refined to a resolution of 2.7 Å and is highly comparable
with the structures of H-FABP and A-FABP (Alwyn Jones et al., 1988; Cowan et al., 1993). Although
M-FABP contains two cysteine residues, no disulfide bridge is present. M-FABP is able to bind
both FA and retinoids according to Uyemura et al. (1984), but the latter could not be established
(Veerkamp et al., 1999).
Recently, the crystal structures of E-FABP (Hohoff et al., 1999) and B-FABP (Balendiran et al.,
2000) became available. Although these FABP types are very similar to H-FABP, M-FABP and A-
FABP, they both display unique features. Human E-FABP contains six cysteine residues. A disulfide
bridge is formed between Cys-120 and Cys-127, which contributes to the stability of the protein.
The presence of cysteine pairs in E-FABP may also function to relieve oxidative stress in the
epidermis and other tissues by thiol-disulfide interchange reaction (Odani et al., 2000). B-FABP
is capable of binding of docosahexaenoic acid (DHA) (Xu et al., 1996). The three-dimensional
structure of human B-FABP in complex with oleate shows that the hydrocarbon tail assumes a
U-shaped conformation (like in H-FABP, A-FABP, and M-FABP) whereas in the complex with DHA
the hydrocarbon tail adopts a helical conformation (Balendiran et al., 2000). The binding specificity
of B-FABP appears to be the result of the non-conserved amino acid Phe-104, which interacts
with double bonds present in the lipid hydrocarbon tail (Balendiran et al., 2000). Richieri et al.
(2000) observed however a weaker affinity of human B-FABP for polyunsaturated FA than for
saturated and monounsaturated FA.
The three-dimensional structure of porcine I-LBP was resolved by high-resolution NMR and
appeared similar to other FABP types but highly flexible with a relatively weak hydrogen-bonding
network (Lücke et al., 1996). NMR data support the hypothesis that the shortened β-strands G
and H found only in I-LBP and L-FABP produce a wider opening (Gantz et al., 1989). This flexibility
probably allows a bile acid, which is larger and more rigid than a fatty acid, to enter the internal
protein cavity. Recently, the solution structure of I-LBP in complex with glycocholate was resolved
(Lücke et al., 2000). The bile acid appeared to be bound inside the protein, with the steroid
moiety penetrating deep into the water-accessible internal cavity. The carboxylate tail of the
ligand is protruding from the proposed bile acid portal into the surrounding aqueous solution.
The non-polar face of the steroid moiety interacts with the hydrophobic residues of β-strands C,
D and E. The polar face makes contact with the side chains of Tyr-97, His-99, Glu-110 and Arg-
121 of βH, I and J.
The crystal structure of rat recombinant L-FABP in the presence of oleic acid was completed
to 2.3 Å resolution (Thompson et al., 1997). Two FA molecules are bound within the central
cavity (Fig. 3). The carboxylate of one FA interacts with Arg-122 and is shielded from free solvent.
It has an overall bent conformation. The more solvent-exposed carboxylate of the other FA is
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located near the helix-turn-helix that caps one end of the β-barrel, while the acyl chain lies in
the interior. The primary and secondary oleate binding sites appear to be totally interdependent,
mainly because favourable hydrophobic interactions form between both aliphatic chains. As in
other FABP types, Arg-122 appeared to be important for the binding of the first FA (Thumser et
al., 1994, 1996). Serine residues at positions 39 and 124 also play a role in ligand binding.
Structural data on L-FABP confirm the presence of shorter βG and βH strands than the average
for the FABP family. The decreased number of intra-main chain hydrogen bonds girding the
portal region suggests a greater degree of possible motion in L-FABP.
All FABP structures detemined until now by NMR or crystallography showed two α-helical
regions (Banaszak et al., 1994). To investigate the structural and functional role of this conserved
helical domain of FABPs, a helix-less variant of rat I-FABP was engineered by deleting residues
15-31 and inserting a Ser-Gly linker after residue 14 (Kim et al., 1996). CD measurements and
NMR spectra indicated that this I-FABP variant (named I-FABP HL) has a high β-sheet content
and a β-clam topology similar to that of the wild-type protein (Kim et al., 1996). Triple-resonance
three-dimensional NMR revealed that the backbone conformation of I-FABP HL is nearly
superimposable with the β-sheet domain of wild-type I-FABP, and that deletion of the α-helical
domain creates a very large opening that connects the interior cavity with the exterior solvent
(Steele et al., 1998). I-FABP HL was less stable to guanidine treatment than wild-type I-FABP. The
FA-protein interactions of I-FABP HL were similar to those of the wild-type I-FABP at the carboxylate
end of the FA, but not at the methyl end. Ligand association rates for the helix-less variant and
the wild-type protein were comparable, but the dissociation rate was 16-fold lower for the wild-
type protein (Cistola et al., 1996). These data indicate that the α-helices of I-FABP are not required
to maintain the integrity of the FA-binding cavity but may serve to regulate the affinity of FA
binding. FA-transfer studies showed that in the absence of the α-helical domain, effective
collisional transfer of FA to phospholipid membranes does not occur, indicating that the α-
helical region of FABP is essential for interaction with membranes (Corsico et al., 1998; Wu et al.,
2001).
1.5. Structure-function relationship of FABPs
Site-directed mutagenesis has been used to study more systematically the structure-function
relationship of FABP. Conserved residues in the amino acid sequence alignment are putative
targets for mutagenesis. Target amino acids are chosen on basis of the putative importance of
their side chains in FA-binding or for the maintenance of the protein conformation, based on
the elucidated three-dimensional structure.
Various single amino acid mutants of different FABP types have been studied for ligand
specificity and affinity, and protein stability. The highly conserved Arg-126 residue appeared to
be important for binding affinity and ligand specificity of A-FABP, since mutation to Gln caused
a strong decrease of the affinity for cis-parinaric acid (Sha et al., 1993). Mutation of Arg-106,
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Arg-126 or Tyr-128 markedly affected FA binding and conformational stability of H-FABP (Prinsen
and Veerkamp, 1996). Replacement of Arg-106 by Gln in rat I-FABP caused a 20-fold increase of
the dissociation constant for oleic acid with a 6-fold decrease of the enthalpic contribution to
the free energy of binding (Jakoby et al., 1993). Also for rat L-FABP, mutation of Arg-122 indicated
a major role of this amino acid in ligand binding and structural integrity (Thumser et al., 1994,
1996). Remarkably, Arg-126 and Tyr-128 of H-FABP, which are known to interact with the carboxyl
group of FA, are also conserved in FAT as Arg-272 and Tyr-275 (Spitsberg et al., 1995).
Hydrophobic amino acid residues are thought to play a role in ligand affinity and/or specificity
by forming Van der Waals contacts with the acyl chain of the bound FA. Amino acid residues
Phe-16 and Phe-57 of H-FABP are both located near the putative FA entry site and make Van der
Waals contacts with the bound ligand. The phenyl ring of Phe-16 may form a key determinant in
FA specificity and affinity of H-FABP (Zanotti et al., 1992), since it may change its orientation
upon ligand binding (Banaszak et al., 1994). The importance of Phe-16 in ligand binding was
confirmed by studies on H-FABP mutants (Prinsen and Veerkamp, 1996; Zimmerman et al.,
1999). Results of mutations of Phe-57 in B-FABP and H-FABP indicate that this residue is not a
major contributor to the FABP/ligand interaction (Xu et al., 1996; Prinsen and Veerkamp, 1996).
In A-FABP however, Phe-57 appeared critical for the formation of the FA/A-FABP complex and
the stability of the protein, but was not involved in determination of selectivity for ligands (Ory et
al., 1997, Simpson and Bernlohr, 1998). Phe-57 displayed a greater mobility in A-FABP relative to
H-FABP (Constantine et al., 1998). Mutation of Gly-33 in B-FABP, which is adjacent to the opening
of the binding pocket, to a bulkier amino acid could prevent the access of the ligand to the
binding pocket by partially occupying the volume normally used by the ligand (Xu et al., 1996).
All members of the FABP family contain nine turns, eight of which are between antiparallel
β-strands. Seven of these turns contain a glycine residue. The turn between β-strands D and E
is of particular interest, since no hydrogen bonds are present between the main-chain atoms of
these two strands. A series of single, double, and triple mutations within this turn in I-FABP
resulted in a large decrease of oleic acid binding and loss of stability (Kim et al., 1997). These
data indicate that this region may be involved in the last stage of the protein folding process
(Kim et al., 1997). I-FABP mutants that lack Leu-64 appeared to have a lower conformational
stability and a high rate of refolding (Kim et al., 1997). Systematic mutation of the glycine residues
located in the turns between the β-strands of I-FABP showed that mutations in any of the three
turns connecting the last four C-terminal strands slow the folding and decrease stability, whereas
for most of the other turn mutations no apparent correlation was observed between stability
and refolding rates (Kim and Frieden, 1998). The α-helices of I-FABP are not required to maintain
the integrity of the binding cavity, since a helix-less variant of I-FABP showed similar β-sheet
and β-clam topology and FA binding characteristics as the wild-type protein (Cistola et al., 1996;
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Kim et al., 1996).
Acetylation and substitution of external lysine residues of H-FABP and A-FABP located on
the β2-turn and helices α-I and α-II did not change the binding affinity for FA, but changed the
transfer rate of 2-(9-anthroyloxy)palmitate (2-AP) to phospholipid membranes (Herr et al., 1995,
1996; Liou and Storch, 2001). A lysine to isoleucine mutation in the nonportal βA-strand of A-
FABP also decreased  the 2AP transfer rate, suggesting that not only the portal region but also
other distinct regions are involved in electrostatical interactions between FABPs and membranes
(Liou and Storch, 2001).
Studies on mutants of I-FABP and A-FABP revealed binding affinities ranging from about
200-fold smaller to 30-fold larger than the wild type proteins (Richieri et al., 1998; 1999a). Reduced
rates of binding were generally, but not exclusively, associated with sites within the portal region.
(Richieri et al., 1999a). In A-FABP, Ala substitutions for Arg-106 and Arg-126, which interact with
the FA carboxylate, reduced affinities by about 100-fold, but in I-FABP R106A has a 30-fold higher
affinity. The latter can be explained since the loss in enthalpy due to the elimination of the
favorable interaction between the FA carboxylate and Arg-106 is compensated for by an increase
in entropy (Richieri et al., 1998; 1999a). Enthalpy and entropy measurements appear to provide
more insight in the FA-FABP interaction than affinity measurements only (Richieri et al., 1999b).
1.6 Fatty acid uptake and transport
Most eukaryotic cells are capable of taking up long-chain FA to be used for a variety of
cellular processes. Extracellularly (in the blood), FA are transported mainly in complexes with
albumin which has three high-affinity binding sites (Spector, 1986). FA uptake by the eukaryotic
cell may occur both by passive diffusion and by protein-mediated binding and translocation
mechanisms. Diffusion of FA across the plasma membrane is a fast process, also called “flip-
flop” (Higgins, 1994; Kamp et al., 1995; Zakim, 1996). It is driven by an inwardly directed FA
gradient, with an extracellular FA concentration in 10-20-fold excess over the intracellular content
(Van der Vusse, 1992; Van der Vusse and Roemen, 1995).
Passive FA uptake involves several distinct steps: 1) dissociation from albumin or plasma
lipoprotein, 2) adsorption, i.e. association to the outer leaflet of the plasma membrane, 3)
movement across the plasma membrane, 4) dissociation from the inner leaflet to enter the
cytosol, 5) diffusion through the cytosol to sites of binding and utilization and 6) metabolism
(Hamilton and Kamp, 1999). Half-times for association, flip-flop and dissociation are all less
than a second, whereas metabolic processes usually occur within minutes (Hamilton and Kamp,
1999). These data suggest fast diffusion fluxes and no a priori necessity for transport proteins.
The authors suggest an indirect function for plasma membrane FA transporters by increasing
the FA partitioning into the membrane or sequestering FA to a membrane-bound enzyme,
thereby enhancing metabolism (Hamilton and Kamp, 1999). Recently, Stump et al. (2001) found
that oleic acid uptake by rat adipocytes is the sum of saturable (facilitated) and linear (flip-flop)
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processes. Over 90% of the transport occurs via the saturable pathway when the oleic acid/BSA
ratio is within the physiological range. In contrast to data reported by Hamilton and Kamp
(1999), Stump et al. (2001) found that rate constants for saturable transmembrane influx were
faster than those for nonsaturable uptake. The discrepancies between the data of the different
groups is possibly due to the different methods used (tracer kinetic studies versus intravesicular
acidification rate measurements).
Protein-facilitated FA uptake has been shown in cardiac myocytes (Sorrentino et al., 1988;
Luiken et al., 1998), adipocytes (Abumrad et al., 1981, 1984) and hepatocytes (Stremmel et al.,
1986; Sorrentino et al., 1989). Several membrane-associated FA transporters have been identified
during the last decade (Abumrad et al., 1999). Plasma membrane FABP (FABP
PM
;Stremmel et al.,
1985), fatty acid translocase (FAT/CD36, Ibrahimi et al., 1996) and fatty acid transport protein
(FATP; Schaffer and Lodish, 1994) act as long chain FA transporters (Luiken et al., 1998). Transfection
of FAT cDNA in fibroblasts resulted in a higher FA uptake rate (Ibrahimi et al., 1996). Muscle-
specific overexpression of FAT enhanced FA oxidation by contracting muscle and reduced plasma
FA and triacylglycerols (Ibrahimi et al., 1999). It was recently suggested that FA transport is
increased acutely by muscle contraction, involving the translocation of FAT from intracellular
depots to the surface of the muscle cell (Luiken et al., 1999; 2000). Due to the induction of
signalling pathways during muscle contraction, protein-acylating enzymes could be induced to
palmitoylate FAT, which in turn is translocated to the sarcolemma where it may accept FA from
FABP
PM
 .The process of FA uptake by membrane-associated proteins in other tissues remains to
be investigated.
Intracellularly, FA are bound by FABPs, which are considered to be important carriers for
intracellular FA. They increase FA solubility and facilitate transport of FA from the plasma
membrane to sites of FA oxidation (mitochondria, peroxisomes), to sites of FA esterification into
triacylglycerols (TG) or phospholipids, or to the nucleus possibly for regulatory functions (Fig. 4).
Several studies have demonstrated FA transfer between FABP and membranes by use of
radiolabeled or fluorescent FA, or by NMR (Cistola et al., 1989; Peeters et al. 1989; Veerkamp et
al., 1991; Veerkamp and Maatman, 1995; Glatz and Van der Vusse, 1996; Storch et al., 1996). In
hepatocytes and adipocytes, uptake of photoactivatable radiolabeled FA was accompanied by
labelling of FABP (Waggoner and Bernlohr, 1990; Waggoner et al., 1991).
FA transfer by FABPs has been studied with the help of fluorescent anthroyloxy-labeled fatty
acids (AOFAs) and phospholipid vesicles (Storch et al., 1996). AOFA transfer from different FABP
types to phospholipid membranes occurs by distinct mechanisms (reviewed in Storch and
Thumser, 2000). AOFAs are transferred from I-FABP, H-FABP and A-FABP by collisional interaction
with an acceptor membrane since their rate of transfer increases linearly with the concentration
of acceptor vesicles. In contrast, L-FABP transfers AOFA to membranes in an aqueous diffusional
manner involving an initial and obligatory release of ligand to the aqueous environment. The
transfer rates differ markedly between different FABP types. With 12-(9-anthroyloxy)oleic acid,
Chapter 1
22
the transfer rate is for A-FABP > H-FABP >> I-FABP >> L-FABP (Storch et al., 1996). When
membranes contain anionic phospholipids, the AOFA transfer rate from H-FABP and A-FABP
increases, suggesting that positively charged amino acid residues on the FABP surface are
involved in the interaction between FABP and membrane. The interaction between A-FABP and
membranes appeared to be electrostatic, since binding was dependent on the molar
concentration of anionic phospholipid, and decreased when acetylated A-FABP was used (Smith
and Storch, 1999). When surface lysine residues of H-FABP and A-FABP were neutralized by
acetylation, the transfer rate decreased markedly and the transfer mechanism changed to
aqueous diffusion instead of collisional interaction (Wootan and Storch, 1994; Herr et al., 1995,
1996). Mutation of single lysine residues showed that the helix-turn-helix domain, and especially
Lys-21 in H-FABP and A-FABP are critical for interaction with anionic acceptor membranes (Herr
et al., 1996; Liou and Storch, 2001). Deletion of the α-helical domain of I-FABP altered the regulation
of AOFA transfer to acceptor membranes, making the normally collision-mediated process more
characteristically diffusion-mediated (Corsico et al., 1998). Transfer of AOFA from phospholipid
membranes to different FABP types also appeared to occur by different mechanisms. Like with
transfer from FABP to membranes, the process is diffusion-mediated for L-FABP and collisional
for I-FABP (Thumser and Storch, 2000).
Figure 4.
Abbreviations: FA, fatty acid; VLDL, very low density lipoproteins; chylos, chylomicrons; LPL, lipoprotein
lipase; ECF, extracellular fluid; M, membrane-associated fatty acid transport proteins; ER, endoplasmic
reticulum; FAAR, fatty acid-activated receptor; FARE, fatty acid responsive element.
Schematical representation of the role of FABP in fatty acid uptake and intracellular fatty acid
trafficking.
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The technique of fluorescence recovery after photobleaching (FRAP) was used to measure the
intracellular transport of a fluorescent fatty acid (12-N-methyl-(7-nitrobenzo-2-oxa-1,3,
diazol)aminostearate; NBD-stearate) (Luxon 1996; Murphy, 1998). Cytoplasmic transport of NBD-
stearate could be inhibited by α-bromo-palmitate (Luxon, 1996). Transfection of L-cell fibroblasts
with L-FABP or I-FABP cDNA increased NBD-stearate uptake and cytoplasmic transport (Murphy,
1998). The latter appeared to be dependent on FABP concentration and binding activity (Luxon
and Milliano, 1997, 1999), which is consistent with the proposition that binding proteins enhance
diffusive transport by reducing ligand binding to immobile intracellular membranes (Weisiger,
1996). Recently, a kinetic model of intermembrane ligand transport was developed in which
diffusional transfer of ligand between membrane and protein is assumed (Zucker, 2001). This
model was tested by using the stopped-flow technique to monitor transfer of 12-anthroyloxy
stearate (12-AS) between model membrane vesicles. The 12-AS transfer rate was shown to
decline asymptotically with increasing concentrations of BSA or L-FABP and was linearly correlated
with the concentration of I-FABP, in agreement with the data of Storch et al. (1996).
Experimental data of different investigators led to paradoxical conclusions about
intermembrane FA transport by L-FABP. Most studies support a diffusional mechanism of FA
transfer (Storch and Bass, 1990; Kim and Storch, 1992a/b; Hsu and Storch, 1996; Zucker, 2001).
Other investigators have shown that the binding of L-FABP to anionic lipid vesicles results in
ligand (DAUDA) release, consistent with a collisional transport mechanism (Davies et al., 1999).
The decrease of the rate of intermembrane 12-AS transfer with increasing FABP concentration
supports however a predominantly diffusional mechanism of L-FABP-mediated transport (Zucker,
2001). FRAP analyses with NBD-stearate support that BSA and L-FABP enhance FA diffusion
(Luxon, 1996) while vesicle transfer studies with 12-AS indicate that BSA and L-FABP inhibit
intermembrane FA translocation (Zucker, 2001). These contrasting observations may be due to
the fact that both NBD-stearate and 12-AS carry a different attached fluorescent group which
may alter the physical properties of the FA molecule. Another explanation is that FRAP analyses
do not distinguish between membrane- and protein-bound ligands and wrongly assume steady-
state conditions (Zucker, 2001).
In a study of FA transfer from immobilized liposomes to rat liver or heart mitochondria,
FABPs stimulate transfer but no preference for any FABP type was observed (Veerkamp et al.,
2000). The transfer rate was higher from positively charged liposomes than from neutral or
negatively charged liposomes. I-LBP did not transfer FA. The significance of intracellular bile
acid-binding proteins for bile acid transport remains to be established (Agellon and Forchia,
2000). I-LBP appears to bind preferentially conjugated bile acids in contrast to L-FABP (Zimmerman
et al., 2001). A correlation was found between the presence of L-FABP in bile and both bile flow
and bile acid release (Foucaud et al., 1999).
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1.7. Function of FABPs in modulation of signal transduction and gene transcription
FA, their CoA and carnitine esters and other lipid mediators, such as eicosanoids and
lysophospholipids, may directly or indirectly influence various cellular processes by their
interactions with enzymes, membranes, ion channels, receptors or genes (Veerkamp et al.,
1991; Sumida et al., 1993; Graber et al., 1994; Glatz and Van der Vusse, 1996; Nunez, 1997). By
modulation of the concentrations of non-esterified FA and their derivatives, FABPs have an indirect
effect on these parameters. L-FABP binds besides FA also lysophospholipids and eicosanoids
(Veerkamp et al., 1993). Recently it was shown that H-FABP binds cytochrome P450
monooxygenase and lipoxygenase pathway products (Widstrom et al., 2001). Distinct FABPs
may differentially affect processes that can be influenced by FA. Examples of such processes
are given below.
FA (in particular unsaturated FA) are able to act as second messengers involved in the
transduction of external signals because their concentrations are rapidly and transiently altered
in response to the binding of specific agonists to plasma membrane receptors. They may
substitute for the classical second messengers of the inositide phospholipid and the cyclic AMP
signal transduction pathways (Sumida et al., 1993; Graber et al., 1994). Non-esterified FA modify
the activity of phospholipases, protein kinases, G-proteins, adenylate and guanylate cyclases
as well as ion channels and other biochemical events involved in stimulus-response coupling
mechanisms. Enzymes of both cyclic AMP and protein kinase C pathways are regulated by FA
(Graber et al., 1994; Nunez 1997). FA have been shown to activate soluble protein kinase C
(Khan et al., 1992) by mimicking the action of diacyglycerol, enhance Ca2+ release from the
endoplasmic reticulum similar to inositol-3-phosphate, and finally inhibit the activity of protein
kinase A in contrast to the action of cAMP. FA inhibit growth factor-induced deacylglycerol kinase
α activation in vascular smooth-muscle cells and increased levels of FA may contribute to chronic
protein kinase C activation associated with diabetes (Du et al., 2001). FA may serve as a relay
when the concentrations of the primarily triggered messengers (diacylglycerol and Ca2+) are
falling (Graber et al., 1994). Most of the actions of FA on signal transduction have been shown
for exogenously supplied FA, but FA can also be released from membrane phospholipids by
cellular phospholipases. Interestingly, accumulation of arachidonic acid can result in a feedback
inhibition of phospholipase A
2
(Alkhunaizi et al., 1996).
Very recently, Collett and co-workers (2001) showed that n-6 and n-3 polyunsaturated FA
differentially modulate oncogenic Ras activation in colonocytes. Docosahexaenoic acid, the
major n-3 polyunsaturated FA constituent of fish oil, reduced Ras localization to the plasma
membrane without affecting posttranslational lipidation and partially blocked downstream signal
transduction (Collett et al. 2001). Linoleic acid, an n-6 polyunsaturated FA, did not exert this
effect.
FA, especially polyunsaturated FA such as arachidonic acid and linoleic acid, directly regulate
Na+, K+, Ca2+ and Cl- ion channels (Ordway et al., 1991; Kang and Leaf, 1996). Different
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mechanisms of FA action have been proposed (Ordway et al., 1991). FA could directly bind to
and activate the channel, like with enzymes such as guanylate cyclase and protein kinase C.
Alternatively, they could alter the interaction of channels with the lipid bilayer, or affect the lipid
membrane fluidity (Meves, 1994). Free polyunsaturated FA reversibly bind to the Na+ channels
of neonatal rat cardiac myocytes and have an antiarrhythmic action (Kang and Leaf, 1996).
They regulate neuronal excitability by modulating Na+ and Ca2+ currents in neurons from rat
hippocampus (Vreugdenhil et al., 1996). In rat sympathetic neurons, arachidonic acid both inhibits
and enhances whole cell Ca2+ currents (Liu et al., 2001). Additionally, arachidonic acid exerts
specific effects on distinct types of K+ channels in retinal glial cells (Bringmann et al., 1998). The
extracellular application of eicosapentaenoic acid, arachidonic acid, and other polyunsaturated
FA produced a concentration-dependent suppression of voltage-gated L-type Ca2+ currents in
rat ventricular myocytes, whereas oleic acid and stearic acid had no effect (Xiao et al., 1997).
Therefore polyunsaturated FA may act as antiarrhythmic agents in vivo. FA also suppress the
Na+ current in transfected human embryonic kidney cells in the inactivated state and prolong
the duration of recovery from inactivation (Xiao et al., 1998).
FA play a role in the transcription of genes, especially those genes which encode proteins
involved in lipid metabolism, e.g. acyl-CoA synthase (Martin et al., 1997), acyl-CoA oxidase
(Clarke and Jump, 1996; Clarke, 2000), stearoyl-CoA desaturase (DeWille and Farmer, 1993;
Clarke and Jump, 1996) and carnitine-palmitoyl transferase (Louet et al., 2001). The transcription
of FABP and FATP genes is also promoted by FA (Amri et al., 1991  a/b; 1994; Distel et al., 1992;
Meunier-Durmort et al., 1996; Martin et al., 1997; Van der Lee et al., 2000). Recently, FA regulation
of gene transcription was reviewed by Duplus et al. (2000). In mammals, the expression of
many genes has been shown to be modulated by FA in a positive or negative manner. The
control of hepatic lipogenic enzymes is an example of negative regulation. Clarke and Jump
(1996) reported that polyunsaturated FA of the n-6 and n-3 families, in contrast to saturated and
monounsaturated FA, inhibit transcription of a number of hepatic lipogenic and glycolytic genes,
e.g. FA synthase. Polyunsaturated FA also regulate genes such as adipocyte glucose transporter
4, lymphocyte stearoyl-CoA desaturase and interleukins (Clarke and Jump, 1996; Jump and
Clarke, 1999). A polyunsaturated FA-rich diet reduced the hepatic mRNA levels for e.g. acetyl-
CoA carboxylase, L-PK, apolipoprotein A-1 and the S14 protein (Niot et al., 1997; Pegorier, 1998;
reviewed in Jump and Clarke, 1999). The data obtained by Clarke and Jump (1996) indicate that
polyunsaturated FA inhibit hepatic de novo lipogenesis by a mechanism that does not involve
peroxisome proliferator-activated receptors (PPARs). It may not be the polyunsaturated FA per
se, but cytotoxic peroxidative products that are the active molecules in this process (Mikkelsen
et al., 1993; Foretz et al., 1999).
Different mechanisms for FA control of gene transcription have been postulated (Duplus et
al., 2000). FA, acyl-CoA or FA metabolites can: 1) induce the modification of a transcription factor
(TF), thereby altering its transactivation capacity, 2) directly bind to and activate a TF, 3) modify
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the mRNA stability or 4) influence the transcription rate of a TF and , 5) change the de novo
synthesis of the TF. One of the mechanisms by which FA regulate transcription occurs via the TF
family of PPARs, a subfamily of the nuclear hormone receptors (Lemberger et al., 1996; Schoonjans
et al., 1997; Gonzalez et al., 1998; Desvergne and Wahli, 1999; Vanden Heuvel, 1999). PPARs
have emerged as one of the central regulators of the nutrient/gene interactions (Wahli et al.,
1995; Desvergne and Wahli, 1999). They exert their effects by binding to a specific responsive
DNA element, called peroxisome proliferator responsive element (PPRE) after heterodimerization
with retinoid X receptors (RXR) (Green and Wahli, 1994; Mangelsdorf and Evans, 1995; Braissant
et al., 1995). Up to now, three types of PPAR have been described: PPARα, PPARβ (also known as
fatty acid-activated receptor (FAAR) or PPARδ) and PPARγ. Their differential tissue distribution
suggests that they have specific roles in different organs. PPARα is predominantly expressed in
the liver and brown adipose tissue and plays an important role in FA catabolism (Lee et al.,
1995). PPARγ is highly expressed in adipocytes where it is involved in the regulation of adipose
differentiation and adipogenesis (Spiegelman and Flier, 1996). PPARδ or FAAR displays a high
level of expression in lipid-metabolizing tissues, such as adipose tissue, small intestine, heart
and skeletal muscle and could regulate the expression of genes implicated in FA uptake and
activation (Amri et al., 1995). It also mediates the effects of long-chain FA on post-confluent cell
proliferation (Jehl-Pietri et al., 2000). Naturally occurring (FA, leukotrienes, prostaglandins) and
synthetic molecules (fibrates, glitazones) that are ligands for these nuclear receptors control the
transcriptional activity of PPARs (Devchand et al., 1996; Fruchart et al., 1999).
Intriguingly, the expression of FABP is regulated by FA and other PPAR ligands. Wy14,643 (a
synthetic activator of PPARα) induces L-FABP, I-FABP and H-FABP mRNA in respective mouse
tissues (Motojima, 2000). Wy14,643 was also shown to enhance the binding activity of PPARα/
RXRα to PPREs of acyl CoA oxidase and L-FABP genes (Mochizuki et al., 2001). Activation of
PPARδ by FA induced transcription of genes encoding FAT, A-FABP and PPARγ in 3T3C2 fibroblasts,
resulting in lipid accumulation and adipocyte differentiation (Bastie et al., 1999). FA are involved
as signal-transducing molecules in the differentiation of preadipose to adipose cells and induce
A-FABP expression (Grimaldi et al., 1992; Amri et al, 1991a/b, 1994). A sunflower oil-enriched
diet specifically increased L-FABP mRNA and protein in duodenum and proximal jejunum, but
did not affect I-FABP levels (Poirier et al., 1997). Targeted disruption of the gene encoding PPARα
fully abolished the hepatic induction by fibrates of the gene encoding L-FABP (Lee et al., 1995).
Interestingly, analysis of long-chain FA- and fibrate-mediated effects on L-FABP mRNA levels in
wild-type and PPARα null mice showed that PPARα in the intestine does not constitute a dominant
regulator of L-FABP gene expression (Poirier et al., 2001). Instead, PPARδ can act as a fibrate/FA-
activated receptor, and L-FABP is a PPARδ target gene in the small intestine (Poirier et al., 2001).
Bile components appear to regulate the I-LBP expression in the ileum (Kanda et al., 1998).
Some of the effects of FA, but certainly not all, can be assigned to PPAR activation. Saturated
and monounsaturated FA promote the transcription of certain genes by PPAR-mediated
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mechanisms, whereas polyunsaturated FA possibly down-regulate transcription of genes by
other transcription factors (Clarke and Jump, 1996; Jump and Clarke, 1999). Furthermore,
transcription factors different from the PPARs could mediate the FA effect. An example is the
orphan hepatic receptor HNF4 which was shown to bind acyl-CoA (Hertz et al., 1998). Alternatively,
FA could regulate gene transcription by altering de novo synthesis of transcription factors,
putatively via sterol regulatory element-binding protein (SREBP) (Xu et al., 1999; Mater et al.,
1999) or via the induction of c-fos and nur-77, as was established in a pancreatic β-cell line
(Roche et al., 1999).
FABPs have been detected in the nucleus of hepatocytes (Bordewick et al., 1989; Fahimi et
al., 1990), heart myocytes (Börchers et al., 1989), locust myocytes (Haunerland et al., 1992) and
astrocytes (Young et al., 1996). Recently, the role of L-FABP in FA transport to the nucleus was
examined using fluorescein-conjugated L-FABP (Lawrence et al., 2000). L-FABP appeared to
interact directly with rat liver nuclei in a specific, ligand-dependent manner. An interaction was
observed between L-FABP and a 33-kDa nuclear protein, which was enhanced in the presence
of oleic acid. These data indicate that L-FABP is involved in communicating the state of FA
metabolism from the cytosol to the nucleus through an interaction with lipid mediators that are
involved in nuclear signal transduction (Lawrence et al., 2000). A direct role for L-FABP in the
regulation of gene expression was reported by Wolfrum et al. (2001). They found colocalization
of L-FABP and PPARα in the nucleus of mouse primary hepatocytes. L-FABP interacted with
PPARα and PPARγ but not with PPARβ and RXRα by protein-protein contacts. With all ligands
applied, a strict correlation of PPARα and PPARγ transactivation with intracellular concentration
of L-FABP was observed. Together these findings strongly suggest a nucleus-directed signalling
by FA and hypolipidemic drugs where L-FABP may act as a cytosolic gateway for these PPARα
and PPARγ agonists (Wolfrum et al., 2001).
1.8. Data on FABP knockout mice
The generation of knockout mice a couple of years ago was an important step forward in
understanding the physiological role of FABPs. Table 4 gives an overview of FABP knockouts
generated up to now and their phenotypical and physiological characteristics. Mice lacking H-
FABP exhibit a severe defect of peripheral long-chain FA utilization. The heart is unable to efficiently
take up plasma long-chain FA which are normally its main fuel, and switches to glucose usage
(Binas et al., 1999). H-FABP deficiency is only incompletely compensated, causing acute exercise
intolerance and, at old age, a localized cardiac hypertrophy (Binas et al., 1999). Furthermore it
was shown that in resting and contracting cardiac myocytes from H-FABP null mice, both uptake
and oxidation of palmitate are markedly reduced (Schaap et al., 1999). In resting H-FABP deficient
cardiac myocytes, glucose oxidation is increased by 80%. Taken together, these findings provide
evidence that H-FABP plays a crucial role in uptake and oxidation of long-chain FA, in fuel
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selection and in metabolic homeostasis.
Mice lacking A-FABP (or aP2) are healthy, develop apparently normal adipose tissue, and
exhibit only minor alterations in their steady-state lipid metabolism (Hotamisligil et al., 1996).
This lack of significant effect of A-FABP deficiency was potentially the consequence of the
compensatory upregulation at the mRNA level of E-FABP (Coe et al., 1999; Shaughnessy et al.,
2000), which is otherwise only slightly present in adipose tissue (Krieg et al., 1993). There was
no difference in the rate of FA influx or esterification in adipocytes of wild-type and A-FABP null
mice, but basal lipolysis was approximately 40% decreased in A-FABP null mice (Coe et al.,
1999). A-FABP null mice with induced obesity failed to express tumour necrosis factor α in adipose
tissue and were significantly protected from hyperinsulinemia and insulin resistance compared
with wild-type mice, suggesting that adipocyte FA metabolism is a critical component of the
mechanisms leading to systemic insulin resistance in obesity (Hotamisligil et al.,1996;
Shaughnessy et al., 2000). The role of A-FABP in pathogenesis of type 2 diabetes may involve
the regulation of hyperinsulinemia and insulin resistance through its impact on both lipolysis
and insulin secretion (Scheja et al., 1999). Experiments with obese A-FABP null mice indicated
that A-FABP deficiency does not only improve peripheral insulin resistance but also preserves
pancreatic β-cell function and has beneficial effects on lipid metabolism (Uysal et al., 2000).
Recently, the expression of A-FABP in macrophages was demonstrated (Makowski et al., 2001).
A-FABP appeared to play a significant role in the biological responses of macrophages and
contributes to the development of atherosclerosis. Apolipoprotein E-deficient mice also deficient
for A-FABP showed protection from atherosclerosis, and A-FABP-deficient macrophages exhibited
alterations in inflammatory cytokine production and a reduced ability to accumulate cholesterol
esters when exposed to modified lipoproteins (Makowski et al., 2001). Oxidized low-density
lipoprotein appears to induce the expression of A-FABP mRNA and protein in human
macrophages (Fu et al., 2000). These data indicate distinct actions of A-FABP in adipocytes and
macrophages and could provide a new therapeutic target for the prevention of atherosclerosis.
I-FABP null mice were used to study the role of I-FABP in the uptake of dietary FA (Vassileva
et al., 2000). I-FABP null mice appeared viable but display alterations in body weight and are
hyperinsulinemic. Male I-FABP null mice had elevated plasma triacylglycerols and weight more
regardless of the dietary fat content. In contrast, female I-FABP null mice gained less weight in
response to a high fat diet. These findings led to the idea that I-FABP is not essential for dietary
fat absorption but may rather function as a lipid-sensing component of energy homeostasis
that alters body weight gain in a gender-specific fashion (Vassileva et al., 2000). I-LBP knockout
mice showed the same phenotype and bile acid pool size as wild-type mice (Agellon, 2001).
E-FABP-deficient mice were viable and showed no macroscopical aberrations compared to
wild-type mice, but the H-FABP gene expression is upregulated and may compensate for the
lack of E-FABP (Owada and Kondo, 2001). The basal transepidermal water loss of the E-FABP
null mice was however decreased compared to wild-type mice, and these animals were not
able to recover this loss when the lipid barrier was disrupted. These results indicate that E-FABP
may be involved in the formation of the water permeability barrier of the skin.
1.9. Expression of FABPs and their role in growth, differentiation and cytoprotection
The expression of FABP mRNA and the synthesis of FABP are dependent on cell differentiation
and postnatal development for various FABP types in different tissues (Veerkamp and Maatman,
1995; Veerkamp, 1995), e.g. I-FABP and L-FABP in intestine (Shields et al., 1986), L-FABP in liver
(Sorof, 1994), and H-FABP in various tissues (Watanabe et al., 1991). For brain more recent data
are available (reviewed in Veerkamp and Zimmerman, 2001). The brain contains three different
types of FABP: H-FABP (Heuckeroth et al., 1987), B-FABP (Feng et al., 1994; Kurtz et al., 1994) and
E-FABP (De Léon et al., 1996; Liu et al., 1997). The genes for these FABP types of brain show a
spatio-temporally differential expression in developing and mature brain (Owada et al., 1996;
Liu et al., 1997). The expression of H-FABP becomes evident in rat brain after birth, with a gradual
increase and confined to the grey matter, suggesting that its mRNA is neuron-specific (Owada
et al., 1996). In mouse brain, H-FABP levels are detectable after fetal day 19 and increase until
postnatal day 14, but become lower in the adult brain (Sellner et al., 1995). In contrast to H-FABP,
the expression of B-FABP and E-FABP is dominant in the prenatal and perinatal mouse and rat
brain (Owada et al., 1996; Liu et al., 1997). B-FABP is first expressed in neuroepithelial precursor
cells of developing brain, but in the adult stage its expression is restricted to radial glial cells
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and immature astrocytes (Feng et al., 1994; Kurtz et al., 1994). E-FABP mRNA and protein are
expressed at high levels during neurogenesis, neuronal migration, and terminal differentiation
of neurons (Liu et al., 1997; Liu et al., 2000). The expression level of E-FABP remains weak in the
adult brain, whereas B-FABP expression disappears. Depletion of E-FABP appears to impair
neurite outgrowth in PC12 cells (Allen et al., 2000).
Hormones and physiological changes affect especially the expression of L-FABP (Veerkamp
et al., 1993; Veerkamp, 1995; Carlson et al., 1998). The H-FABP content of heart was markedly
changed by exercise and testosteron (Veerkamp, 1995; Glatz en Van der Vusse, 1996). Bacterial
lipopolysaccharide downregulated H-FABP in rat heart and muscle and L-FABP in liver, while
cytokines downregulated L-FABP in liver (Memon, 1999). In contrast to L-FABP, I-FABP expression
is limited to fully differentiated human Caco-2 cells and can be more easily regulated by lipids,
hormones and cytokines (Dubé et al., 2001).
Members of the FABP family also appear to be connected with the modulation of cell growth.
L-FABP modulates the mitogenesis of liver and hepatoma cells (Sorof, 1994). L-FABP cDNA
transfection of hepatoma cells increased the efficacy of the utilization of unsaturated FA, especially
linoleic acid, leading to a higher proliferation rate (Keler and Sorof, 1993). Furthermore, the
maintenance of the membrane integrity and the preservation of the morphology was promoted
in L-FABP cDNA transfected hepatoma cells, although others found an increase of plasma
membrane fluidity in L-FABP cDNA-transfected L-cell fibroblasts (Woodford et al., 1993). Two
classes of carcinogenic peroxisome proliferators are activated by L-FABP, resulting in cell
multiplication in hepatoma cells (Khan and Sorof, 1994). L-FABP expression in rat enzyme-altered
foci is determined by the initiating carcinogenic regimen (Thullberg et al., 1998). Embryonic
stem cells, transfected with cDNA encoding L-FABP showed morphological changes, a reduced
level of stage-specific embryonic antigen-1, and localization of L-FABP in both the cytosol and
the nucleus (Schroeder et al., 2001). These findings suggest that L-FABP may play a role in
regulating embryonic stem cell differentiation by acting in the nucleus as well as the cytoplasm.
Other FABP types have also been implicated in some cases in the regulation of growth and
differentiation. Bovine mammary-derived growth inhibitor (MDGI) which was identified as a
mixture of H-FABP and A-FABP (Specht et al., 1996), and H-FABP caused specific growth inhibition
and terminal differentiation of mammary epithelial cells (Böhmer et al., 1987; Yang et al., 1994).
H-FABP cDNA transfection caused a modest antiproliferative activity in human breast cancer
cells (Huynh et al., 1995). In addition, in vivo tumorigenicity of transfectants expressing H-FABP
was reduced (Huynh et al. 1995). It is of interest to note that human H-FABP was mapped to
chromosome 1 p33-p35, a common region of loss in sporadic breast cancer (Phelan et al.,
1996). Furthermore, MDGI appeared to be a potent inhibitor of bovine, mouse, and human
mammary epithelial proliferation in cell and organ culture (Lehman et al., 1989; Zavizion et al.,
1993; Yang et al., 1994). Evidence for decreased H-FABP expression was found in human breast
cancer (Huynh et al., 1995). MDGI-derived peptide P108 inhibits tumour growth of breast cancer
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FABP as a tumour suppressor (reviewed in Hohoff and Spener, 1998). Differentiation-promoting
effects of MDGI/H-FABP were observed in pluripotent mouse embryonic stem cells (Wobus et
al., 1990), mammary epithelial cells (Yang et al., 1994), and cardiac myocytes (Burton et al.,
1994). Expression of bovine H-FABP in yeast caused inhibition of growth (Scholz et al., 1990), but
L6 muscle cells transfected with H-FABP cDNA did not show changes in growth or differentiation
compared to mock-transfected cells (Prinsen and Veerkamp, 1998). Interestingly, the expression
of H-FABP in C
2
C
12
 muscle cells appeared to be differentiation-dependent (Rump et al., 1996).
Cultured rat and human muscle cells also show an increase of H-FABP at differentiation (Benders
et al., 1991; Prinsen and Veerkamp, 1998). The increasing H-FABP content upon differentiation
may relate to an increasing FA oxidation that has been reported for differentiated L6 cells (Sauro
and Strickland, 1987). Transfection of L6 cells with A-FABP cDNA increased the proliferation rate
and blocked the fusion of these cells, simultaneously with changes in their phospholipid
composition (Prinsen and Veerkamp, 1998).
In some cases, FABPs could be used as tumour marker (Table 5). The development of liver
and gut cancer appears to be related to changes of FABP content. The FABP content decreases
with further dedifferentiation and progression of the tumour. Generally, the level of L-FABP and
I-FABP decreased in rat and human colon carcinoma (Carroll et al., 1990; Davidson et al., 1993).
In human hepatic tumours and rat hepatoma the L-FABP staining decreased and showed
mosaicism (Roomi et al., 1988; Suzuki et al., 1990). Furthermore, L-FABP expression is suitable
for use as new presurgical prognostic marker for patients undergoing hepatic surgery for
colorectal cancer metastases (Yamazaki et al., 1999).
A-FABP synthesis was only detected in lipoblasts in both lipoblastoma and liposarcoma, but
not in other benign adipose tissue tumours and malignant connective tissue or epithelial tumours
(Bennett et al., 1995). In contrast, A-FABP expression by normal bladder urothelium was lost at
various stages of carcinoma progression (Celis et al., 1996). In addition, low-grade tumours
contained more A-FABP than their high-grade counterparts. Protein abundancy and mRNA
levels of A-FABP correlate in non-invasive and invasive bladder transitional cell carcinomas,
and the loss of A-FABP was not compensated by an increase in E-FABP as is the case in A-FABP
knockout mice (Gromova et al., 1998).
B-FABP is expressed in correlation with glial fibrillary acidic protein (GFAP) in a subset of
human malignant glioma cell lines (Godbout et al., 1998). Its expression is regulated by differential
phosphorylation of nuclear factor I, which is able to bind to two NFI binding sites in the B-FABP
gene (Bisgrove et al., 2000). E-FABP expression is increased in drug-resistant human
adenocarcinoma of the pancreas and was suggested to be part of a mechanism of sequestration
or removal of cytotoxic drugs (Sinha et al., 1999). The E-FABP gene is overexpressed in most
human prostate carcinomas and some squamous carcinomas of the bladder and skin
(Ostergaard et al., 1997; Watanabe et al., 1997; Jing et al., 2000). The increased E-FABP expression
cell lines in nude mice (Wang et al., 2000). Together, these observations led to consider H-
H, human; R, rat; M, mouse; +, presence;    , decrease;  ,   increase
 may be involved in the malignant dissemination of some human cancers, and the E-FABP gene
is suggested to be a metastasis-inducing gene (Jing et al., 2000). Studies on rat mammary
epithelial cells (Rama 37 cells) demonstrated that E-FABP induces metastasis by up-regulating
the expression of the vascular endothelial growth factor gene, which is one of the most potent
stimulating factors for angiogenesis (Jing et al., 2001).
The presence of FABP has also been suggested to provide protection against high intracellular
FA concentrations and to prevent their toxic effects on membranes and cells (Veerkamp et al.,
1993). H-FABP was suggested to bind FA accumulating under pathophysiological circumstances
(Vork et al. 1993). H-FABP could also protect the heart by scavenging of free radicals (Samanta
et al., 1989) and by inhibition of a β-adrenergic response as observed in cultured neonatal rat
heart cells (Wallukat et al., 1991). The presence of FABP would enable a more rapid exchange of
FA among subcellular and intercellular sites, so as to counteract a local FA accumulation (Glatz
et al., 1993).  Up to now, no definitive conclusion could be drawn about the putative cytoprotective
effect of FABPs.
1.10. FABP as diagnostic marker for tissue damage
Because of their small size, high solubility, and tissue specificity, FABPs are supposed to be
good candidates as biochemical markers for tissue injury under experimental and pathological
conditions. The FABP type and its serum concentration may give information about the nature
and extent of tissue damage. Human H-FABP can be determined in extracellular fluids as plasma
and urine (Tanaka et al., 1991; Vork et al., 1991; Kleine et al., 1992; Ohkaru et al., 1995). FABP
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released after acute myocardial infarction is quantitatively recovered in plasma which makes
FABP a useful biochemical plasma marker for the estimation of infarct size in humans (Kleine et
al., 1992; Glatz et al., 1994; Haastrup et al., 2000). The diagnostic sensitivity was significantly
higher for H-FABP than for myoglobin (Glatz et al., 1998). In addition, the differences in contents
of myoglobin and FABP in heart and skeletal muscles and their simultaneous release upon
muscle injury allow the plasma ratio of myoglobin/FABP to be applied for discrimination of
myocardial from skeletal muscle injury (Van Nieuwenhoven et al., 1995). In contrast to these
data, results obtained by Ghani et al. (2000) indicate that H-FABP does not demonstrate the
sensitivity and specificity necessary to detect acute myocardial infarction significantly earlier
than do existing markers. Plasma concentrations of H-FABP are also markedly elevated in patients
with chronic renal failure (Gorski et al., 1997). Therefore, caution must be taken when using H-
FABP as a marker for early diagnosis of myocardial infarction, in case of renal insufficiency.
L-FABP was released from liver in various liver diseases (Maezawa et al. 1981). I-FABP is
released into the circulation in the acute phase of intestinal ischemia and is therefore a potential
biochemical marker to facilitate the early detection of mesenteric ischemia (Gollin et al., 1993;
Kanda et al., 1995; 1996; Liebermann et al., 1997, 1998). Studies on neonates suffering from
necrotizing enterocolitis indicated that the sensitivity of the I-FABP marker may be limited to late
stages of this disease. L-FABP seems to be a more sensitive marker, since it could be detected
already in stage I (Guthmann et al., 2001). Acute intestinal allograft rejection could be detected
earlier with I-FABP as serum marker compared to other markers (Marks et al., 1993; Morrissey
et al., 1996) although this was contradicted by others (Kaufman et al., 2001).
1.11. Aim and outline of this thesis
Although much is known about the three-dimensional structure of members of the FABP
family, their specific physiological functions remain obscure. A role in FA uptake and transfer
has been proposed, but also modulation of FA concentration and indirect regulation of various
cellular systems and processes (signal transduction, gene transcription) have been indicated.
FA binding characteristics and protein stability are important parameters in this respect. Several
studies have been performed on FA binding to different FABP types, but simultaneous studies
on all FABP types using the same procedure are scarce. In Chapter 2 we present the results of
an extensive study on ligand specificity and conformational stability of eight different human
FABP types. Additionally we investigated bile acid-binding characteristics of I-LBP, an FABP type
with typical structural properties which is thought to have a specific role in bile acid reabsorption
in the ileum.
H-FABP is the most abundant FABP type and is thought to be essential for proper functioning
of the heart and skeletal and smooth muscles. In the past, studies on H-FABP mutants have
shed light on the relationship between structure and function of this protein. We have extended
this work by using site-directed mutagenesis and recombinant expression to create a series of
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new H-FABP mutants. The substituted amino acids were chosen on the basis of their presumed
role in ligand binding and/or specificity and conformational stability (Chapter 3).
In Chapter 4, the three-dimensional solution structure of human B-FABP is presented.
Although B-FABP shows a strong homology with H-FABP (67%) and A-FABP (56%), their ligand
binding characteristics and functions may not be quite the same. High resolution NMR
spectroscopy was used as an analytical tool to investigate both structural and dynamic aspects
of B-FABP, for comparison with the elucidated structures other FABP types.
FA transport is thought to be one of the main functions of FABPs. In the study described in
Chapter 5 we applied liposomes and isolated rat heart or liver mitochondria to compare the
effect of membrane charge and of different FABP types and H-FABP mutants on intermembrane
FA transport. We used the mitochondrial FA oxidation rate as a measure of FA transfer.
Besides their role in FA transport, FABPs may be indirectly involved in various cellular processes
such as signal transduction, gene expression, cell growth and differentiation, and cytoprotection.
Direct evidence for such functions however is lacking. We tested the role of FABP in cell growth
by investigating the influence of different FABP types on protein synthesis in a cell-free system
(Chapter 6). Additionally the putative protective effect of FABPs against induced cytotoxicity was
tested in Madin Darby Canine Kidney cells, stably transfected with H-FABP, A-FABP or L-FABP
cDNA (Chapter 7).
Finally, Chapter 8 gives a survey and summary of the investigations described in this thesis.
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ABSTRACT
Fatty acid binding proteins (FABPs) are small cytosolic proteins with virtually identical backbone
structures that facilitate the solubility and intracellular transport of fatty acids. At least eight
different types of FABP occur, each with a specific tissue distribution and possibly with a distinct
function. To define the functional characteristics of all eight human FABPs, viz. heart (H), brain
(B), myelin (M), adipocyte (A), epidermal (E), intestinal (I), liver (L) and ileal lipid-binding protein (I-
LBP), we studied their ligand specificity, their conformational stability and their immunological
crossreactivity. Additionally, binding of bile acids to I-LBP was studied.
The FABP types showed differences in fatty acid binding affinity. Generally, the affinity for palmitic
acid was lower than for oleic and arachidonic acid. All FABP types, except E-FABP, I-FABP and I-
LBP interacted with 1-anilinonaphtalene-8-sulphonic acid (ANS). Only L-FABP, I-FABP and M-
FABP showed binding of 11-((5-dimethylaminonaphtalene-1-sulfonyl)amino)undecanoic acid
(DAUDA). I-LBP showed increasing binding of bile acids in the order taurine-conjugated > glycine-
conjugated > unconjugated bile acids. A hydroxylgroup of bile acids at position 7 decreased
and at position 12 increased the binding affinity to I-LBP. The fatty acid-binding affinity and the
conformation of FABP types were differentially affected in the presence of urea.
Our results demonstrate significant differences in ligand binding, conformational stability and
surface properties between different FABP types which may point to a specific function in certain
cells and tissues. The preference of I-LBP (but not L-FABP) for conjugated bile acids is in accordance
with a specific role in bile acid reabsorption in the ileum.
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INTRODUCTION
Fatty acid-binding proteins (FABPs) are members of a family of 14-15 kDa cytosolic proteins.
Nine different FABP types, named after the first tissue of isolation, have been identified up to
now [reviewed in 1,2]. Some types (L-FABP, H-FABP) occur in more than one tissue whereas
others (I-FABP, A-FABP, M-FABP, B-FABP) are limited to only one tissue. Some organs contain
more FABP types, located either in different cell types (brain, kidney, ovary, stomach), or in the
same cell (enterocyte). FABPs show 22-73% similarity of amino acid sequence and have a similar
clam shell-like structure, comprising of 10 antiparallel β-strands and 2 nearly parallel α-helices.
The conformation of the bound fatty acid differs among the different FABP types [3,4].
All members of the FABP family, except ileal lipid-binding protein (I-LBP), have a high affinity
for fatty acids. However, differences in ligand specificity have been observed. I-FABP and H-
FABP are specific binders of fatty acids, whereas L-FABP and I-LBP bind more bulky, hydrophobic
ligands as lysophospholipids, bile acids, eicosanoids, and some drugs [2,5-7]. L-FABP has a
unique stoichiometry since it can bind two fatty acids simultaneously [4].
Although the FABP structure has been studied extensively, the specific physiological functions
of FABPs are still unknown. A role in fatty acid uptake and transfer has been proposed, but also
modulation of fatty acid concentration and regulation of various cellular systems and processes
(signal transduction, gene transcription) have been indicated [1,2]. Fatty acid binding
characteristics and protein stability are important parameters in this respect. Several studies
have been performed on fatty acid binding to different FABP types [reviewed in 1,2]. However,
direct comparison of binding parameters is difficult due to different techniques used.
Simultaneous studies on all FABP types using the same procedure are scarce. Only Richieri et
al. [8] studied the fatty acid binding characteristics of four FABP types with the ADIFAB procedure,
and we reported some preliminary data for five FABP types [9].
Cholic acid and chenodeoxycholic acid are secreted by the liver into the bile as N-acyl
conjugates of glycine or taurine and are mainly reabsorbed in the terminal ileum. Bile acids
bind to I-LBP and L-FABP [10,11]. In L-FABP and I-LBP, the four residue gap in the region between
β-strands G and H may result in a wider opening which may enable the binding of bile acids
[12,13]. The greater flexibility of the backbone may allow a bile acid to enter the I-LBP binding
cavity [13]. The binding of some bile acids to I-LBP was investigated by NMR [10], titration
calorimetry [14] and gelfiltration [15], but quantitative and comparative data are lacking.
We performed comparative studies on ligand binding, conformational characteristics and
surface properties of eight human FABP types, to provide more insight in their specific localization
and possible functions. We describe the fatty acid-binding characteristics of H-FABP, L-FABP, I-
FABP, A-FABP, M-FABP, E-FABP, B-FABP and I-LBP. Additionally, interactions with the fluorescent
probes (11-((5-dimethylaminonaphtalene-1-sulfonyl)amino)undecanoic acid (DAUDA) and 1-
anilinonaphtalene-8-sulfonic acid (ANS) were studied. The bile acid binding to I-LBP was
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investigated for unconjugated and glyco- and tauroconjugated deoxycholic, chenodeoxycholic
and cholic acid by fluorescence. We studied the stability of the binding centre of each FABP type
on basis of its fatty acid binding activity in the presence of denaturant. Their conformational
stability was determined on basis of tryptophan fluorescence. Finally, surface properties of the
FABP types were examined by measuring their reactivity with antibodies raised against the
different types in rabbit.
MATERIALS AND METHODS
Materials
All human FABP preparations were obtained by recombinant cDNA technology as described
[9,16,17]. Human brain (B-)FABP cDNA in pBluescript was a kind gift of Dr. F. Shimizu (Otsuka GEN
Research Institute, Tokushima, Japan). B-FABP cDNA was cloned into the pET3d expression
vector via BamHI and NcoI restriction sites. Extraction from inclusion bodies and purification
were performed as described for H-FABP mutants [18], except that the anion exchange step
was omitted. Human I-LBP cDNA in the pET3d vector was kindly provided by Prof. J.C. Sacchettini
(Texas A&M University College Station, TX, USA). Expression and purification of human I-LBP
was performed as described for H-FABP [17]. Human epidermal (E-)FABP preparations were a
kind gift from Prof. F. Spener (University of Münster, Germany).
1-14C-labeled preparations of palmitic acid, oleic acid, arachidonic acid, and [1-14C]glycocholic
acid and [carboxyl-14C]chenodeoxycholic acid were obtained from Amersham Pharmacia Biotech;
unlabeled bile acids from Sigma (St. Louis, MO, USA); 1,8-ANS and DAUDA from Molecular
Probes, Leiden, The Netherlands.
All protein concentrations are given in µg/ml, based on the Lowry procedure with bovine
serum albumin as a standard. Standardization to molar concentrations was not applied, since
except for H-FABP and L-FABP correction factors are not known.
Binding assays
Prior to binding assays, FABP preparations were delipidated using the Lipidex procedure
[19]. Fatty acid-binding assays were performed at 37°C in 0.5 ml 10 mM Tris-HCl (pH 8.0), using
10 µg FABP and 0-3 µM 1-14C-labeled oleic acid, palmitic acid or arachidonic acid, respectively.
K
d
and B
max
values were determined by Scatchard analysis. At least three independent assays
were performed in triplicate.
Emission spectra and fluorescence enhancement of 1 µM DAUDA or ANS were measured in
1 ml 10 mM Tris-HCl (pH 8.0)/1% ethanol after addition of 90 µg FABP. Excitation wavelengths
used were 335 and 369 nm for DAUDA and ANS, respectively. Assays were carried out at 25°C
(3.0 nm slits) with a Shimadzu RF-5301 PC spectrofluorophotometer.
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Bile acid binding assay
Binding of nine different bile acids and bile acid conjugates, viz. (tauro- or glyco-)cholic acid,
(tauro- or glyco-)deoxycholic acid, and (tauro- or glyco-) chenodeoxycholic acid to I-LBP was
determined by fluorescence spectroscopy. Increasing concentrations (0-8 mM) of the different
bile acids were added stepwise to 15 µg I-LBP in 20 mM K
2
HPO
4
/0.05% NaN
3
, pH 8.0. Emission
spectra were recorded from 310-360 nm, at an excitation wavelength of 280 nm, with 3.0 nm
slits. Fluorescence intensity at maximal wavelength was plotted against the bile acid
concentration to obtain binding curves. Curve fitting was used to determine the bile acid
concentration giving half-maximal fluorescence.
Protein denaturation studies
In order to determine the stability of the fatty acid-binding center, fatty acid binding was
measured in the presence of various urea concentrations at 0.8 nmol [1-14C]oleic acid and 10 µg
protein in 400 µl 10 mM Tris/HCl, pH 8.0 using the Lipidex procedure. We used urea stock
solutions of 9.6 and 11.2 M (pre-warmed at 37 °C) to obtain urea concentrations of 0-7 M. The
mixture was prepared and incubated as described previously [20]. Curve fitting was used to
determine the concentration of urea giving half the initial binding activity (midpoint).
Equilibrium unfolding as a function of urea concentration was monitored by fluorescence
spectroscopy. The tryptophan fluorescence was measured by the shift of the maximum emission
wavelength at an excitation wavelength of 283 nm (1.5 nm slits). Emission spectra were recorded
from 300 to 400 nm. For L-FABP, tyrosine fluorescence was measured at an excitation wavelength
of 278 nm (3.0 nm slits), and emission spectra were recorded from 290 to 315 nm. Mixtures of
different urea concentrations, 10 mM Tris/HCl, pH 8.0 and 15 µg/ml protein were incubated for
15 min at 37°C prior to fluorescence measurements. All values were corrected for the fluorescence
of the same mixture of urea/Tris-HCl (pH 8.0) without protein. The emission wavelength yielding
maximum fluorescence was plotted against the urea concentration for each preparation to
visualize the unfolding profile. Curve fitting was used to determine [D]
50
, the concentration of
denaturant at the midpoint of the transition.
Cross-reactivity of anti-FABP antisera
Antisera against all FABP types were raised in rabbits as described previously [21]. Cross-
reactivities of FABP types with the antisera were determined in ELISA with 2 ng protein coated
per well (6 wells for each FABP type). Monoclonal peroxidase-conjugated goat-anti-rabbit IgG
(γ-chain specific) was used as a secondary antibody, and the reaction was visualized using
ortho-phenylene diamine. Antisera were applied at a concentration giving an extinction value
of 1.0-1.2 at 492 nm with its own FABP type. Cross-reactivity was defined as the reciprocal of the
serum dilution required to half maximal absorbance and expressed as percentage of the value
obtained with the specific antigen-anti-serum combination.
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RESULTS AND DISCUSSION
Binding assays
First we studied the binding for various fatty acids with the Lipidex assay. We observed
differences in fatty acid binding affinities between the various types of FABP. Generally, the
affinity for palmitic acid was lower than for oleic and arachidonic acid (Table 1).
Kd
 values  (in µM) were determined from Scatchard plots with 0-3 µM [1-14C] fatty acid and 10 µg protein by
the Lipidex procedure. Values are means ± SD of at least three independent experiments. I-LBP did not
show significant binding to any fatty acid used. Values for H-FABP, M-FABP, A-FABP, I-FABP and L-FABP are
derived from [9], and given for comparison.
B-FABP shows, like H-FABP, M-FABP and I-FABP, a higher affinity for both oleic acid and
palmitic acid than L-FABP and A-FABP. Arachidonic acid is bound with high affinity by B-FABP,
comparable to H-FABP, M-FABP and L-FABP, whereas I-FABP, A-FABP and E-FABP show higher
K
d
 values. Maximal binding (B
max
) values were generally 20-30 nmol/mg protein except for A-
FABP (10 nmol/mg). Binding data on some FABP types agree with previous results on human
and rat FABPs [9,16,21,22]. In a competition assay with ANS, Simpson et al. [23], found 2-3 fold
lower affinity of oleic and palmitic acid for murine E-FABP than for A-FABP. In contrast, we found
that human E-FABP binds these fatty acids and arachidonic acid with higher affinity than A-
FABP (Table 1). With the Lipidex procedure, human E-FABP was shown to bind stearic acid with
high affinity, but oleic acid and arachidonic acid with lower affinity [24]. Bovine E-FABP showed
high affinity for palmitic acid [25]. Our data are generally in agreement with these findings,
although our K
d
 value of E-FABP for oleic acid is about 2-fold lower. Murine B-FABP showed very
high affinity for docosahexaenoic acid but no affinity for palmitic acid [26]. In contrast, human
B-FABP shows high affinity for palmitic acid as well as for oleic and arachidonic acid (Table 1).
These data does not support the idea that specific binding properties of B-FABP are necessary
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for the realization of the characteristic fatty acid composition of brain tissue.
Although the Lipidex assay gives rise to higher dissociation constants than the acrylodated
intestinal fatty acid-binding protein (ADIFAB) procedure [8], due to possible disturbance of the
equilibrium after Lipidex addition, it is still a useful comparative method. Recently, Richieri et al.
[27] showed with the ADIFAB procedure that no FABP type revealed a high degree of selectivity
for a particular fatty acid. Affinities of all FABPs decrease with decreasing chain length and
increasing double bond number. Binding affinities varied with FABP type according to brain ≅
myelin ≅ heart > liver > intestine > adipocyte [27]. Our present data are generally in agreement
with these findings. Both the fatty acid-protein interaction and the aqueous solubility of fatty
acids appear to play a marked role in determining the fatty acid binding affinity [27]. In a recent
study [22] we showed that all FABP types except I-LBP increased FA transfer from immobilized
liposomes to mitochondria to a similar extent.
We were not able to detect any fatty acid binding to I-LBP using the Lipidex procedure. In
earlier studies, binding of oleate and palmitate to I-LBP was found by 13C NMR spectroscopy [10]
and titration calorimetry [14]. I-LBP was shown to bind oleate and palmitate in a 1:1 molar ratio
[10], but the affinities for these fatty acids were much lower with rat I-LBP than with rat L-FABP
[15]. Titration calorimetry revealed a K
d
 value of 36 µM for oleate [14].
DAUDA was used as a ligand to study L-FABP [16,28]. We previously showed that I-FABP also
binds this fluorescent ligand well, whereas H-FABP, M-FABP and A-FABP do not [9]. We now
report that neither B-FABP, E-FABP nor I-LBP have affinity for DAUDA (Table 2). Binding of DAUDA
to L-FABP and I-FABP caused a marked shift in the maximum fluorescence emission wavelength
from 533 to 505 and to 498 nm, respectively, and an increase in fluorescence intensity. A shift
and fluorescence enhancement were not or hardly observed for the other FABP types.
Remarkably, I-LBP did not bind DAUDA, although it closely resembles L-FABP on basis of its
structure and its binding of bile acids.
ANS is a commonly used probe employed to observe the character of different regions of
globular and membrane proteins. It has been shown to be a competitive inhibitor for binding of
fatty acids [23,29]. Like fatty acids, it binds in the internal cavity although in a different orientation
as shown for A-FABP [30]. Previously we observed ANS binding to human H-FABP, M-FABP, A-
FABP and L-FABP, but marginally to I-FABP [9]. B-FABP also binds ANS, whereas E-FABP and I-LBP
do not (Table 2). Maximal fluorescence with this probe was reached at wavelengths of 461 to
474 nm. ANS showed a K
d
 value of 16 µM to rat I-FABP and of 0.41 µM and 0.53 µM to murine A-
FABP and E-FABP, respectively [29,31,32]. In contrast to murine E-FABP [29], two human E-FABP
preparations we used did not bind ANS. We found however very low B
max
 values of these E-FABP
preparations with fatty acids (about 5 nmol/mg protein in contrast to 20 nmol/mg for the E-
FABP preparation used in the Lipidex assay).
Taken together, these data and previously reported results [27] indicate that the different
binding affinities of FABP types may reflect tissue-specific differences in fatty acid metabolism
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and function. The highly conserved affinities displayed by FABPs of the same type but different
species support such a relationship [27]. Differences in fatty acid affinity could influence the
intracellular free fatty acid levels. For example, the occurrence of FABP types with lower affinity
such as A-FABP and E-FABP could cause higher intracellular fatty acid levels resulting in fatty
acid export. In contrast, FABP types with high affinity like H-FABP and B-FABP might be able to
concentrate fatty acids from the serum into the cell. Interactions with (signalling) molecules as
peroxisomal proliferator-activated receptors may be dependent on FABP type and independent
of fatty acid binding [33].
10 µg of FABP was incubated with 1 µM ligand in 1 ml 10 mM Tris/HCl, pH 8.0/0.1 % ethanol. Fluorescence
is directly related to ligand binding and is linear up to 30 µg protein [9]. Fluorescence values (in arbitrary
units) at maximal emission wavelength were corrected for the values with only ligand at the corresponding
wavelength, and are shown as means ± SD for three independent experiments.
Bile acid binding
We compared the binding of nine different conjugated and non-conjugated bile acids to
human I-LBP, since their binding to L-FABP previously showed marked differences [7,11]. Other
FABP types were suggested not to bind bile acids. Previously, chenodeoxycholic acid binding to
porcine I-LBP was shown using 13C NMR spectroscopy [10,13]. Binding of glycocholate and
glycochenodeoxycholate to rat I-LBP was determined by titration calorimetry [14]. Since ANS
and DAUDA did not bind to I-LBP, displacement studies with bile acids as for L-FABP [7,11] were
impossible. We did not observe binding of chenodeoxycholic acid or glycocholic acid to I-LBP at
gel filtration with 14C-labeled bile acids. Therefore, we studied the effect of bile acids on tryptophan
fluorescence of I-LBP as a measure for binding. A comparable procedure was used to establish
binding affinities of retinol and related compounds to retinol-binding protein [34]. H-FABP is
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known not to bind bile acids. Consistently, this FABP type did not show a change in its intrinsic
fluorescence intensity after addition of various concentrations of different bile acids (results not
shown). Figure 1 shows the binding of the main bile acids to I-LBP. Conjugation appears to
markedly increase the binding affinity which is somewhat higher for taurine-conjugated than
for glycine-conjugated bile acids. Consistent with our results, affinity of human I-LBP with
taurocholate, but not with chenodeoxycholate, was found by gel filtration [15]. Azotaurocholate
labeling of rat I-LBP was inhibited by bile acids in the order taurocholate >
taurochenodeoxycholate > chenodeoxycholate > cholate, whereas oleic acid had no effect
[35]. Preferential binding of conjugated bile acids to I-LBP seems to be important for reabsorption,
Binding of bile acids to ileal lipid-binding protein.
Bile acid binding was studied with 0-1 mM bile acid and 15 µg I-LBP in 1 ml 20 mM phosphate buffer, pH
8.0. Nine bile acids were used: cholic acids (A), deoxycholic acids (B) and chenodeoxycholic acids (C),
either unconjugated ( )or conjugated with taurine ( ) or glycine ( ). Fluorescence emission spectra
were recorded from 310-360 nm, at 280 nm excitation wavelength. Titration curves represent maximal
fluorescence intensities at each bile acid concentration and were determined by a curve fitting program.
Typical curves out of 2-3 experiments are shown.
since in the bowel mainly conjugated bile acids are present either or not modified by bacterial
enzymes [36].
Figure 1.
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.
Bile acid concentrations at half-maximal fluorescence were derived from titration curves, using 0-1 mM
bile acid and 15 µg I-LBP in 1 ml 20 mM phosphate buffer, pH 8.0 (Figure 1). Fluorescence emission spectra
were recorded from 310-360 nm, at 280 nm excitation wavelength. Values are means of two (range) or
three* (± SD) experiments.
The affinity for I-LBP is increasing in the order deoxycholic acid > cholic acid >
chenodeoxycholic acid (Table 3). If a hydroxyl group at the 12 position is absent, as is the case
with chenodeoxycholic acid and its derivatives, binding to I-LBP decreases markedly as is
indicated by the relatively low fluorescence intensity and the high concentration of
chenodeoxycholic acid necessary for half-maximal fluorescence intensity (Table 3). Titration
calorimetry experiments also showed better binding of glycocholic acid than of
glycochenodeoxycholic acid [14]. Absence of the hydroxyl group at the 7 position (in deoxycholic
acids and its conjugates) generally resulted in a lower concentration necessary for half-maximal
fluorescence, indicating stronger binding (Table 3). Data suggests an important role for the 7α-
and 12α-hydroxyl groups of bile acids in binding to I-LBP. The 7-α hydroxyl group decreases
affinity, and the 12-hydroxyl group apparently promotes binding, possibly by its proposed
interaction with Tyr-97 [37].
Two-dimensional NMR spectroscopy indicated a different orientation of chenodeoxycholate
compared to fatty acid in the binding cavity of porcine I-LBP [13]. The carboxyl group is located
near the proposed entry portal while the steroid ring moiety is penetrating deeper inside. A
recent study of the solution structure of I-LBP in complex with glycocholate shows mainly
hydrophobically driven interactions between the protein and the ligand [37].
Since L-FABP contains no tryptophan residues, it was not included in our fluorescence study
on bile acid binding. Cholate, chenodeoxycholate and deoxycholate bound with low affinity to
rat L-FABP according to a DAUDA displacement assay [7]. Lithocholate and taurolithocholate
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showed the highest binding affinity [7]. Displacement of ANS from L-FABP showed that both rat
and human L-FABP bind monohydroxy bile acids with higher affinity than trihydroxy bile acids
[11]. Both assays showed a lower affinity of bile acids to L-FABP after conjugation [7,11] in contrast
to I-LBP (Table 3). Many similarities and a high flexibility exist in the structure of L-FABP and I-LBP,
but several important differences may explain the distinctions in their interaction with the ligands
[36]. Differential binding of DAUDA (previous paragraph), conjugated and unconjugated bile
acids and fatty acids to L-FABP and I-LBP implies distinct roles for both proteins, which is supported
by their different distribution in the intestine [10]. The significance of these proteins in the
intracellular transport of bile acids remains to be investigated [38].
Effect of urea denaturation on the fatty acid binding centre and conformational stability
The sensitivity of the fatty acid-binding centre differs among FABP types under denaturating
conditions (Figure 2). Oleic acid binding to H-FABP and I-FABP is less sensitive to urea than for
other FABP types. The binding centre of E-FABP shows the lowest stability, which agrees with the
low B
max
 value of the E-FABP preparations.
Figure 2.
Effect of urea denaturation on the oleic acid binding activity of different FABP types.
Oleic acid binding was determined with the Lipidex procedure at 0.8 nmol oleic acid and 10 µg protein in
0.4 ml Tris/HCl, pH 8.0 in the presence of 0-7 M urea. Binding activity is given relative to the initial binding
activity of each FABP type. Experiments were carried out in triplicate. Typical curves (out of 3-4 experiments)
for each FABP type are represented.
The conformational stability of the different FABP types was evaluated by examination of the
fluorescence spectra of the proteins at different urea concentrations. Basically, the intrinsic
fluorescence of FABPs arises from two conserved Trp residues that are located outside the fatty
acid-binding center. Exceptions are I-LBP which contains only one Trp residue at position 49 and
L-FABP which does not contain Trp residues. We found marked differences in intrinsic fluorescence
and in conformational stability among the examined FABP types (Table 4).
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Oleic acid binding was studied with 0.8 nmol [1-14C] oleic acid and 10 µg protein in 400 µl 10 mM Tris-HCl
(pH 8.0) at 0-7 M urea. The midpoint is the concentration of urea giving 50% of the maximal binding.
Equilibrium unfolding was measured by the shift of maximum emission wavelength of tryptophan
fluorescence at an excitation wavelength of 283 nm (for L-FABP tyrosine fluorescence was measured at
307 nm) in 0-8 M urea for 15 µg protein in 1 ml 10 mM Tris/HCl, pH 8.0. [D]50 is the urea concentration at
which 50 % of the protein is unfolded. Values are means ± SD for at least three independent experiments.
Data are derived from curves, as given in Fig. 2 and 3, respectively. N.d., not determined (no fatty acid
binding to I-LBP, no tryptophan fluorescence of L-FABP).
Treatment of H-FABP with urea resulted in a red shift of the fluorescence emission maximum
from 331 to 351 nm, and the unfolding transition occurs in the range 5-7 M (Figure 3), which is in
agreement with previous data [18,20]. Data suggest a single cooperative transition between
folded and unfolded forms [20], but unfolding intermediates can only be excluded by NMR. The
transition profiles of A-FABP and I-FABP are comparable to H-FABP (Figure 3). However, the
transition curves of M-FABP and E-FABP and, to less extent, B-FABP and I-LBP are shifted to the
left. Their midpoints of transition are markedly lower than those for H-FABP, I-FABP and A-FABP
(Table 4). In spite of the presence of a disulfide bridge, E-FABP has the lowest stability, which is
in agreement with previous findings [24] and our other results. The stability of L-FABP was
measured by monitoring the increase in tyrosine fluorescence. Maximal fluorescence (307 nm)
indicating complete denaturation was obtained at 4 M urea. The midpoint was determined at
1.85 M urea.
Comparison of the midpoints shows that the binding affinity is more sensitive than the
conformation (Table 4). Only M-FABP and E-FABP show a similar sensitivity of binding and
conformation. H-FABP and all its mutant proteins also showed a higher sensitivity of their binding
centres to urea [18,20]. L-FABP shows a lower conformational stability, but this was determined
by a different method. The differences in conformational stability may reflect a variable turnover
in the cellular environment.
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Figure 3.
Shift in the tryptophan emission maximum of different FABP types.
The Trp fluorescence of proteins was measured at 15 µg in 1 ml 10 mM Tris/HCl, pH 8.0, and at an excitation
wavelength of 283 nm. Emission spectra were recorded from 300 to 400 nm. Results represent the means
± S.D. for at least three independent experiments.
Immunological cross-reactivity of anti-FABP antisera
Surface residues of several FABP types were suggested to play an important role in the
transfer rate and transfer mechanisms of anthroyloxy-labeled fatty acids (AOFA) to membranes
[39, 40]. Especially lysine residues on H-FABP and A-FABP appeared to influence the rate and
mechanism of AOFA transfer. Previously, the electrostatical and hydrophobic topology of the
surfaces of A-FABP, M-FABP, H-FABP, I-FABP and L-FABP were studied [41].
Immunological cross-reactivity may serve as another indicator for surface properties of the
human FABP types. We now compare eight FABP types instead of five [9] and applied 2 ng FABP
in each well instead of the previously used amount of 400 ng to increase accuracy. We used
polyclonal antibodies since they are directed against more epitopic regions than monoclonals.
Remarkably, all FABP types, except H-FABP and A-FABP showed only significant reactivity with
their own antiserum (Table 5).
There is some cross-reactivity of anti H-FABP antiserum with all the other types. H-FABP
showed a marked cross-reactivity with anti B-FABP, although B-FABP did not strongly cross-
react with anti H-FABP. Besides with its own antiserum, A-FABP strongly interacted with anti M-
FABP and anti B-FABP. These findings suggest that H-FABP shares epitopes with B-FABP, and
that A-FABP shares epitopes with M-FABP and B-FABP, which can be explained by their similarity
on the amino acid level. LiCata and Bernlohr [41] reported similarity of hydrophobic residues on
the surface of A-FABP, M-FABP and H-FABP, whereas I-FABP and L-FABP were unique. With
respect to electrostatic topology, all these FABP types were unique [41]. In agreement with these
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data we found cross-reactivity of A-FABP with anti M-FABP (but not vice versa). The surface
properties of B-FABP have not been examined yet. Thus, immunological data suggest
heterogeneity at the outer surface of FABP types, although some types share epitopes. These
findings are in agreement with the primary sequence of these parts of the proteins.
Cross-reactivities were determined in ELISA with 2 ng protein coated per well (6 wells for each FABP type).
A peroxidase-conjugated goat-anti-rabbit IgG (γ-chain specific) was used as secondary antibody. For
each FABP type, values were normalized to their own antiserum. Values (in %) are means ± SD for at least
three independent experiments.
ACKNOWLEDGEMENTS
The authors thank Ms. S. Huang and Dr. C. Lücke (Institut für Biophysikalische Chemie, J.W.Goethe
Universität, Frankfurt a. M., Germany) for information on the bile acid-binding assay and valuable
communication.
REFERENCES
1. Veerkamp, J.H. and Maatman, R.G.H.J. (1995) Cytoplasmic fatty acid-binding proteins: their structure and genes.
Prog. Lipid Res. 34, 17-52
2. Glatz, J.F.C. and Van der Vusse, G.J. (1996) Cellular fatty acid-binding proteins: their function and physiological
significance. Prog. Lipid Res. 35, 243-282
3. Banaszak, L., Winter, N., Xu, Z., Bernlohr, D.A., Cowan, S. and Jones, T.A. (1994) Lipid-binding proteins: a family
of fatty acid and retinoid transport proteins. Adv. Prot. Chem. 45, 89-151
4. Thompson, J., Winter, N., Terweij, D., Bratt, J. and Banaszak L. (1997) The crystal structure of the liver fatty acid-
                                  Characteristics of FABPs
67
binding protein, J. Biol. Chem. 272 , 7140-7150
5. Veerkamp, J.H., Van Kuppevelt, T.H.M.S.M., Maatman, R.G.H.J. and Prinsen, C.F.M. (1993) Structural and
functional aspects of cytosolic fatty acid-binding proteins. Prostaglandins Leukot. Essent. Fatty Acids 49,  887-906
6. Rolf, B., Oudenampsen-Krüger, E., Börchers, T., Færgeman, N.J., Knudsen, J., Lezius, A. and Spener, F. (1995)
Analysis of the ligand binding properties of recombinant bovine liver-type fatty acid binding protein. Biochim. Biophys.
Acta 1259,  245-253
7. Thumser, A.E.A. and Wilton, D.C. (1996) The binding of cholesterol and bile salts to recombinant rat liver fatty acid-
binding protein. Biochem. J. 320, 729-733
8. Richieri, G.V., Ogata, R.T. and Kleinfeld, A.M. (1994) Equilibrium constants for the binding of fatty acids with fatty
acid-binding proteins from adipocyte, intestine, heart, and liver measured with the fluorescent probe ADIFAB, J. Biol.
Chem. 269, 23918-23930
9. Veerkamp, J.H., Van Moerkerk, H.T.B., Prinsen, C.F.M. and Van Kuppevelt, T.H. (1999) Structural and functional
studies on different human FABP types. Mol. Cell. Biochem. 192, 137-142
10. Sacchettini, J.C., Hauft, S.M., Van Camp, S.L., Cistola, D.P. and Gordon, J.I. (1990) Developmental and struc-
tural studies of an intracellular lipid binding protein expressed in the ileal epithelium. J. Biol. Chem. 265, 19199-19207
11. Takikawa, H. and Kaplowitz, N. (1986) Binding of bile acids, oleic acid and organic anions by rat and human
hepatic Z protein. Arch. Biochem. Biophys. 251, 385-392
12. Gantz, I., Nothwehr, S.F., Lucey, M., Sacchettini, J.C., Delvalle, J., Banaszak, L.J., Naud, M., Gordon, J.I. and
Yamada, T. (1989) Gastrotropin: not an enterooxyntin but a member of a family of cytoplasmic hydrophobic ligand
binding proteins. J. Biol. Chem. 264, 20248-20254
13. Lücke, C., Zhang, F., Rüterjans, H., Hamilton, J.A. and Sacchettini, J.C. (1996) Flexibility is a likely determinant of
binding specificity in the case of ileal lipid binding protein. Structure 4, 785-800
14. Miller, K.R. and Cistola, D.P. (1993) Titration calorimetry as a binding assay for lipid-binding proteins. Mol. Cell.
Biochem. 123, 29-37
15. Fujita, M., Fujii, H., Kanda, T., Sato, E., Hatakeyama, K. and Ono, T. (1995) Molecular cloning, expression, and
characterization of a human intestinal 15-kDa protein. Eur. J. Biochem. 233, 406-413
16. Maatman, R.G.H.J., Van Moerkerk, H.T.B., Nooren, I.M.A., Van Zoelen, E.J.J. and Veerkamp, J.H. (1994)
Expression of human liver fatty acid-binding protein in Escherichia coli and comparative analysis of its binding charac-
teristics with muscle fatty acid-binding protein. Biochim. Biophys. Acta 1214, 1-10
17. Peeters, R.A., Ena, J.M. and Veerkamp J.H. (1991) Expression and characterization of the fatty acid-binding
protein from human muscle in Escherichia coli. Biochem. J. 278, 361-363
18. Zimmerman, A.W., Rademacher, M., Rüterjans, H., Lücke, C. and Veerkamp, J.H. (1999) Functional and confor-
mational characterization of new mutants of heart fatty acid-binding protein. Biochem. J. 344, 495-501
19. Glatz, J.F.C. and Veerkamp, J.H. (1983) A radiochemical procedure for the assay of fatty acid binding by proteins.
Anal. Biochem. 132, 89-95
20. Prinsen, C.F.M. and Veerkamp, J.H. (1996) Fatty acid binding and conformational stability of mutants of human
muscle fatty acid-binding protein. Biochem. J. 314, 253-260
21. Paulussen, R.J.A., Van Moerkerk, H.T.B. and Veerkamp, J.H. (1990) Immunochemical quantitation of fatty acid-
binding proteins. Tissue distribution of liver and heart FABP types in human and porcine tissues. Int. J. Biochem. 22,
393-398
22. Veerkamp, J.H., Van Moerkerk, H.T.B. and Zimmerman, A.W. (2000) Effect of fatty acid-binding proteins on
intermembrane fatty acid transport. Studies on different types and mutant proteins. Eur. J. Biochem. 267, 5959-5966
Chapter 2
68
23. Simpson, M.A., LiCata, V.J., Ribarik Coe, N. and Bernlohr D.A. (1999) Biochemical and biophysical analysis of
the intracellular lipid binding proteins of adipocytes. Mol. Cell. Biochem. 192, 33-40
24. Hohoff, C., Börchers, T., Rüstow, B., Spener, F. and Van Tilbeurgh, H. (1999) Expression, purification, and crystal
structure determination of recombinant human epidermal-type fatty acid binding protein. Biochemistry 38, 12229-
12239
25. Kingma, P., Bok, D. and Ong, D.E. (1998) Bovine epidermal fatty acid-binding protein: determination of ligand
specificity and cellular localization in retina and testis. Biochemistry 37, 3250-3257
26. Xu, L.Z., Sanchez, R., Sali, A. and Heintz, N. (1996) Ligand binding properties of brain lipid-binding protein. J.
Biol. Chem. 271, 24711-24719
27. Richieri, G.V., Ogata, R.T., Zimmerman, A.W., Veerkamp, J.H. and Kleinfeld, A.M. (2000) Fatty acid binding
proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 39, 7197-7204
28. Wilkinson, T.C.I. and Wilton, D.C. (1986) Studies on fatty acid-binding proteins. The detection and quantification of
the protein from rat liver by using a fluorescent fatty acid analogue. Biochem. J. 238, 419-424
29. Kane, C.D. and Bernlohr, D.A. (1996) A simple assay for intracellular lipid-binding proteins using displacement of
1-anilinonaphtalene 8-sulfonic acid. Anal. Biochem. 233, 197-204
30. Ory, J.J. and Banaszak, L.J. (1999) Studies of the ligand binding reaction of adipocyte lipid binding protein using
the fluorescent probe 1,8-anilinonaphtalene-8-sulfonate. Biophys. J. 77, 1107-1116
31. Kirk, W.R., Kurian, E. and Prendergast, F.G. (1996) Characterization of the sources of protein-ligand affinity: 1-
sulfonato-8-(1’)anilinonaphtalene binding to intestinal fatty acid-binding protein. Biophys. J. 70, 69-83
32. Arighi, C.N., Rossi, J.P.F.C. and Delfino, J.M. (1998) Temperature-induced conformational transition of intestinal
fatty acid binding protein enhancing ligand binding: a functional, spectroscopic, and molecular modeling study. Bio-
chemistry 37, 16802-16814
33. Wolfrum, C., Borrmann, C.M., Börchers, T. and Spener, F. (2001) Fatty acids and hypolipidemic drugs regulate
peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding
protein: A signaling path to the nucleus. Proc. Natl. Acad. Sci. USA 98, 2323-2328
34. Cogan, U., Kopelman, M., Mokady, S. and Shinitzky, M. (1976) Binding affinities of retinol and related compounds
to retinol binding proteins. Eur. J. Biochem. 65, 71-78
35. Gong, Y-Z., Everett, E.T., Schwartz, D.A., Norris, J.S. and Wilson, F.A. (1994) Molecular cloning, tissue distribu-
tion, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. Proc. Natl. Acad. Sci. USA 91,  4741-
4745
36. Hay, D.W. and Carey, M.C. (1990) Chemical species of lipids in bile. Hepatology 12, 6S-16S
37. Lücke, C., Zhang, F., Hamilton, J.A., Sacchettini, J.C. and Rüterjans, H. (2000) Solution structure of ileal lipid
binding protein in complex with glycocholate. Eur. J. Biochem. 267, 2929-2938
38. Agellon, L.B. and Torchia, E.C. (2000) Intracellular transport of bile acids, Biochim. Biophys. Acta 1486, 198-209
39. Storch, J., Herr, F.M., Hsu, K-T., Kim, H.K., Liou, H.L. and Smith, E.R. (1996) The role of membranes and
intracellular binding proteins in cytoplasmic transport of hydrophobic molecules: fatty acid-binding proteins. Comp.
Biochem. Physiol. 115B, 333-339
40. Hsu, K-T. and Storch, J. (1996) Fatty acid transfer from liver and intestinal fatty acid-binding proteins to membranes
occurs by different mechanisms. J. Biol. Chem. 271, 13317-13323
41. LiCata, V.J. and Bernlohr, D.A. (1998) Surface properties of adipocyte lipid-binding protein: response to lipid
binding, and comparison with homologous proteins. Proteins: Structure, Function and Genetics 33,  577-589
                              Mutants of heart-type FABP
69
Functional and conformational
characterization of new mutants of heart fatty
acid-binding protein

Aukje W. Zimmerman
Martin Rademacher
Heinz Rüterjans
Christian Lücke
Jacques H. Veerkamp
Biochem. J. 1999, 344: 495-501
Chapter 3
70
ABSTRACT
In this study we investigated the possible involvement of several amino acids (not located in the
ligand-binding centre) in fatty acid-binding and conformational stability of heart fatty acid-binding
protein (H-FABP). We prepared recombinant human H-FABP proteins with mutations in the
hydrophobic patch (Phe-4, Trp-8 and Phe-64), portal region (Phe-16), hinge region (Leu-66, Gly-
67), second portal region (Glu-72) and at the protein surface (Lys-21), respectively. Oleic acid-
binding affinity and conformational stability of human H-FABP are significantly decreased or
completely lost by mutation of Trp-8 or Phe-16. NMR spectra confirmed that these residues are
important for the stability of the protein fold. Substitution of Phe-4 or Phe-64 resulted in less
stability, but oleic acid-binding affinity was not affected. Mutation of Lys-21 had no effect on
both structural integrity and fatty acid-binding affinity. Replacement of Leu-66 or Gly-67 did not
affect fatty acid-binding but protein stability was reduced. Finally, mutation of Glu-72 to Ser
caused no change of affinity, but NMR spectra and urea denaturation curves showed an
extremely poor stability of this mutant. In conclusion, no relationship was observed between
fatty acid-binding affinity and conformational stability.
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INTRODUCTION
Fatty acid-binding proteins (FABPs) are members of a family of conserved intracellular lipid-
binding proteins with low-molecular mass (14-15 kDa) [1,2]. Nine different FABP types have been
identified up to now: heart, liver, adipose, myelin, intestinal, epidermal, brain, ileal and testicular.
All FABPs are cytosolic and display sequence similarity of between 28 and 70%. Crystallography
and/or NMR studies revealed the tertiary structure of myelin (M-FABP), intestinal (I-FABP),
adipocyte (A-FABP), heart (H-FABP) and liver  (L-FABP) types [2,3]. Their structural features are
similar and the proteins are composed of 10 antiparallel β-strands forming a β-barrel, and of
two nearly parallel α-helices which close the barrel on one side.
Human H-FABP is expressed in skeletal and cardiac muscle, kidney, lung, testis and brain
[1]. The fatty acid has a U-shaped conformation in the binding cavity [4]. The carboxylate group
of the fatty acid forms hydrogen bonds in the interior with the side-chains of Tyr-128 and Arg-
126, and via one ordered water molecule also to Arg-106 and Thr-40 [5]. Previously we showed
that mutation of Arg-106 and Arg-126 resulted in a dramatically decreased fatty acid-binding
activity and reduced conformational stability [6].  The involvement of Thr-40 in the hydrogen-
bonding network did not appear to be essential, since its mutation to Val or Gln did not change
fatty acid binding [6].
Several amino acid residues are thought to play an important role in the maintenance of the
FABP structure. A conserved hydrophobic patch of amino acid residues Phe-4, Trp-8 and Phe-
64 is located near the bottom of the gap between the βD and βE strands and may be related to
protein stability. For Trp-8, a role in folding was already suggested, since mutation of Trp-8 to
Phe or Tyr in A-FABP resulted in an insoluble protein [2].
The fatty acid is thought to enter the cavity of the protein via a portal in its surface, while
interior solvent is released through a secondary opening [4]. NMR-studies on apo and holo rat
I-FABP showed that the portal region is dynamic, exhibiting an order-disorder equilibrium which
shifts to the ordered state upon fatty acid-binding and to the disordered state upon fatty acid-
release [7]. Phe-16 and Phe-57 are located near the portal region and make Van der Waals
contacts with the bound ligand. The side chain of Phe-57 possibly limits access to the opening
in the protein surface [4], maybe by influencing the order-disorder equilibrium as in I-FABP [7].
Mutation of Phe-57 in H-FABP however did not affect fatty acid-binding [6]. Phe-16 may be a key
determinant of ligand specificity and affinity of H-FABP [5] and seems to be essential since it
shows a low tolerance for substitution [6].
Lys-21 is located at the protein surface in α-helix I and seems to be important for interaction
with negatively charged membranes since both acetylation and replacement by isoleucine
resulted in a slower transfer of anthroyloxy-labeled fatty acids by H-FABP to phospholipid vesicles
[8]. The charged face of α-helix I may participate in membrane interactions as was shown by
experiments with a helix-less variant of I-FABP [9,10]
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Studies on molecular dynamics of the cellular retinol-binding protein (CRBP) showed that
mutation of Gly-67 resulted in loss of retinol-binding [11]. In I-FABP, the turn between β-strands
D and E consisting of amino acid residues 63-66 is possibly involved in flexibility of the protein
upon ligand binding and is therefore called hinge region [12]. In H-FABP a similar hinge region
consisting of Leu-66, Gly-67 and Val-68 is present.
A small gap, or secondary portal, is present between β-strands βD and βE. The side chain of
the ionizable residue Glu-72 extends into this gap and is thought to form an electrostatic network
that also involves His-93 and Arg-106 and three ordered water molecules, which enables water
efflux [4]. In I-FABP, a small opening into the interior cavity could be observed, but from NMR
data it remains unclear whether this opening is significant or not [7].
In this study we used site-directed mutagenesis to construct mutant proteins of human H-
FABP to investigate the importance of abovementioned amino acid residues outside the bin-
ding centre for the binding of fatty acid and the conformational stability. Structural differences
were analysed by fluorescence and NMR spectroscopy.
EXPERIMENTAL
Materials
Oligonucleotide primers were obtained from Eurogentec, Seraing, Belgium, and Biolegio,
Malden, The Netherlands; in vitro mutagenesis kit Muta-gene M13 was from Bio-Rad
Laboratories, Richmond, CA, U.S.A.; Taq DNA polymerase was from Promega, Madison, WI,
U.S.A.; ABI PRISMTM Dye Terminator Cycle Sequencing Ready Reaction Kit was from Perkin Elmer,
Norwalk,  CT, U.S.A.; TA-cloning Kit was from Invitrogen, Leek, The Netherlands; pET-3d expression
vector was from Novagen, Madison, WI, U.S.A.; isopropyl β-D-thiogalactopyranoside (IPTG),
restriction endonucleases and urea were from Life Technologies Inc., Gaithersburg, MD, U.S.A.;
ampicillin and tetracycline were from Sigma, St. Louis, MO, U.S.A.; DEAE-Sepharose, Sephadex
G-50 fine and low-molecular mass marker proteins were from Pharmacia Biotechnologies,
Uppsala, Sweden; [1-14C]oleic acid (204 GBq/mmol) was from Amersham Pharmacia Biotech,
Roosendaal, The Netherlands.; Lipidex 1000 was from Canberra Packard, Groningen, The
Netherlands. Recombinant human H-FABP was prepared as described [13]. All other reagents
were of analytical grade.
Oligonucleotide-directed in vitro mutagenesis
To prepare site-directed mutations in the cDNA coding for human H-FABP, the Muta-Gene
M13 in vitro mutagenesis kit instructions were basically followed. The method used is based on
the uracil selection technique described by Kunkel [14].  The cDNA encoding H-FABP [15] was
cloned into M13mp18 and transformed into dut,ung Escherichia coli strain CJ236. Uracil-
containing single-stranded cDNA  of H-FABP was isolated and used in oligonucleotide-directed
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mutagenesis. The target amino acid residues for mutation and the oligonucleotides which were
used as mutagenic primers are shown in Table 1. After second strand synthesis and ligation,
constructs were transformed into wild-type strain MV1190 and single stranded mutant cDNA
was isolated. Identification of the mutant cDNAs was done by sequence analysis on the  ABI
PRISM 310 Genetic Analyzer, using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction
Kit.
The nucleotide positions which were targets for mutagenesis are in upper case. The nucleotides in square
brackets were mixed in equal amounts during synthesis of the oligonucleotides. N indicates each of the
four nucleotides.
Cloning and sequencing of mutant FABP cDNA
Primers derived from the human H-FABP cDNA sequence were designed so as to amplify
the mutated coding region: forward primer,  5’-GCCTAGCCCAGCATCACCATGGTGGAC-3’; reverse
primer,  5’-ATCACCAGTGGATCCAGGTCATGCCTC-3’. These primers contain recognition sites for
the restriction enzymes NcoI and BamHI, respectively, which facilitate directional cloning in pET-
3d (formerly pET-8c). The PCR reactions were performed as described before [6]. PCR products
were ligated into the pCR2.1 vector by TA cloning. In this procedure a single deoxyadenosine
was added to the 3’ ends of the PCR product by Taq polymerase, allowing ligation in the linearized
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pCR2.1 vector witch has single 3’ deoxythymidine residues. The nucleotide sequences of the
mutant coding regions were verified, using the automatic ABI PRISM 310 Genetic Analyzer, the
ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit and 3.5 pmol M13 -40 primer.
Expression and purification of mutant H-FABPs
The sequenced mutant H-FABP cDNAs were isolated from low melting-point agarose after
digestion with NcoI and BamHI and ligated with pET-3d vector previously digested with the
same enzymes. The plasmids pET-3d/mutant H-FABP were used to transform the Escherichia
coli B strain BL21(DE3). A 5 ml overnight culture of cells expressing the mutant FABP was used to
inoculate 1.5 l of 2YT medium (1.5% casein hydrolysate/1% yeast extract/0.5% NaCl; all w/v).
Large cultures were performed in 4 flasks containing 1.5 l of medium. Bacteria were grown with
shaking at 37 °C. At an A
550
 of 0.5-1.0, protein expression was induced with 0.5 mM IPTG and
incubation was continued overnight at 37 °C.
Mutants that were expressed in inclusion bodies were solubilized by treatment with 5.6 M
urea, followed by dialysis against 10 mM Tris/HCl pH 8.0, with or without 1-2 M urea. Mutant
F64S was soluble after culturing at 25 °C. Purification of the mutant FABPs was essentially as for
the wild-type H-FABP [13], except that ammonium sulphate precipitation for soluble mutant
proteins was carried out at 50% saturation instead of 70%. Mutant preparations solubilized
from inclusion bodies by urea and dialysis were not subjected to ammonium sulphate
precipitation, but only purified by anion exchange and gel filtration chromatography.
Proteins were > 95% pure on the basis of SDS-PAGE and Coomassie Brilliant Blue staining.
All proteins were concentrated to 1-3 mg/ml in 50 mM Tris/HCl pH 8.0 and kept at -80 °C until
use.
Protein denaturation studies
Equilibrium unfolding as a function of urea concentration was monitored by fluorescence
spectroscopy. The tryptophan fluorescence was measured by the shift of the maximum emission
wavelength at an excitation wavelength of 283 nm (1.5 nm slits) using a Shimadzu RF-5301 PC
spectrofluorophotometer. Mixtures of different urea concentrations, 10 mM Tris/HCl, pH 8.0,
and 1 µM protein were incubated for 15 min at 37°C before measuring the fluorescence. All
values were corrected for the same mixture of urea/10 mM Tris/HCl, pH 8.0, without protein.
The emission wavelength yielding maximum fluorescence was plotted against urea
concentration for each sample to reveal the unfolding profile. Curve fitting by a computer program
was used to determine [D]
50
, the concentration of denaturant at the midpoint of the transition.
NMR experiments and analysis
For all NMR measurements, 1-4 mM samples of H-FABP wild-type or mutants were prepared
in 20 mM K
2
HPO
4
, 0.05% (w/v) NaN
3
 and 90% H
2
0/10% D
2
O. Some mutants had to be kept in 1
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M urea (L66G and E72S) or 2 M urea (F4S/W8E and W8E). The NMR data were collected on a
DMX600 spectrometer using a 5mm inverse triple-resonance probe (Bruker Instruments).
The 1D 1H-NMR experiments were performed with quadrature detection and selective
presaturation to suppress the water signal. The free induction decay was acquired with 16K
data points and a spectral width of 8389 Hz. Prior to Fourier transformation, the free induction
decay was zero-filled once and multiplied by a phase-shifted sine-bell function.
The TOCSY and NOESY spectra were recorded in a phase-sensitive mode with time-
proportional phase incrementation of the initial pulse. Quadrature detection was used in both
dimensions with the carrier placed in the centre of the spectrum on the water resonance. The
TOCSY and NOESY data sets were acquired with 2048 and 512 data points in t
2
 and t
1
 respectively.
The spectral width was set to 8389 Hz. The mixing time used for the NOESY spectra was 200
ms; the spinlock times for the clean TOCSY spectra (MLEV-17) were set to either 3 ms, to obtain
COSY-type information with less spectral overlap, or 80 ms. The water signal was suppressed
by selective presaturation during the relaxation delay. In the NOESY experiments, water saturation
was also applied during part of the mixing time. Prior to Fourier transformation, the free induction
decays were zero-filled in both dimensions to obtain a 2048 x 2048 real data matrix and
multiplied by phase-shifted sine bell and squared sine bell functions in t
1
 and t
2
, respectively. In
all 1D and 2D spectra, baseline distortions were eliminated by applying a baseline correction
with fifth-order polynomial in ω
2
. The chemical shift values were calibrated with respect to sodium
3-(trimethylsilyl)[2,2,3,3-2H
4
]propionate (Cambridge Isotope Laboratories) as external reference.
The processing and analysis of all NMR data was performed on an Indy work station (Silicon
Graphics) using the XWIN-NMR 1.3 and Aurelia 2.5.9 software packages (Bruker Instruments).
Other procedures
Standard procedures were used for SDS/PAGE. Protein concentrations were determined by
the procedure of Lowry et al. [16] with BSA as a standard. A comparative assay of the fatty acid-
binding activity of H-FABP and the mutants was performed with 1 µM protein at 2 µM [1-14C]oleic
acid according to the Lipidex procedure. The dissociation constant (K
d
) for the binding of [1-
14C]oleic acid to H-FABP and the mutant proteins was determined at 0.1-2.0 µM fatty acid and
0.5 µM protein [6]. Protein samples were first delipidated with Lipidex 1000 at 37 °C [17]. The
binding parameters K
d
 and maximal binding constant (B
max
) were obtained from Scatchard plot
analysis. At least three independent assays were performed in triplicate.
RESULTS
Mutagenesis and expression of mutant FABPs in E. coli
By using the oligonucleotides described in Table 1, we prepared 11 different cDNAs encoding
mutant H-FABPs. Two oligonucleotides contained ‘wobbles’ on the target position of mutation.
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Mutant proteins F4S, F4E, W8E, F4S/W8E, F16S, F64S, L66G and E72S were not expressed as
soluble proteins in E. coli, but instead accumulated in inclusion bodies. After culturing at 25 °C,
F64S was expressed as a soluble protein. The other insoluble mutants were isolated from
inclusion bodies by urea extraction and renatured by dialysis. For the soluble mutants K21I and
G67S the same purification scheme was used as for the wild-type protein [13]. Mutants F4E,
W8E, F4S/W8E, F16S, L66G and E72S were less soluble than wild-type H-FABP and were therefore
stored in 1-2 M urea. These mutants also  precipitated partially during purification, indicating
less conformational stability. Yields of mutant proteins varied from 5 to 50 mg/litre of culture.
Fatty acid-binding activity of H-FABP mutants
First, relative binding activities were measured with excess oleic acid over protein, and
expressed relative to the binding activity of wild-type H-FABP (Table 2). All mutants except F16S
showed a marked fatty acid-binding activity. Subsequently the dissociation constant (K
d
) and
the maximal binding (B
max
) were determined to obtain more accurate parameters of binding.
The K
d
 value reflects the affinity. The maximal binding is dependent on the fatty acid/protein
molar ratio and the number of active protein molecules. The latter is dependent on the stability
of the protein. The maximal binding for human H-FABP is always about 20-25 nmol/mg protein,
which reflects a stoichiometry of 0.5-0.6 mol fatty acid per mol of protein [13]. This stoichiometry
less than unity was also consistently found for rat and bovine H-FABP preparations by others
[18].
Relative binding activities were measured at 2 µM [1-14C]oleic acid and 1 µM protein by the Lipidex procedure.
Kd and Bmax values were derived from three Scatchard plots of binding assays at 0.1-2 µM oleic acid and
0.5 µM protein. Values are the means ± SD of at least three independent assays.
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Replacement of Phe-4 by polar Ser or negatively charged Glu did not affect the K
d  
value for
oleic acid. Introduction of Glu at position Trp-8 strongly affected this parameter. Double mutation
of Phe-4 to Ser and Trp-8 to Glu and mutation of Phe-16 to Ser or Glu also resulted in a strongly
decreased oleic acid-binding affinity. Substitution of Ile for Lys-21 or Gly for Leu-66 did not change
the K
d
 value, but led to an increased relative oleic acid binding by a higher B
max
 value. Replacement
of Phe-64 or Gly-67 by Ser did not affect the K
d
 value for oleic acid. Mutation of Glu-72 to serine
did not significantly affect the K
d
 value, but resulted in a strongly decreased relative oleic acid
binding by decrease of Bmax. The different Bmax values reflect the stability of the various mutants,
also inferred from the experiments on Trp fluorescence, which are described below.
Effect of urea denaturation on tryptophan fluorescence
The stability of the structures of H-FABP and the H-FABP mutants was evaluated by
examination of the fluorescence spectra of the proteins at different urea concentrations (Table
3). The intrinsic fluorescence of H-FABP may arise from two Trp residues, Trp-8 and Trp-97,
which are not involved in the fatty acid-binding centre. Trp-8 lies internally on strand βA while
Trp-97 is on strand βG [5]. Similarly, I-FABP contains two Trp residues at positions 6 and 82, but
approx. 80 % of the intrinsic fluorescence arises from Trp-82 [19]. We found that mutants F4S/
W8E and W8E showed no significant difference in fluorescence at 333 nm, compared with wild-
type H-FABP. Mutants F4S, F16S, F16E and G67S show a lower fluorescence at 333 nm compared
with wild-type H-FABP, whereas mutants F4E, K21I, F64S, L66G and E72S show wild-type or
higher values (Table 3).
Stability was measured by the shift of maximum emission wavelength of tryptophan fluorescence at an
excitation wavelength of 283 nm in 0-8 M urea for 1 µM protein. Tryptophan fluorescence at 333 nm is
expressed in arbitrary units. [D50] is the urea concentration at which 50% of the protein is unfolded. Values
are the means ± SD of at least three independent assays.
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Treatment of H-FABP with urea results in a red-shift of the fluorescence emission maximum
from 331 nm to 351 nm, and the unfolding transition occurs in the range 5-7 M urea [6]. The
transition profiles for H-FABP and the H-FABP mutants are shown in Figure 1. There is a large
variation among the mutants in their initial wavelengths of maximum fluorescence and their
midpoints of transition (Table 3). The curves for mutants F4S, F16E, K21I, F64S and L66G show
similar initial wavelengths as for wild-type H-FABP, but the lower midpoints indicate a lower
conformational stability. The curves for mutants F4E, W8E, F4S/W8E, F16S and E72S start at a
higher emission wavelength and their midpoints of transition are much lower than for the wild-
type, indicating that these preparations are partially denatured and are very unstable. The
type.
Figure 1.
Shift in the tryptophan emission maximum of wild-type and mutant H-FABPs on urea-induced
unfolding.
The tryptophan fluorescence of proteins was measured at 1 µM concentration in 10 mM Tris-HCl (pH 8.0)
and at an excitation wavelength of 283 nm. Emission spectra were recorded from 300 to 400 nm. Results
represent the means ± SD of at least three independent experiments.
curves and the midpoints of transition are in the same range for K21I and G67S as for the wild-
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Figure 2.
One-dimensional 1H-NMR spectra of human H-FABP wild-type and mutants.
All spectra were collected at 600MHz proton resonance frequency, at pH 7.0 and 25 °C. The water
resonance at 4.8 ppm has been excluded. The large proton resonance dispersion from 10.2 ppm to -0.4
ppm is evident in all spectra except for W8E and F4S/W8E, suggesting a conserved overall structural fold
in all cases except the Trp-8 mutants. The large and broad signal observed at 5.8 ppm in some of the
spectra represents urea. Spectra are representative for at least two experiments.
NMR analysis
In order to check the structural integrity of the H-FABP mutants, we have collected 1D- and
2D-NMR spectra. On the basis of the NMR proton resonance assignment of bovine H-FABP [20],
the complete 1H assignment of human H-FABP (89% sequence identity) was obtained at pH 5.5
and 37°C. Because of decreased sample stability of various mutants at low pH and high
temperature, the experimental conditions were eventually adjusted to pH 7.0 and 25°C for all
samples in order to ensure the comparability of the results.
The 1D NMR spectra (Figure 2) show that the resonance dispersion of the mutant spectra
from 10.2 ppm to –0.4 ppm is similar to the wild-type, except for the Trp-8 mutants W8E and
F4S/W8E. Thus, the overall protein structure has changed only in the latter two mutants
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dramatically. This effect, however, should not be due to the urea concentration (2 M), since wild-
type H-FABP in 2 M urea is correctly folded under identical conditions (Figure 2). All other mutants
appear to have conserved the mainly β-sheet structure, which is indicated by the high percentage
of amide protons between 9-10 ppm, as described previously for bovine H-FABP [21].
For a more detailed analysis of the structural changes, 2D NMR spectra were collected.
Because of the relatively high pH, not all spin-systems could be identified on the basis of their
amide proton resonances. However, the spectral data were sufficient to allow partial
assignments, which provided the basis of a secondary-structure analysis. In addition, the
mutation sites were confirmed for all mutants, except for E72S on account of the poor quality of
its spectra.
Certain mutant samples displayed rather low stability during 1-2 days of 2D NMR data
collection under the above mentioned experimental conditions, resulting in poor-quality spectra.
The worst cases are F16S and E72S, which showed marked loss of protein without any visible
precipitation. Consequently, the 2D spectra of these two mutants could merely provide a chemical
shift comparison of a limited number of proton resonances. The facts that the high resonance
dispersion was still present, and that the high- and low-field shifted spin systems were identical
with the wild-type, indicate that the overall fold typical for H-FABP has been conserved in both
F16S and E72S. Presumably a significant amount of these two proteins has been denatured,
though with only a fraction of the native protein left in solution. This is supported by the relatively
low intensity of the methyl proton resonances below 0.5 ppm relative to the bulk of methyl
proton resonances at 1.0-0.9 ppm.
The 2D spectra of the Trp-8 mutants W8E and F4S/W8E, on the other hand, suggest complete
denaturation. Even though some pronounced differences in the spectral patterns of both Trp-8
mutants were apparent, no further analysis of this data could be performed owing to the low
proton resonance dispersion.
Finally, marked precipitation was observed for F4E and little precipitation for F16E. Nevertheless,
the spectral quality of these two mutants was sufficient to perform the spectral analysis of the
secondary-structural elements in the same way as for all other stable mutants: interstrand
nuclear Overhauser effects, found throughout the β-sheet, indicate that the β-barrel type structure
was retained in these mutants. Secondly, strong d
NN
(i,i+1) as well as various d
αβ(i,i+3), dαN(i,i+3)
and d
NN
(i,i+2) connectivities observed in the α-helix regions, also suggested the conservation of
the helix-turn-helix element. Furthermore, additional confirmation of the proper fold was obtained
from a chemical shift comparison of the assigned resonances. However, in the case of the Phe-
16 mutants, the region of α-helix I is only poorly defined owing to missing proton resonances
around the mutation site.
The H-FABP mutants that displayed significant instability in the 2D NMR study are identical
with those which showed both higher emission wavelengths at 0 M urea and lower midpoints
of transition in the urea-induced unfolding. It can be concluded from  the 1D and 2D NMR
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experiments, that no significant changes in the overall fold of the H-FABP mutants investigated
in the present study have become evident, except for the two Trp-8 mutants.
DISCUSSION
Various studies indicated the importance of several amino acid residues outside the binding
centre of H-FABP for binding of fatty acids and maintenance of the conformational stability
[4,5,11,12]. In the present study we show that mutation of Trp-8 (either or not in combination with
mutation of Phe-4 to Ser) resulted in loss of oleic acid-binding and a very unstable conformation.
NMR data shows a dramatic loss of protein structure. The Trp-8 residue is highly conserved in
most members of the FABP family. Only L-FABP and ileal lipid-binding protein carry a Tyr residue
in this position. In all cases, however, the aromatic ring is part of a large hydrophobic cluster in
the interior of the protein cavity [22]. Thus the complete loss of the typical β-barrel structure in
both Trp-8 mutants could indicate an important role of this residue in the structural stability
and/or folding of H-FABP, as was previously suggested for A-FABP and CRBP II [2,23]. In agreement
with these findings, replacement of Trp-6 to Tyr in rat I-FABP reduced protein stability upon
denaturation [24]. The Phe residues at positions 4 and 64 of the hydrophobic patch however,
do not seem to play an important role in fatty acid-binding but are involved in the maintenance
of the conformational stability of H-FABP. Mutation of Phe-62 in rat I-FABP led to a slightly
decreased binding affinity for oleic acid [25,26]. The affinity of H-FABP mutant F64S for oleic acid
was only slightly lower.
The α-helical region of I-FABP is suggested to participate in the regulation of ligand affinity
[9]. Phe-17 is located in α-helix I and could undergo a structural change, which causes the
helical domain to shift to a conformation more favourable for ligand-binding [18]. In H-FABP,
Phe-16 is located in the portal region, within 4.5 Å of the acyl chain of the fatty acid [5]. Mutation
of Phe-16 to either Ser or Glu caused a loss or marked decrease of fatty acid-binding affinity and
a reduced stability. 1D and 2D NMR spectra however showed that the β-barrel structure of these
mutants was retained. These results confirm the role of Phe-16 in ligand affinity and binding,
whereas it is not critical for maintenance of the structural integrity of H-FABP.
The α-helical region is also suggested to be involved in transient interactions between FABP
and membranes [10]. In particular, Lys-21, located in α-helix I at the protein surface was shown
to be essential for interactions between A-FABP or H-FABP and negatively charged membranes
[8,27]. Mutation of Lys-21 in H-FABP had no effect on oleic acid-binding affinity, indicating that
fatty acid-binding is independent of this α-helical surface residue. Lys-21 appeared to be not
essential for folding of H-FABP. It was previously suggested that the loss of a hydrogen bond
between Lys-20 and Glu-120 contributed to the lower stability of the helix-less variant of I-FABP
[28]. The absence of this hydrogen bond in H-FABP which contains a Gly residue instead of Glu
acid at position 120 may explain our observation that Lys-21 is not involved in the structural
stability of H-FABP.
Chapter 3
82
Glu-72 forms part of the the edge of a secondary portal located in the gap between β-
strand D and E [4]. This region may act as a conduit for efflux of water molecules upon fatty acid
binding or release. Glu-72 is conserved throughout the complete FABP family and mutation of
Glu-72 to Ser in H-FABP resulted in dramatic loss of stability, but not of binding affinity, indicating
a crucial role for this residue in the conformation.
The turn between β-strands D and E is highly conserved within the FABP family. I-FABP mutants
that lack Leu-64 have a lower stability and a high rate of refolding [12]. Mutation of Leu-66 in H-
FABP resulted in less conformational stability, indicating that the role of this Leu residue may be
identical in I-FABP and H-FABP. Studies on molecular dynamics of CRBP showed that mutation
of the turn residue Gly-67 causes inhibition of a motion which has been implied as important for
retinol binding [11]. Mutation of Gly-65 to Val in I-FABP yielded a very unstable protein with a
lower fatty acid-binding affinity [29]. Replacing Gly-65 with Ala in I-FABP gave only a small loss
of stability and no effect on binding [12]. In contrast, Gly-67 in H-FABP does not appear to be
involved in fatty acid binding, nor in conformational stability. These data suggest a different role
for this flexible residue in H-FABP and other members of the FABP family.
A number of mutants was isolated from inclusion bodies and kept in urea to prevent
aggregation. This method does not seem to disturb the binding centre, since most of the inclusion
body-derived mutants still have wild-type fatty acid-binding affinity. Mutant proteins isolated
from inclusion bodies show a lower conformational stability, but NMR spectra showed that
these mutants generally retain the typical β-strand structure. Turn mutants of I-FABP in which
Gly was substituted by Val showed a correlation of expression in inclusion bodies and a lower
stability [29].
In the present study we showed that mutations in human H-FABP resulted in distinct
differences in oleic acid-binding and conformational stability. The results of the fluorescence
and NMR experiments were in good agreement. There was no clear relationship between fatty
acid-binding affinity and stability,  as was also reported earlier for A-FABP, I-FABP and H-FABP
[6,29,30]. Mutants K21I and G67S showed no significant change in fatty acid binding and stability.
F4S, F4E, F64S, L66G and E72S had a similar binding affinity as wild-type H-FABP, but their structural
integrity was reduced. Mutant proteins F16S, F16E, W8E and F4S/W8E showed a strong decrease
or complete loss of binding affinity and structural stability.
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ABSTRACT
Human brain-type fatty acid-binding protein (B-FABP) has been recombinantly expressed in
Escherichia coli both unlabelled and 15N-enriched for structure investigation in solution using
high-resolution NMR spectroscopy. The sequential assignments of the 1H and 15N resonances
were achieved by applying multidimensional homo- and heteronuclear NMR experiments. The
ensemble of the 20 final energy-minimized structures, representing human B-FABP in solution,
have been calculated based on a total of 2490 meaningful distance constraints. The overall B-
FABP structure exhibits the typical backbone conformation described for other members of the
FABP family, consisting of ten antiparallel β-strands (βA to βJ) that form two almost orthogonal
β-sheets, a helix-turn-helix motif that closes the β-barrel on one side, and a short N-terminal
helical loop. A comparison with the crystal structure of the same protein complexed with
docosahexaenoic acid (Balendiran et al.: J Biol Chem 275: 27045-27054, 2000) reveals only
minor differences in both secondary structure and overall topology. Moreover, the NMR data
indicate a close structural relationship between human B-FABP and heart-type FABP with respect
to fatty acid binding inside the protein cavity.
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INTRODUCTION
The brain fatty acid-binding protein (B-FABP) belongs to a family of highly conserved
intracellular lipid-binding proteins with low molecular mass (14-16 kDa). The main function of
fatty acid-binding proteins (FABPs) is the intracellular binding and transport of hydrophobic
ligands like fatty acids (FA). By modulating the FA concentration they may influence gene
expression, cellular growth, and the function of enzymes, membranes, ion channels and
receptors. Nine different FABP types have been identified up to now, named after the first tissue
of isolation [1, 2]. They display 28-70% sequence similarity and are expressed in a broad variety
of tissues. According to sequence and binding characteristics, the members of the FABP family
can be grouped into four subfamilies: (I) the cellular retinol- and retinoic acid-binding proteins
(CRBP and CRABP); (II) the ileal lipid-binding protein (ILBP; binds bile acids) and liver- (L-)FABP
(binds two FA); (III) intestinal- (I-)FABP (binds the FA in a linear conformation); and (IV) adipocyte-
(A-), brain- (B-), heart- (H-), epidermal- (E-) and myelin-type (M-)FABP, which bind the FA in a
highly bent or U-shaped conformation [2].
Three different FABP types, B-FABP, E-FABP and H-FABP, are present in the brain [3]. They
show a spatio-temporally differential expression during development and maturity [4]. B-FABP
is expressed at high levels in neuroepithelial precursor cells of the developing brain, and later
becomes restricted to radial cells and immature astrocytes [5, 6]. At the adult state, B-FABP
expression persists only in glial cells of the olfactory bulb. Since B-FABP is produced in large
amounts during neurogenesis and/or neuronal migration, it may play an important role during
central nervous system development [6]. Human fetal retina and brain as well as malignant
glioma also express B-FABP [7].
In contrast to other FABP types, murine B-FABP appears to display a higher affinity for long-
chain polyunsaturated fatty acids such as arachidonic acid and docosahexaenoic acid (DHA)
than for oleic acid [8]. Richieri and coworkers, on the other hand, reported a weaker affinity of
human B-FABP for polyunsaturated FA than for saturated and monounsaturated FA [9].
Considering the binding of several different FA to various FABP types, B-FABP apparently shows
the highest binding affinity together with H-FABP and M-FABP [9, 10]. A putative function of B-
FABP is the storage and/or delivery of FA that are essential as components of phospho- and
glycolipids in membranes [11]. Alternatively, the protein could be involved in transport of fatty
acids to specific sites of regulation or may protect polyunsaturated FA from undergoing free
radical-catalyzed peroxidation.
Recently two crystal structures of human B-FABP have been solved, in complex with DHA
and oleate [12]. The overall structure is typical of FABP family members. Detailed knowledge
about the structural and functional properties of B-FABP compared to other FABP types,
nevertheless, may shed more light on its physiological significance. In the present study, we
have employed high-resolution NMR spectroscopy as an analytical tool to investigate various
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structural aspects of B-FABP in solution.
MATERIALS AND METHODS
Expression and purification of recombinant human B-FABP
Recombinant human B-FABP complexed with a mixture of  bacterial FA was obtained as
described elsewhere [10]. Human B-FABP cDNA in pBluescript was a kind gift of Dr. F. Shimizu
(Otsuka GEN Research Institute, Tokushima, Japan). Briefly, B-FABP cDNA was cloned into a
pET3d expression vector (Novagen, Madison, WI, USA) via BamHI and NcoI restriction sites. The
protein was expressed in E. coli BL21(DE3) cells. Extraction from inclusion bodies and purification
were performed as previously described for H-FABP mutants [13], except that the anion-exchange
step was omitted. For 15N-enrichment, the cells were grown in M9 minimal medium containing
15N ammonium chloride (Cambridge Isotope Laboratories, Andover, MA, USA). The B-FABP
preparations showed the usual FA binding and stability characteristics [10].
NMR spectroscopy
All NMR experiments were performed at pH 7.0 and 298 K. The protein samples were
prepared at 2-4 mM concentration in argon-purged 20 mM phosphate buffer (H
2
O:D
2
O = 90:10
v/v) containing 0.05 % NaN
3
. NMR data collection has been carried out on a Bruker DMX
spectrometer operating at 600.13 MHz 1H resonance frequency and using a 5 mm triple-
resonance (1H/13C/15N) probe with XYZ-gradient capability. Homonuclear two-dimensional (2D)
spectra (TOCSY and NOESY) as well as 15N-edited multidimensional spectra (HSQC, HTQC, TOCSY-
HSQC and NOESY-HSQC) were collected. The TOCSY experiments were performed with spin-
lock times of 80 ms or 6 ms (to obtain COSY-type information). Mixing times of 147 and 200 ms
were used for the 3D and 2D NOESY experiments, respectively. The homonuclear spectra were
recorded in a phase-sensitive mode with time-proportional phase incrementation of the initial
pulse. Quadrature detection was used in both dimensions with the carrier placed in the center
of the spectrum on the water resonance. All three-dimensional (3D) experiments made use of
pulsed field gradients for coherence selection and artifact suppression, and utilized gradient
sensitivity enhancement schemes wherever appropriate [14, 15]. Quadrature detection in the
indirectly-detected dimensions was achieved by either the States-TPPI or the echo/antiecho
method. 1H chemical shifts were referenced to external sodium 2,2-dimethyl-2-silapentane-5-
sulfonate (Cambridge Isotope Laboratories, Andover, MA, USA). Heteronuclear spectra were
calibrated in the 15N dimension according to the method of Wishart et al. [16].
The spectral data were processed on a Silicon Graphics Indy workstation using the Bruker
XWIN-NMR 1.3 software package. Peak-picking and data analysis of the transformed spectra
were performed using the AURELIA 2.5.9 program (Bruker).
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Constraint generation and structure calculation
The sequence-specific 1H and 15N resonance assignments have been obtained via the classical
assignment strategy proposed by Wüthrich [17]. The NOE-derived distance constraints were
determined from 2D homonuclear NOESY and 3D 15N-edited NOESY-HSQC spectra. Automated
assignments of the NOEs, based only on chemical shifts, were obtained with the program
nmr2st [18]. The upper distance limits were set by an internal calibration based on the intensities
of sequential and medium-range NOE values obtained for residues within well-defined secondary
structure elements. The cross-peak intensities were grouped into five different distance categories
of 2.5, 3.0, 3.5, 4.5 and 6.0 Å. To compute the protein structure, simulated annealing combined
with molecular dynamics in torsion angle space was performed using the DYANA 1.5 program
package [19]. Assignments of meaningful NOE cross-peaks were made by applying a structure-
aided filtering strategy in repeated rounds of structure calculations. Starting ab initio, 100
conformers were calculated in 8000 annealing steps each. A total of 106 stereo-specific
assignments of prochiral methylene and isopropyl groups were obtained using the program
GLOMSA [20]. Pseudo-atom correction for unassigned stereo partners and magnetically
equivalent protons was applied as proposed by Wüthrich and coworkers [21]. No hydrogen
bond constraints were used in the structure calculation.
In the final calculation run, a total of 300 structures were computed. Subsequent energy
minimization in the presence of the NOE-derived distance restraints was performed on the 20
best DYANA conformers using the DISCOVER module of the INSIGHT II program package
(Molecular Simulations Inc., San Diego, CA, USA). The CVFF force field was used [22] with a
dielectric constant equal to r (distance in Å). A force constant of 20 kcal mol-1 Å-2 was applied in
the NOE restraint term. The resulting structures were analysed with PROCHECK-NMR [23].
RESULTS AND DISCUSSION
Sequential resonance assignments
Nearly complete sequence-specific 1H and 15N backbone assignments (available as
supplemental material) have been obtained for all residues except K37. For S13 and T56 the 15N
assignment is missing. Sequential backbone connectivities throughout the entire polypeptide
chain were obtained via a combined analysis of the 3D 15N-edited TOCSY-HSQC and NOESY-
HSQC spectra. The side-chain proton assignments derived from the 3D data were confirmed
and completed using the 2D homonuclear TOCSY spectra. A combination of 2D 1H/15N- HTQC
and 3D 15N-edited NOESY-HSQC spectra was employed to assign the side-chain amide
resonances of all asparagine and glutamine residues. Remarkably, in the case of the R78 side-
chain, also the resonances of one NH
2
  group could be identified. All 15N chemical shift values
were eventually taken from the 2D 1H/15N-HSQC spectrum (Figure 1).
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Figure 1.
1H/15N-HSQC spectrum of human B-FABP at pH 7.0 and 298K (1H frequency of 600.13 MHz).
The sequence-specific peak assignments of the backbone and side-chain (sc) amide groups are indicated.
Due to spin-system heterogeneities, some residues display multiple signals, which are not additionally
labelled.
Solution structure of human B-FABP
In order to identify the secondary structure elements, short- and medium-range NOEs
between backbone protons were assigned based on the 2D and 3D NOESY data (Figure 2).
Consequently, extended β-strand structures, indicated by strong sequential Hα-HN connectivities,
were found for the segments spanning residues 6-14, 39-44, 49-54, 59-64, 69-74, 78-86, 91-
96, 101-108, 113-118 and 123-130. Helical structures, characterized by strong sequential HN-HN
as well as weaker Hα-HN(i,i+1), HN-HN(i,i+2), Hα-HN(i,i+2), Hα-HN(i,i+3), Hα-Hβ(i,i+3), and
possibly Hα-HN(i,i+4) NOEs, were present in segments 1-4, 16-23 and 27-35. In addition, NOE
connectivity patterns common to antiparallel β-sheet structures were detected between the
backbone protons of β-strands βA through βD, βE through βJ, as well as between βA and βJ.
Only between β-strands βD and βE  no backbone NOE connectivities were observed.
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Figure 2.
Survey of short- and medium-range NOEs based on 2D and 3D NOESY data.
For sequential connectivities, the thickness of the bars represents the NOE intensities; medium-range
NOEs are identified by lines connecting the two coupled residues. Helical structure elements are indicated
by NOEs spanning 2-4 residues, while b-strands are characterized by strong daN(i,i+1) connectivities.
On the basis of 2490 NOE-derived non-redundant distance constraints, 300 structures were
generated as described under Materials and Methods. The 20 best structures with the lowest
target function value (below 0.1 Å2) were subsequently subjected to restrained energy
minimization. The resulting final structure ensemble is shown in Figure 3 and the structural
statistics are presented in Table 1. While the backbone root-mean-square deviation (RMSD) for
the residues 2-130 is 0.85 ± 0.12 Å, it drops down to 0.72 ± 0.10 Å when the residues of the so-
called portal region (residues 24-38, 55-58, 74-78) are excluded. This indicates an increased
conformational dispersion around the fatty acid portal, whereas the rest of the protein structure
is quite well defined.
Overall, the solution structure of human B-FABP (Figure 4) resembles a so-called β-clam,
consisting of a continuous β-sheet that encompasses 10 antiparallel β-strands (βA to βJ) with a
gap between β-strands βD and βE. In detail, the N-terminal residues form a helical loop (V1-F4),
which leads into β-strand βA (A6-Q14) with a β-bulge at T11-N12. Following the first β-strand,
two short α-helices, helix αI (F16-L23) and αII (F27-V35), are arranged in a helix-turn-helix motif.
The rest of the structure is defined by a series of antiparallel β-strands connected by mostly
hairpin turns: βB (T39-Q44), βC (V49-L54), βD (N59-F64), βE (E69-T74), βF (R78-L86), βG (L91-
K96), βH (E101-I108), βI (M113-T118), βJ (V123-K130.
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Figure 3.
An increased conformational dispersion is clearly visible in the portal region encompassing helix II as well
as β-turns CD and EF. The N- and C-terminal ends are labelled.
Stereodiagram showing the Cα traces of the 20 conformers representing the solution structure of
B-FABP after restrained energy minimization.
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Figure 4.
Ribbon diagram of human B-FABP in solution.
The β-strands (βA through βJ) and α-helices (αI and αII) are labelled. An additional helical loop is present
at the N-terminus. The ligand binding site is located inside the large cavity defined by the β-barrel structure.
(This figure has been produced with MOLSCRIPT [36] and Raster3D [37].)
In order to compare the solution structure of B-FABP with the 2.1 Å resolution X-ray structure
of the same protein complexed with DHA [12] (deposited as 1FDQ in the RCSB Protein Data
Bank), the 20 NMR conformers were superposed with each molecule (chain A and B) in the
asymmetric unit of the crystal structure. For the backbone atoms of residues 2-130, average
RMSD values of 0.81 ± 0.08 Å and 0.82 ± 0.09 Å were obtained relative to both X-ray monomers,
which in turn show a backbone RMSD of 0.43 Å between each other. This indicates a good
overall agreement between crystal and solutions structures. Moreover, both length and location
of the secondary structure elements are comparable.
The helical loop at the N-terminus is a unique feature found in all members of the FABP
subfamily IV, which consists of A-, B-, E-, H- and M-FABP. All retinoid-binding proteins, on the
other hand, only show a small bulge in an otherwise extended N-terminal structure [24, 25] (L.
Franzoni, personal communication), while the other FABPs, i.e. I-FABP, L-FABP and ILBP, have a
slightly shorter N-terminus that does not allow the formation of a helical turn. The helical
conformation at the N-terminus (V1-F4) could play an additional role, besides the hydrophobic
cluster, in the stabilization of the bottom part of the β-barrel. Both V1 and F4 show NOE contacts
to residues in the GH turn region. While the highly conserved side-chain of F4 (replaced by L7 in
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E-FABP) is a central part of the hydrophobic cluster, V1 interacts with the side-chains of both L66
and L86 to form a nonpolar barrier for the external solvent. This might explain the high protein
stability found for most members of the FABP subfamily IV [10].
Comparison with H-FABP
Several unique features observed in the NMR spectra of human B-FABP indicate a close
structural and functional relationship to H-FABP. Such strong similarities have not become evident
for most other members of the FABP family studied by NMR to date, such as E-FABP, I-FABP, ILBP,
CRBP I, CRBP II and CRABP II [26-30] (L.H. Gutiérrez-González and L. Franzoni, personal
communications). However, additional studies on A-FABP [31] and possibly M-FABP (no NMR
data available at present) could eventually give results comparable to B-FABP and H-FABP.
First, because of the high sequence homology between brain- and heart-type FABP (67% for
human B-FABP compared to both human and bovine H-FABP), the resonance assignments of
many amino acid spin-systems in B-FABP are nearly identical to H-FABP [32, 33]. In fact, more
than 50% of all amino acid residues and more than 80% of the conserved residues show maximal
chemical shift deviations ≤0.30 ppm for the backbone and side-chain protons (Table 2), which
emphasizes the high structural similarity between these two proteins [34].
Secondly, similar to bovine and human H-FABP [33], several residues that are located mainly
around the so-called portal region show spin-system heterogeneities in human B-FABP. More
precisely, 12 out of 14 residues that display multiple proton spin-systems are located in this
particular region, such as residues G26, Q31, V32, G33, F57, A75 with two, residues L23, V35,
T36, K58 and T60 with three, and residue N59 with even four separate spin-systems. These
data indicate that up to 4 different stable conformational states occur in the portal region of
human B-FABP due to the mixture of endogenous FA present in the sample, like previously
reported in the case of bovine H-FABP [33]. The two non-portal residues that display proton
spin-system heterogeneities are F104 and V105. This may be due to the contact between the
bound ligand and the F104 phenyl ring, which is absent in H-FABP. Thus, B-FABP appears to
bind FA via a ‘selected-fit´ backbone arrangement in the portal region - analogous to H-FABP.
Finally, the labile 1H resonances S82 OγH (5.89 ppm) and H93 Nε2H (11.93 ppm), which
usually would not be detected in NMR spectra, have been observed in B-FABP due to very slow
exchange with the solvent. The same two resonances have recently been found in H-FABP (C.
Lücke, unpublished data) and were attributed to an extremely intricate hydrogen-bonding
network involving several (13) bound water molecules as well as hydrophilic side-chains – in
particular E72, S82, H93 and R106 – inside the protein cavity [35]. This electrostatic network of
water molecules appears to be an integral part of the H-FABP structure, which prevents the
imidazole ring of H93 inside the binding cavity to titrate within the stability limits of the protein
(pH 4-9) both in the apo and the holo form (C. Lücke, unpublished data). Thus, the side-chains
of H93 and S82 apparently are inaccessible to the external solvent, even when the ligand is not
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present in the binding cavity.
This very stable water layer structure inside the protein interior may contribute to the high
conformational stability and FA affinity found for both H-FABP and B-FABP. A nearly identical
binding scenario can therefore be assumed for B-FABP, since residues E72, S82, H93 and R106
are all conserved, and since a U-shaped ligand with a few (5) highly ordered water molecules
is found inside the binding cavity of the oleate complex [12].
The major difference between human B-FABP and H-FABP appears to be the presence of  a
phenyalanine ring at position 104 inside the protein cavity. In the B-FABP:DHA complex, F104
seems to form a π-π interaction with the C4-C5 double bond of the ligand, possibly providing a
rationale for the binding of long-chain polyunsaturated FA [12]. Such a π-π interaction may also
occur in mouse and rat B-FABP, where F104 is replaced by a cysteine, whereas in bovine B-FABP
the side-chain of residue L104 is unable to form any π-π interactions. Certainly, just as for heart-
type FABPs, a hydrophobic residue at position 104 is favourable for FA binding to brain-type
FABPs.
While the B-FABP:oleate complex shows the ligand in a U-shaped conformation like in H-
FABP, the bound DHA adopts a helical shape [12]. The latter arrangement is supposed to be
facilitated by π-π interactions of the 6 cis double bonds present in DHA with several protein
side-chains. The ω-tail of DHA protrudes into the central part of the highly ordered water layer,
possibly disrupting the stabilizing effect of the hydrogen-bonding network. As a consequence,
only 3 (out of 6) non-linked water positions inside the cavity of the B-FABP:DHA complex are
found to be conserved (within 0.1 Å) relative to H-FABP. This disturbance of the internal water
layer might be the reason for the lower binding affinities of B-FABP and H-FABP for long-chain
polyunsaturated FA, as reported by Richieri et al. [9] and Zimmerman et al. [10].
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Conclusions
Based on nearly complete sequential 1H and 15N resonance assignments, the large number
of subsequently derived distance constraints has led to a well-resolved solution structure of
human B-FABP. The overall fold is highly analogous to other FABPs, and a comparison with the
crystal structure of holo B-FABP [12] revealed no significant differences in the backbone
conformation (average backbone RMSD of 0.81 ± 0.08 Å). Several features, including high
sequence identity (67%), similar proton resonance assignments, spin-system heterogeneities
in the portal region, a U-shaped conformation of the bound ligand and an electrostatic network
of highly ordered water molecules, indicate a significant similarity in ligand binding between B-
FABP and H-FABP, except for the presence of F104 that possibly creates a preference for long-
chain polyunsaturated FA in the brain protein. The present study provides the basis for future
15N relaxation studies to obtain additional information on B-FABP backbone dynamics.
ACKNOWLEDGEMENTS
The European Large Scale Facility for Biomolecular NMR at the University of Frankfurt is kindly
acknowledged for the use of its equipment.
REFERENCES
1. Veerkamp, J.H. and  Maatman, R.G.H.J. (1995) Cytoplasmic fatty acid-binding proteins: their structure and genes.
Prog. Lipid Res. 34, 17-52
2. Hohoff, C. and  Spener, F. (1998) Fatty acid binding proteins and mammary-derived growth inhibitor. Fett/Lipid 100,
252-263
3. Veerkamp, J.H. and  Zimmerman, A.W. (2001) Fatty acid-binding proteins of nervous tissue. J. Mol. Neurosci. 16,
133-142
4. Owada, Y., Yoshimoto, T. and Kondo, H. (1996) Spatio-temporally differential expression of genes for three members
of fatty acid binding proteins in developing and mature rat brains. J. Chem. Neuroanat. 12, 113-122
5. Feng, L., Hatten, M.E. and Heintz, N. (1994) Brain lipid-binding protein (BLBP): a novel signaling system in the
developing mammalian CNS. Neuron 12, 895-908
6. Kurtz, A., Zimmer, A., Schnütgen, F., Brüning, G., Spener, F. and Müller, T. (1994) The expression pattern of a
novel gene encoding brain fatty-acid binding protein correlates with neuronal and glial cell development. Develop-
ment 120, 2637-2649
7. Godbout, R., Bisgrove, D.A., Shkolny, D. and Day, R.S. (1998) Correlation of B-FABP and GFAP expression in
malignant glioma. Oncogene  16, 1955-1963
8. Xu, L.Z., Sánchez, R., Sali, A. and Heintz, N. (1996) Ligand specificity of brain lipid-binding protein. J. Biol. Chem.
271, 24711-24719
9. Richieri, G.V., Ogata, R.T., Zimmerman, A.W., Veerkamp, J.H. and Kleinfeld, A.M. (2000) Fatty acid binding
proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 39, 7197-7204
                  Solution structure of brain-type FABP
97
10. Zimmerman, A.W., Van Moerkerk, H.T.B. and Veerkamp, J.H. (2001) Ligand specificity and conformational
stability of human fatty acid-binding proteins. Int. J. Biochem. Cell Biol. 33, 865-876
11. Green, P., Glozman, S., Kamensky, B. and Yavin, E. (1999) Developmental changes in rat brain membrane lipids
and fatty acids: the preferential prenatal accumulation of docosahexaenoic acid. J. Lipid Res. 40, 960-966
12. Balendiran, G.K., Schnütgen, F., Scapin, G., Börchers, T., Xhong, N., Lim, K., Godbout, R., Spener, F., and
Sacchettini, J.C. (2000) Crystal structure and thermodynamic analysis of human brain fatty acid binding protein. J.
Biol. Chem. 275, 27045-27054
13. Zimmerman, A.W., Rademacher, M., Rüterjans, H., Lücke, C. and Veerkamp, J.H. (1999) Functional and
conformational characterization of new mutants of heart fatty acid-binding protein. Biochem. J. 344, 495-501
14. Kay, L.E., Keifer, P. and Saarinen, T. (1992) Pure absorption gradient enhanced heteronuclear single quantum
correlation spectroscopy with improved sensitivity. J. Am. Chem. Soc. 114, 10663-10665
15. Schleucher, J., Sattler, M. and Griesinger, C. (1993) Coherence selection via gradients without loss of sensitivity.
The 3D-HNCO experiment. Angew. Chem. Int. Ed. Eng. 32, 1489-1491
16. Wishart, D.S., Bigam, C.G., Yao, J., Abildgaard, F., Dyson, H.J., Oldfield, E., Markley, J.L. and Sykes, B.D.
(1995) 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J. Biomol. NMR 6, 135-140
17. Wüthrich,  K. (1986) NMR of Proteins and Nucleic Acids. Wiley, New York
18. Pristovšek, P., Lücke, C., Reincke, B., Ludwig, B. and Rüterjans, H. (2000) Solution structure of the functional
domain of Paracoccus denitrificans cytochrome c552 in the reduced state. Eur. J. Biochem. 267, 4205-4212
19. Güntert, P., Mumenthaler, C. and Wüthrich, K. (1997)  Torsion angle dynamics for NMR structure calculation with
the new program DYANA. J. Mol. Biol. 273, 283-298
20. Güntert, P., Braun, W. and Wüthrich, K. (1991) Efficient computation of three-dimensional protein structures in
solution from nuclear magnetic resonance data using the program DIANA and the supporting programs CALIBA,
HABAS and GLOMSA. J. Mol. Biol. 217, 517-530
21. Wüthrich, K., Billeter, M. and Braun, W. (1983) Pseudo-structures for the 20 common amino acids for use in
studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear
magnetic resonance. J. Mol. Biol. 169, 949-961
22. Dauber-Ogusthorpe, P., Roberts, V.A., Ogusthorpe, D.J., Wolff, D.J., Genest, M. and Hagler, A.T. (1988)
Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase trimethoprin, a drug-receptor
system. Proteins 4, 31-47
23. Laskowski, R.A., MacArthur, M.W., Moss, D.S. and Thornton, J.M. (1993) AQUA and PROCHECK-NMR: programs
for checking the quality of protein structures solved by NMR. J. Appl. Crystallogr. 26, 283-291
24. Noy, N. (2000) Retinoid-binding proteins: mediators of retinoid action. Biochem. J. 348, 481-495
25. Folli, C., Calderone, V., Ottonello, S., Bolchi, A., Zanotti, G., Stoppini, M. and Rudolfo, B. (2001) Identification,
retinoid binding, and X-ray analysis of a human retinol-binding protein. Proc. Natl. Acad. Sci. U.S.A. 98, 3710-3715
26. Hodsdon, M.E. and Cistola, D.P. (1997) Discrete backbone disorder in the nuclear magnetic resonance structure
of apo intestinal fatty acid-binding protein: implications for the mechanism of ligand entry. Biochemistry 36, 1450-1460
27. Zhang, F., Lücke, C., Baier, L.J., Sacchettini, J.C. and Hamilton, J.A. (1997) Solution structure of human intestinal
fatty acid-binding protein: implications for ligand entry and exit. J. Biomol. NMR 9, 213-228
28. Lücke, C., Zhang, F., Rüterjans, H., Hamilton, J.A. and Sacchettini, J.C. (1996) Flexibility is a likely determinant
of binding specifity in the case of ileal lipid binding protein. Structure 4, 785-800
Chapter 4
98
29. Lu, J., Lin, C-L., Tang, C., Ponder, J.W., Kao, J.L.F., Cistola, D.P. and Li, E. (1999) The structure and dynamics of
rat apo-cellular retinol-binding protein II in solution: comparison with the X-ray. J. Mol. Biol. 286, 1179-1195
30. Wang, L., Li, Y., Abildgaard, F., Markley, J.L. and Yan, H. (1998) NMR solution structure of type II human cellular
retinoic acid binding protein: implications for ligand binding. Biochemistry 37, 12727-12736
31. Constantine, K.L., Friedrichs, M.S., Wittekind, M., Jamil, H., Chu, C-H., Parker, R.A., Goldfarb, V., Mueller, L.
and Farmer, B.T. (1998) Backbone and side chain dynamics of uncomplexed human adipocyte and muscle fatty acid-
binding proteins. Biochemistry 37, 7965-7980
32. Lassen, D., Lücke, C., Kveder, M., Mesgarzadeh, A., Schmidt, J.M., Specht, B., Lezius, A., Spener, F. and
Rüterjans, H. (1995) Three-dimensional structure of bovine heart fatty-acid-binding protein with bound palmitic acid,
determined by multidimensional NMR spectroscopy. Eur. J. Biochem. 230, 266-280
33. Lücke, C., Rademacher, M., Zimmerman, A.W., Van Moerkerk, H.T.B., Veerkamp, J.H. and Rüterjans, H.
(2001) Spin-system heterogeneities indicate a selected-fit mechanism in fatty acid binding to heart-type fatty acid-
binding protein (H-FABP). Biochem. J. 354, 259-266
34. Wishart, D.S., Sykes, B.D. and Richards, F.M. (1991) Relationship between nuclear magnetic resonance chemical
shift and protein secondary structure. J. Mol. Biol. 222, 311-333
35. Young, A.C.M., Scapin, G., Kromminga, A., Patel, S.B., Veerkamp, J.H. and Sacchettini, J.C. (1994) Structural
studies on human muscle fatty acid binding protein at 1.4 Å resolution: binding interactions with three C18 fatty acids.
Structure 2, 523-534
36. Kraulis, P.J. (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J.
Appl. Crystallogr. 24, 946-950
37. Merrit, E.A. and Bacon, D.J. (1997) Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505-524
                  Solution structure of brain-type FABP
99
Appendix
Chapter 4
100
                  Solution structure of brain-type FABP
101
Chapter 4
102
                             FABPs in fatty acid transport
103
Effect of fatty acid-binding proteins on
intermembrane fatty acid transport
Studies on different types and mutant proteins

Jacques H. Veerkamp
Herman T.B. van Moerkerk
Aukje W. Zimmerman
Eur. J. Biochem. 2000, 267: 5959-5966
Chapter 5
104
ABSTRACT
Liposomes of different charge fixed to nitrocellulose filters were applied to study fatty acid transfer
to rat heart or liver mitochondria in the presence of fatty acid-binding protein (FABP) or albumin.
[14C]palmitate oxidation was used as parameter. Different FABP types and heart (H-)FABP mutants
were tested. The charge of liposomes did not influence the solubilization and mitochondrial
oxidation of palmitate without FABP and the solubilized amount of palmitate in the presence of
FABP. Mitochondria did not show preference for oxidation of FABP-bound palmitate from their
tissue-specific FABP type. All FABP types increased palmitate oxidation by heart and liver mito-
chondria with neutral, positive and negative liposomes 2.5-, 3.2- and 2-fold, respectively. Ileal
lipid-binding protein and H-FABP mutants which do not bind fatty acid had no effect. Other H-
FABP mutants had different effects, dependent on the site of mutation. The effect of albumin
was comparable, but not dependent on liposome charge. The ionic strength had only a slight
effect.
In conclusion, the transfer of palmitate from liposomal membranes to mitochondria was in-
creased by all FABP types to a similar extent. The membrane charge had a large effect in contrast
to the origin of the mitochondria.
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INTRODUCTION
Fatty acid-binding proteins (FABPs) have been isolated from cytosols of tissues of verte-
brates and invertebrates as 13-15 kDa proteins. Nine FABP types have been named up to now
after the first tissue from which they were isolated. They show a characteristic tissue and cellular
distribution [1]. In spite of the large knowledge on their molecular structure, their binding properties
and their genes, the functions of these different FABP types are still unclear. They are postulated
to be involved in fatty acid uptake and targeting, in modulation of fatty acid concentration and
in this way in regulation of metabolism, signal transduction, gene transcription and detoxification
[1,2]. Theoretical considerations ascribed a role to FABPs in fatty acid transport in hepatocytes
[3] and cardiomyocytes [4]. In model systems of liposomes, monolayers, mitochondria and
microsomes, fatty acid transfer was demonstrated from FABP to membranes, from membranes
to FABP and from membranes via FABP to membranes by use of radiolabeled or fluorescent
fatty acids, or NMR (see refs. in 1,2,5-8). FABP facilitated the diffusion of oleate in a model cytosol
system [9]. Photoactivatable radiolabeled fatty acids were taken up and labeled FABP in
hepatocytes and adipocytes [10,11]. FABP-bound fatty acids were oxidized by mitochondria [8,12-
14] and peroxisomes [14] or used for acyl-CoA synthesis by microsomes [15]. The technique of
fluorescence recovery after photobleaching was used to measure the intracellular transport of
a fluorescent fatty acid (12-N-methyl-(7-nitrobenzo-2-oxa-1,3-diazol)aminostearate), NBD-
stearate [16,17]. Inhibition of fatty acid-binding to FABP by α-bromo-palmitate reduced intracellular
transport in hepatocytes [16]. Transfection with FABP cDNA increased NBD-stearate uptake and
cytoplasmic diffusion in L cells [17].
Rasmussen et al. [18] showed that acyl-CoA binding protein could mediate acyl-CoA transport
from liposomes to microsomes and mitochondria. They observed also a positive effect of liver
FABP (L-FABP) on the transport of immobilized acyl-CoA esters to β-oxidation in mitochondria. It
is not known if other FABP types than L-FABP and heart FABP (H-FABP) have a similar function in
fatty acid transfer. Also the effect of membrane charge and the possible tissue specificity of
FABP-mitochondrion interaction are of interest.
In this study we applied liposomes of different charge fixed to nitrocellulose filters and isolated
rat heart and liver mitochondria to compare the effect of membrane charge and of different
FABP types and H-FABP mutants on intermembrane fatty acid transport. We could use fatty acid
oxidation as parameter of fatty acid transfer, since other conditions were chosen to realize
optimal oxidation.
MATERIALS AND METHODS
Materials
All human FABP preparations used and rat H-FABP were obtained by recombinant cDNA
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expression and isolation as described previously [19-21]. Human ileal lipid-binding protein (I-
LBP) cDNA was kindly provided by Dr. J.C. Sacchettini (Texas A&M University, College Station, TX,
USA), human brain FABP cDNA by Dr. H. Shinomiya (Otsuka Gen Research Institute, Tokushima,
Japan). Human epidermal FABP was a kind gift from Dr. F. Spener (University Münster, Germany).
Mutant human H-FABP proteins were prepared by oligonucleotide-directed in vitro mutagen-
esis and recombinant expression [22,23]. Rat L-FABP was isolated from rat liver [24]. Male, fed,
random-bred Wistar rats (180-200 g) were used for isolation of liver and heart mitochondria.
The procedures were described previously [25], but in this series of experiments albumin was
omitted.
[1-14C]Palmitic acid and [1-14C]oleic acid were obtained from Amersham Pharmacia Biotech,
egg phosphatidyl choline (PC), phosphatidylglycerol (PG), and stearoylamine from Sigma Chemi-
cal Co. 1-Anilinonaphtalene-8-sulphonic acid (ANS) and 11-((5-dimethylaminonaphtalene-1-
sulphonyl)amino)undecanoic acid (DAUDA) were obtained from Molecular Probes Europe, Leiden,
The Netherlands
Preparation of liposomes and fixation on nitrocellulose filters
Neutral liposomes were prepared by resuspension of a mixture of 40 µmol egg PC, 13 µmol
cholesterol and 2 µmol [1-14C] palmitic acid (specific radioactivity 3300 dpm/nmol) in 10 ml 100
mM NaCl/10 mM Tris-HCl (pH 7.4) by gentle agitation for 3 h. For negatively and positively
charged liposomes 10 µmol PC was substituted by 10 µmol PG or 10 µmol stearylamine, respec-
tively. The suspension was centrifuged for 10 min at 12000 g. Liposomes were fixed on 1 cm2
nitrocellulose membranes by incubation of 20 filters in the supernatant for 30 min at 37 °C.
Filters were washed twice in 100 mM NaCl/10 mM Tris-HCl (pH 7.4) Radioactivity measurements
were used in every experiment to determine the bound palmitic acid. Usually about 20-22 nmol
was present per filter. Liposomes with DAUDA or ANS were prepared in the same way by
resuspension of 2 µmol fluorescent fatty acid with the indicated amounts of other lipids and
coated on filters.
Release of fatty acid from immobilized liposomes
Filters coated with liposomes were incubated with gentle shaking with or without 150 µg
FABP or albumin in 1 ml buffer A for 2-30 min at 37 °C. Buffer A, specific for fatty acid oxidation
experiments, contained 25 mM sucrose/10 mM K
2
HPO
4
/5 mM MgCl
2
/1 mM EDTA/1 mM NAD+/
5 mM ATP/25 µM cytochrome c/0.1 mM Coenzyme A/0.5 mM L-carnitine/0.5 mM L-malate/75
mM Tris (pH 7.4). The radioactivity solubilized in 50 µl sample was determined by liquid scintillation
counting to calculate the palmitate concentration in the aqueous phase. In the case of filters
with fluorescent fatty acids the increase of fluorescence intensity was measured at the excitation
wavelengths 335 and 369 nm and the emission wavelengths 503 and 465 nm for DAUDA and
ANS, respectively.
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Oxidation of FABP-bound palmitate by heart and liver mitochondria
FABP-bound palmitate was prepared by incubation of 18 mg human H-FABP or L-FABP with
1.8 µmol [1-14C]palmitate and removal of free palmitate with the Lipidex procedure [24]. Rat
heart mitochondria (80-100 µg protein) or rat liver mitochondria (200-300 µg protein) were incu-
bated with 29 and 20 nmol palmitate bound to 1200 µg L- or H-FABP, respectively in 1 ml oxidation
buffer A at 37 °C. After 2 and 5 min, oxidation of [1-14C]palmitate was measured as the sum of
14CO
2
 and 14C-labeled acid-soluble products [25].
Transfer of liposome-bound palmitate to mitochondrial oxidation system
Filters coated with liposomes containing about 20 nmol palmitate were preincubated with
gentle shaking for 10 min with 150 µg FABP or albumin in 1 ml oxidation buffer A. Subsequently
50 µl of a suspension of rat heart or rat liver mitochondria (100 or 200-300 µg protein respectively)
were added and  incubation continued for 10 min at 37 °C. Oxidation was stopped with 0.4 ml
of 3 M perchloric acid and 14CO
2
 and 14C-labeled acid-soluble products were assayed [25].
Other assays
Fatty acid-binding of different FABP preparations was determined at 10 µg protein and 0-2
µM [1-14C]oleic acid in 1 ml 50 mM Tris-HCl (pH 8.0). FABP preparations were delipidated by the
Lipidex procedure [26]. K
d 
values and maximal binding data were derived from Scatchard plots.
Relative fatty acid-binding was determined for human H-FABP and H-FABP mutants at 10 µg
protein and 2 µM [1-14C]oleic acid [22]. Protein concentrations were assayed by the Lowry pro-
cedure with bovine serum albumin as standard. For H-FABP and L-FABP 1 mg protein is equivalent
on this base to about 45 and 33 nmol, respectively.
Quantification
All experiments were performed in triplicate. All values are given as means ± SD of the
indicated number of independent experiments.
RESULTS
All human FABP preparations used were recombinant proteins. They showed similar K
d
 and
B
max
 values for oleic acid by the Lipidex assay except adipocyte FABP (Table 1). Ileal FABP did not
show measurable oleate binding. Protein concentrations are based on the Lowry assay with
albumin as standard. Molar concentrations could not be applied, since except for L-FABP and
H-FABP correction factors are not known. Therefore, the B
max
 values (in nmol per mg protein)
can only be converted to binding stoichiometry for H-FABP and L-FABP to 0.48 and 1.02 mol/
mol, respectively. The low B
max
 values observed are presumably due to partial denaturation of
the recombinant proteins during purification and delipidation [5, 27]. The K
d
 values of different
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neutral liposomes: *P<0.05.After 2-30 min the radioactivity of a 50 µl-sample was determined. Values (in
pmol palmitate/ml) are means ± SD of 3-5 independent experiments.
Values are means ± SD of 3-5 independent experiments. N.D, not detectable.
Liposomes were prepared from mixtures of 13 mM cholesterol, 2 mM [1-14C]palmitate and either 40 mM
PC (neutral) or 30 mM PC and 10 mM stearylamine (positive) or 30 mM PC and 10 mM PG (negative).
Liposomes fixed on one 1 cm2 nitrocellulose filter contained 21 ± 2 nmol [1-14C]palmitate. Human H-FABP,
L-FABP or albumin (150 µg) were added to 1 ml of buffer A containing one filter. Significantly different from
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FABP types show less variation for oleate binding and are higher than the values determined
with the more accurate ADIFAB procedure [27] but the relative differences, for example the
higher values for adipocyte FABP, are similar.
First we studied the solubilization of palmitic acid from liposomes by FABP. In the absence of
FABP the palmitate concentration in the medium was only 70-90 nM. Human H-FABP and L-
FABP solubilize similar amounts (550-600 pmol/150 µg) of palmitic acid from neutral, positive
and negative liposomes under the conditions used (Table 2).
The binding of palmitic acid from liposomes to FABP showed a lag time. At 2 min the binding
was neglible, and at 5 min only about 50% of the maximal value. The maximal solubilization
was reached after 10-15 min in all cases. Calculation results in an occupancy of about  0.1 mol
fatty acid per mol protein. Addition of albumin had an effect similar to FABP, a similar lag time
and extent of solubilization (Table 2). The solubilization from negative liposomes was only slightly
lower than from neutral liposomes. An inactive H-FABP mutant (Phe16Ser) did not solubilize any
palmitate. Similar experiments were carried out with fluorescent fatty acids in immobilized
liposomes. The release of DAUDA to L-FABP (data not shown) and of ANS to L-FABP and H-FABP
(Figure 1) measured by fluorescence showed with all types of liposomes a comparable lag time
of 2-4 min and a maximal value after 10-12 min.
We previously showed efficient oxidation of H-FABP-bound palmitate by rat heart mitochon-
dria [12] and oxidation of L-FABP-bound palmitate by rat liver mitochondria [13,14]. Here we
observed for an incubation with ~ 25 µM palmitate bound to 1200 µg FABP no significant differ-
ences between both FABP types with both types of mitochondria. Heart mitochondria showed
oxidation rates of 4.75 ± 0.73 and 5.68 ± 1.03 nmol min-1 per mg protein with H-FABP-bound
and L-FABP-bound palmitate, respectively. Liver mitochondria oxidized 5.07 ± 1.01 and 4.46 ±
0.57 nmol palmitate min-1 per mg with H-FABP-bound and L-FABP-bound palmitate, respectively.
Thus, no specificity of a certain FABP type for the origin of mitochondria is present.
To exclude the effects of lag time on transfer of fatty acid from fixed liposomes to FABP, we
studied the effects of FABP on fatty acid transfer from liposomes to mitochondria in all experiments
after 10 min preincubation without mitochondria. The presence of H-FABP increases the oxidation
rate of palmitate from fixed neutral liposomes by rat heart and liver mitochondria in a concen-
tration-dependent way up to a maximal value (Table 3). Oxidation rates are linear for at least 10
min. The presence of 150 µg H-FABP (7 nmol) and its binding of about 600 pmol palmitate (Table
2) increase palmitate oxidation per 10 min by 2.2 and 3.0 nmol in rat heart and liver mitochondria,
respectively.
The charge of liposomes did not influence the oxidation rate of palmitate by rat heart and
liver mitochondria without FABP (Tables 4 and 5). This is in accordance with the similar solubili-
zation without FABP (Table 2). The extent of solubilization was also not affected by the presence
of mitochondria.
All FABP types increased the oxidation of immobilized palmitate by both rat heart and liver
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mitochondria (Tables 4 and 5, respectively). The increase was to the same order for all types
except I-LBP, but was dependent on the charge of the liposomes. The effect of FABP was maximal
with positively charged and minimal with negatively charged liposomes. There was no species-
related effect, since rat and human H-FABP or L-FABP behaved similarly. Addition of albumin
also promoted the oxidation, but its effect was not dependent on the charge of liposomes.
Figure 1.
Solubilization of ANS from fixed liposomes by L-FABP and H-FABP.
Fluorescence was measured at 369 nm (excitation) and at 465 nm (emission).
Neutral liposomes containing 22 ± 1 nmol [14C]palmitate and fixed on 1 cm2 nitrocellulose filters were
incubated for 10 min in 1 ml buffer A in the absence or presence of human H-FABP and subsequently for
10 min with rat heart mitochondria (100 µg) or rat liver mitochondria (300 µg). Relative oxidation rates are
given in % of the oxidation rate without H-FABP. These oxidation rates are 1.37 ± 0.03 and 0.50 ± 0.05
nmol/mg protein per min for heart and liver mitochondria, respectively. Values are means ± SD for 3
independent experiments.
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Liposomes fixed on 1 cm2 nitrocellulose filter paper contained 21 ± 2 nmol [14C]palmitate and were incubated
for 10 min with or without 150 µg FABP or albumin and subsequently for 10 min with rat heart mitochondria
(100 µg protein). Values are given in % of the oxidation rates without FABP or albumin as means ± SD of
the number of independent experiments between parentheses. Significantly different from neutral
liposomes: * P<0.05; ** P<0.01. ND, not determined. Oxidation rates without FABP were 1.28 ± 0.22 (18),
1,26 ± 0.09 (4) and 1.32 ± 0.28 (11) nmol/min per mg protein with neutral, positive and negative liposomes,
respectively and did not differ significantly.
The concentration of rat liver mitochondria was 200-300 µg protein per ml. Oxidation rates without FABP
were 0.57 ± 0.21 (18), 0.52 ± 0.05 (4) and 0.58 ± 0.10 nmol/min per mg protein with neutral, positive and
negative liposomes, respectively and did not differ significantly. For further details see legend Table 4.
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Mitochondria were incubated with 150 µg human FABP mutant and fixed negative liposomes for 10 min
as described in Table 4 and 5. The oxidation rate is given in % of the oxidation rate without FABP (mutant).
Values are means ± SD of 3 independent experiments. Significantly different from wild type H-FABP:
*P<0.05; ** P<0.01.
Mitochondria were incubated with 150 µg human H-FABP mutant and neutral liposomes fixed on 1 cm2
nitrocellulose paper for 10 min as described in Table 4 and 5. The relative binding of oleic acid (measured
at 2 µM oleic acid and 0.5 µM FABP) is given for each mutant in % of the wild type. The oxidation rate is
given in % of the oxidation rate without FABP (mutant). Values are means ± SD of 3-7 independent
experiments. Significantly different from wild type H-FABP: * P<0.05; ** P<0.01.
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The effect of changes of FABP structure on the fatty acid transfer from fixed liposomes was
investigated with mutants of human H-FABP. We tested proteins mutated in the binding center
(Arg-106), in the portal region (Phe-16 and Phe-57), the hydrophobic patch (Phe-4 and Trp-8),
the “second portal” region (Glu-72) and at the surface (Lys-21). The last of these amino acids
seems to be important for interaction of H-FABP with negatively charged membranes [28]. The
relative binding of oleic acid compared to wild type is given for all mutant preparations (Table 6),
as they differ not only in binding affinity but also in maximal binding activity (per mg protein)
[22,23]. The latter is due to differences in stability of the proteins [23]. The effect of the mutations
on fatty acid transfer from neutral liposomes is dependent on the relative fatty acid-binding
(Table 6). Mutants with no or slight relative binding activity (F16S, F16E, R106T) cause no or a
slight increase of oxidation. Mutants with similar (F4S, F4E) or lower relative binding (W8E, F16Y,
E72S) have effects generally similar to the wild-type. The K21I mutation, despite of similar binding,
resulted in a decrease of oxidation with heart mitochondria but not with liver mitochondria.
Mutation of Phe57 even did not influence the binding but decreased the FABP effect on fatty
acid oxidation by both types of mitochondria. Mutations had generally similar effects on fatty
acid transfer when fixed negative or positive liposomes were applied (Table 7 and 8). The K21I
mutation had no effect with both types of mitochondria. Mutation of Phe57 reduced the effect of
H-FABP only with positive liposomes and liver mitochondria.
The presence of high ionic strength decreased and increased the transfer of aphysiological
fluorescent anthroyloxy fatty acids (AOFA) to phospholipid vesicles from L-FABP and H-FABP,
respectively [29,30]. An increase of ionic strength decreased, however, fatty acid-binding to rat
L-FABP and I-FABP [31,32]. We therefore first tested the effect of NaCl addition on oleic acid
binding to human H-FABP and L-FABP (Table 9). We observed only a slight effect of 0.1 M NaCl
on this. An increase to 0.3 M NaCl caused 15 and 33% inhibition of binding to H-FABP and L-
FABP, respectively. Binding of oleic acid to rat L-FABP was reported to be about 40% and 60%
lower at 0.1 and 0.2 M NaCl, respectively [31]. We didn’t even observe any effect of glucose 6-
phosphate and glucose on fatty acid-binding to FABPs, in contrast to the increase reported in
[31].
The presence of a high ionic strength in oxidation experiments may influence not only the
binding of fatty acids to FABP, but also their release from the liposomes and their transfer from
FABP to mitochondrial membranes. The presence of 0.3 M NaCl however did not, or only slightly
change the effect of FABP on palmitate oxidation from neutral liposomes. With heart mitochondria,
NaCl increased the oxidation in the presence of H-FABP and L-FABP by 9 ± 3 and 7 ± 4 %
respectively. With liver mitochondria the ionic strength effect was absent (2 ± 5 %) and 6 ± 2 %
in the presence of H-FABP and L-FABP, respectively.
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Mitochondria were incubated with 150 µg human FABP mutant and fixed positive liposomes for 10 min as
described in Table 4 and 5. The oxidation rate is given in % of the oxidation rate without FABP (mutant).
Values are means ± SD of 3 independent experiments. Significantly different from wild type H-FABP: *
P<0.05; **P<0.01.
14C]oleic acid binding was determined in 10 mM Tris-HCl (pH 8.0) at 2 µM oleic acid and 15 µg FABP with
and without indicated addition. Values are means ± SD of 3 independent experiments. Significantly different
from control: **P<0.01.
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DISCUSSION
The palmitate oxidation rate of mitochondria is dependent on the release of palmitate from
liposomes to FABP, the diffusion rate of free palmitate and palmitate-loaded FABP and the release
of palmitate from FABP to mitochondrial acyl-CoA synthase. The maximal palmitate oxidation
capacity of mitochondria is not limiting at the used conditions. It is much higher than the rates
in our present system, about 17 and 7 nmol min-1 per mg protein for rat heart and liver
mitochondria, respectively [25]. Preparations of human H-FABP and L-FABP proved to be good
acceptors of liposomal fatty acids as was previously shown for H-FABP from various species
and rat L-FABP by radiochemical procedures [8,33-35], fluorescence [36] or NMR spectroscopy
[6]. They could solubilize palmitate in this way and increase the palmitate level in the aqueous
phase from about 80 nM to 650 nM at the used protein concentration (5-7 µM) (Table 2).
Studies on the effects of FABPs on fatty acid transport are hampered by the solubility and
rapid spontaneous transfer of fatty acids in in vitro systems [8,37]. Associative interaction of
vesicles and other membrane systems such as mitochondria or microsomes may also inter-
fere, but can be prevented by the use of an equilibrium dialysis cell or a system of two separate
monolayers [8,15]. Use of immobilized multilamellar liposomes also appeares to be an efficient
system to demonstrate the effect of FABPs on fatty acid transport to mitochondria, as we showed
by a functional assay (β-oxidation). Multilamellar liposomes contain less lipid on their outermost
leaflets than vesicles and their fatty acid exchange rate is less rapid [15].
Investigations on the correlation between the cytoplasmic FABP concentration and the mobility
of fatty acids suggested that FABPs could stimulate cytoplasmic fatty acid diffusion by reducing
their membrane binding [3,16,38,39]. Very recently it was shown that albumin saturably increased
NBD-stearate mobility through a dense suspension of liposomes used as a model cytoplasm
[40]. Aqueous diffusion of the protein-bound form of the fatty acid and exchange of fatty acid
between albumin and membranes appeared to regulate the mobility [40]. In our system the
exchange is limited by the immobilization of liposomes and the uptake by mitochondria. The
addition of FABP increased the palmitate oxidation, in a concentration-dependent and saturable
manner.
The absence of any effect of liposome charge on solubilization and oxidation of palmitate
without FABP and the marked increase of the FABP effect on oxidation with change from negative
to neutral to positive liposomes indicates that the fatty acid transfer from the liposomal membrane
to FABPs is influenced by the membrane charge. Storch et  al. [7,28,30] showed that the transfer
rate of AOFA to phospholipid vesicles by H-FABP, intestinal FABP and adipocyte FABP was in-
creased by a negative charge of the membrane. Collisional interaction was observed with all
three FABP types. No effect of membrane charge and no collisional interaction occurred with L-
FABP [29]. Wilton et al. [41], however, found a release of DAUDA from L-FABP at collisional inter-
action with anionic phospholipid vesicles. Transfer rates of AOFA differed among the FABP types
Chapter 5
116
by orders of magnitude, in spite of their similar binding constants [7]. The equilibrium between
fatty acids and FABP however is rapid (within 2 s at 37 °C) for five physiologically important fatty
acids and H-FABP, intestinal FABP and adipocyte FABP [42].
The interaction of FABP with donor membranes may affect the dissociation of the fatty acid,
but how is unclear. The membrane charge of liposomes may strongly influence the fatty acid
release rate and this effect may exceed the possibly different properties of different FABP types,
since all FABP types stimulated oxidation of palmitate from liposomes with a similar charge to
the same extent. The same may apply to the absence of differences with some H-FABP mutant
proteins that exhibit less binding than wild-type (W8E, F16Y and E72S). Albumin however did not
show significant differences in its effect on the mitochondrial oxidation rates. The solubilization
of palmitate was similar to that by FABP. In this case the albumin-fatty acid binding characteristics
could be dominant over the liposome charge effect.
FABP preparations donate fatty acids to liposomal [7,8,28,29,36] and mitochondrial mem-
branes [8] and to the β-oxidation system of intact mitochondria [8,12-14] quite well. In this study
we showed that rat heart and liver mitochondria do not discriminate between the different FABP
types. The oxidation rates of heart and liver mitochondria with FABP-bound palmitate were not
dependent on the FABP type (heart or liver). Also, the FABP type and the species type of FABP
(human or rat) did not determine the extent of the enhancing effect of FABP on oxidation of
liposomal palmitate. Mitochondria and mitochondrial outer membranes contain a high per-
centage of acidic phospholipids, including diphosphatidylglycerol [43,44]. Since the outer mem-
brane of liver mitochondria shows phospholipid asymmetry [45], the acceptor membrane may
be negatively charged, but proteins may compensate the charge. Compositional differences
are present between heart and liver mitochondria, but did not influence the effect of any FABP
type. Some differences were, however, found with H-FABP mutant proteins.
Conservation of the binding activity was necessary to get stimulation of intermembrane
fatty acid transfer by H-FABP mutants. Some information was obtained on amino acids (domains)
involved in the transfer processes. The α-helical domain is critical for the collisional transfer of
AOFA from intestinal FABP to phospholipid membranes [46]. Lys-21 of the α-I helix was essential
for effective AOFA transfer from H-FABP to neutral and especially anionic phospholipid vesicles
[28]. AOFA may not, however, be bound in the binding cavity of FABPs, except possibly for L-
FABP. In our study the K21I mutant of H-FABP only had less of an effect than wild-type in the fatty
acid transfer from neutral liposomes to rat heart mitochondria. It is not clear why the mutation
had no effect on the transfer from negative or positive liposomes to heart mitochondria and in
all cases with liver mitochondria. The interaction with both types of membranes may play a
role. The F16S and F16E mutant proteins did not, or only slightly bind and transfer palmitate. The
F16Y mutation had some effect on binding, but not on transfer activity. A T28K mutation of the α-
II domain resulted in a fourfold higher transfer rate of AOFA from H-FABP to neutral and anionic
vesicles [28].
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Mutations in the β-2 turn, which forms part of the portal region, affect the fatty acid transfer,
but not the binding. The K59I mutant of H-FABP showed a twofold higher transfer rate of AOFA
to neutral and negatively charged phospholipid vesicles than wild-type [28]. We found a decrease
of palmitate transfer between neutral liposomes and mitochondria and between positive
liposomes and liver mitochondria for the F57S mutant. Recently, Richieri et al. [32] suggested
that Arg-56 of intestinal FABP and Arg or Lys on equivalent positions of other FABPs may serve
as the initial site of fatty acid binding on the protein’s surface, before it passes through the
portal surface. The reverse of these steps should occur at dissociation. Mutations of the
hydrophobic patch and the second portal region did not show involvement of these amino
acids except a decrease of transfer with the F4E mutant from negatively charged liposomes.
Mutation of Lys-10 or Lys-113 on β-strands A and I to isoleucine had no effect on AOFA transfer
from H-FABP to vesicles [28].
We observed less of an effect of ionic strength on binding of oleic acid to FABPs than has
been reported [31]. Ionic strength had no, or only a marginal effect on the oxidation of liposomal
palmitate by rat heart and liver mitochondria in the presence of H-FABP or L-FABP. The
intermembrane transfer of palmitate by H-FABP or L-FABP was thus not influenced by ionic
strength in contrast to its different effect on the transfer of AOFA from L-FABP and H-FABP to
phospholipid vesicles [29,30]. Our data does not suggest large differences in the transfer
mechanisms of H-FABP and L-FABP.
In summary, fatty acid binding is essential for FABP to have an effect on intermembrane fatty
acid transport. The different FABP types are not specific in their transfer activity from fixed
liposomes to heart or liver mitochondria, but the release from liposomes to FABP seems to be
charge dependent. The effects of mutations in H-FABP at different positions on transfer activity,
without an effect on binding, suggests that specific amino acids are involved in the uptake and
release of fatty acids from and to membranes, respectively.
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ABSTRACT
Fatty acid-binding proteins (FABPs) are 15-kDa cytosolic proteins which are involved in the
intracellular binding and targeting of fatty acids. Some members have been implicated in the
regulation of cell growth and differentiation. In this study we investigated the effect of a series of
FABPs and heart FABP (H-FABP) mutants on cell-free protein synthesis. Human myelin, intestinal,
heart and brain FABP showed a dose-dependent inhibition of in vitro mRNA translation. Adipocyte,
liver and epidermal types had no effect. The inhibition was not influenced by delipidation and
for H-FABP mutants not related to their affinity for fatty acids. Our results indicate that some
FABPs may modulate cell growth and/or differentiation by inhibition of protein synthesis.
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INTRODUCTION
Fatty acid binding proteins (FABPs) are members of a family of conserved intracellular lipid-
binding proteins and comprise at least eight types: liver (L-FABP), intestinal (I-FABP), heart or
muscle (H-FABP), adipocyte (A-FABP), myelin (M-FABP), ileal (I-LBP), epidermal (E-FABP) and brain
(B-FABP) [1,2]. All FABPs are 14-16 kDa cytosolic proteins and display sequence similarity of
between 38 and 70%. The main function of FABP is thought to be intracellular binding and
targeting of fatty acids. They may also modulate the effect of fatty acids on various metabolic
enzymes and receptors and on cellular processes as signal transduction and gene expression.
Some members of the FABP family have been implicated in the regulation of growth and
differentiation.  Bovine mammary-derived growth inhibitor (MDGI) which was identified as a
mixture of H-FABP and A-FABP [3], caused specific growth inhibition and terminal differentiation
of mammary epithelial cells [4], and H-FABP cDNA transfection caused a modest antiproliferative
activity in human breast cancer cells.  Expression of bovine H-FABP in yeast inhibited cell growth
[5]. Changes in FABP content have been observed in tumor cells, in an FABP type - and cell type
- dependent way [6-11]. Oka et al. reported the isolation and cloning of a 14-kDa perchloric acid-
soluble protein (PSP) from rat liver [12]. This protein exhibited a dose-dependent inhibition of
mRNA translation. Another PSP isolated from rat heart, identical to H-FABP also inhibited protein
synthesis in vitro [13]. On the basis of these observations we studied the effect of a series of
FABPs (different in type, species, preparation, lipidation), mutant FABPs and other proteins on in
vitro mRNA translation.
MATERIALS AND METHODS
Materials
Human H-FABP, I-FABP, M-FABP and A-FABP were obtained by recombinant expression and
isolation, as described earlier by Veerkamp et al. [14]. Human B-FABP cDNA in pBluescript vector
(obtained from Dr. F. Shimizu, Otsuka GEN Research Institute, Kagasuno, Tokushima, Japan)
was amplified and modified with PCR to obtain NcoI and BamHI sites, checked on sequence in
pCR 2.1 vector and ligated in the pET-3d expression vector. B-FABP was expressed in transformed
BL21(DE3) cells and isolated as described for H-FABP [14]. Human L-FABP was obtained by
recombinant expression, according to the method described by Maatman et al. [15]. Recombinant
human E-FABP and bovine H-FABP were obtained from Dr. F. Spener (Dept. Biochemistry, University
of Münster, Germany) and Dr. C. Lücke (Institute Biophysical Chemistry, Frankfurt, Germany),
respectively. Rat H-FABP and A-FABP were obtained by recombinant expression and isolation
as described by Prinsen and Veerkamp [16]. Rat and porcine H-FABP were isolated from heart
tissue of these species as described previously [17]. Human H-FABP mutants were obtained by
oligonucleotide-directed in vitro mutagenesis and recombinant expression [18]. If indicated,
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FABPs were delipidated by the Lipidex procedure [19]. All FABP preparations were > 95% pure
on the basis of SDS-PAGE and Coomassie Brilliant Blue staining.
Bovine serum albumin (BSA), ovalbumin and horse heart myoglobin were from Sigma, St.
Louis, MO, U.S.A.; cytochrome c from Aldrich Chemical Company Inc., Milwaukee, MI, U.S.A.;
RNasin from Promega, Madison, WI, U.S.A.; rabbit reticulocyte lysate system, tobacco mosaic
virus mRNA, Xenopus β-globin mRNA and RNase A from Boehringer, Mannheim, Germany; GF/
C filters from Whatman International, Maidstone, UK; pCR2.1 vector from Invitrogen, Leek, the
Netherlands. All other reagents were of analytical grade.
Cell-free mRNA translation
Cell-free protein synthesis was carried out in the presence or absence of different FABP
preparations, H-FABP mutants or other proteins with a rabbit reticulocyte lysate assay system,
containing tobacco mosaic virus (TMV) mRNA. The kit instructions were basically followed, except
that the incubation time was 45 min at 30°C and the TMV mRNA concentration was reduced to
24 µg/ml. After incubation, 4 µl of the mixture were incubated with 0.5 ml 1 M NaOH containing
5% (v/v) H
2
O
2
 for 10 min at 37°C. Proteins were precipitated by addition of 0.4 ml 50% trichloric
acid (TCA)/ 2% (w/v) casein and put on GF/C filters. Filters were washed with 0.5% (w/v) TCA/ 10
mM Na
4
P
2
O
7
 and radioactivity was measured in a liquid scintillation counter.
Assay for RNase activity
Various concentrations of RNase A or FABP were added to 250 µl of a solution containing 50
mM Tris-HCl (pH 7.5), 750 µg total yeast RNA, and  the reaction mixture was incubated at 37°C
for 30 min. The reaction was stopped by precipitation with 0.1 vol. of 3 M NaAc (pH 5.2) and 2.5
vol. of  96% EtOH. RNA pellets were washed with 70% EtOH, resolved in Milli Q and applied on
1.0 % agarose gel containing 0.003% ethidium bromide. After electrophoresis the amount of
RNA present in every lane was measured by densitometry.
RESULTS
Effect of FABPs on cell-free protein synthesis
The effect of FABPs on cell-free protein synthesis was examined in a rabbit reticulocyte lysate.
Stimulation of translation by TMV mRNA amounted to 350-fold in control incubations. At 150
µg/ml, protein synthesis was inhibited to about 30% and 40% by recombinant human B-FABP
and H-FABP respectively (Table 1). Recombinant human M-FABP and I-FABP inhibited protein
synthesis almost completely, whereas human L-FABP, E-FABP and A-FABP did not affect protein
synthesis. At 15 µg/ml, the inhibitory effect of FABPs was less. Only human M-FABP inhibited
protein synthesis by 70% (Table 1). The same extent of inhibition was caused by human M-FABP,
I-FABP and H-FABP with Xenopus β-globin mRNA instead of TMV mRNA, indicating that inhibition
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Translation was measured at 24 µg/ml TMV mRNA in the absence or presence of  15 or 150 µg/ml protein
as described under “Materials and methods”, and expressed as percentage of [35S]methionine incorporation
of control without protein. Values are means ± SD (range) for the number of independent experiments
indicated. All FABP preparations are human, recombinant and undelipidated proteins, except otherwise
indicated.
To examine the effect of bound ligands on protein synthesis, the effect of delipidation was
studied. Delipidation of recombinant M-FABP and I-FABP did not alter their inhibitory effect (Table
1). Several human H-FABP mutants with different binding affinities for oleic acid were also tested.
Mutants F57S, F4E, G67S and F4S have a high binding affinity for oleic acid (K
d
 values are 0.38,
0.39, 0.35 and 0.47 µM respectively), whereas mutants F16E and R106T do not bind fatty acids
or with           very low affinity. Mutants F57S, F16E and R106T inhibited protein synthesis, whereas
by FABPs is not dependent on the mRNA type.
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 mutants F4E, G67S and F4S did not affect protein synthesis. Together, these results indicate that
there is no relation between protein synthesis inhibition and bound ligands as fatty acids or
binding activity.
Besides human recombinant FABP types, recombinant and tissue-derived FABPs from other
species were tested on their ability to inhibit protein synthesis. Recombinant rat H-FABP did not
show any inhibition at 150 µg/ml, whereas recombinant bovine and human H-FABP inhibited
by 75% and 62%, respectively. In contrast to recombinant rat H-FABP, tissue-derived rat H-FABP
inhibited protein synthesis. Tissue-derived porcine H-FABP did not show any inhibitory effect.
Recombinant rat A-FABP had no effect like human A-FABP. Protein synthesis was not, or to a
smaller extent, affected by proteins like albumin, ovalbumin, myoglobin and cytochrome c,
indicating that inhibition of protein synthesis is specific for some FABPs.
Inhibition of protein synthesis by FABPs appeared to be dose-dependent (Fig.1). Recombinant
human M-FABP exhibited 50% inhibition (IC
50
) at 9.5 µg/ml, whereas IC
50
 values were 36 µg/ml
and 88 µg/ml for recombinant human I-FABP and H-FABP, respectively.
Figure 1.
Effect on cell-free protein synthesis by FABPs and RNase A.
Translation was measured in the presence of different concentrations of human recombinant M-FABP,
H-FABP or I-FABP, or RNase A. Each point represents the mean value ± SD (range) for at least two
independent experiments, expressed as percentage of [35S]methionine incorporation of control.
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Test on RNase activity
Since contaminating RNase activity might cause the inhibition, we determined the effect of
different RNase A concentrations on the translation assay (Fig. 1). Its IC
50
 value amounted to 4.9
µg/ml. This value is the same order of the IC
50
 value for M-FABP. Subsequently we tested all
FABP solutions on the presence of RNase activity, by incubation with yeast RNA and subsequent
agarose gel electrophoresis. RNase A clearly showed activity at a concentration of 1.5 µg/ml or
higher, whereas all FABPs did not show any RNase activity at a concentration of 150 µg/ml
protein. Densitometry revealed that all FABP preparations showed about the same density as
the positive control which contained  RNA only. Even 1.5 mg/ml of human recombinant H-FABP
did not show any RNase activity. To confirm these data, the effect of RNasin in combination with
RNase A or FABP on protein synthesis was investigated. However, 2 U/µl RNasin stimulated the
protein synthesis of the control by about 300% and could therefore not be used to examine the
presence of RNase activity in FABP preparations.
DISCUSSION
Several members of the FABP family are possibly involved in the regulation of cell growth
and differentiation. In this study we show that M-FABP, I-FABP, B-FABP and H-FABP inhibit in vitro
protein synthesis at physiological concentrations of about 1-10 µM. This inhibition appeared to
be dose-dependent and is not, or to a smaller extent, exhibited by other proteins. Both agarose
gel electrophoresis and the translation assay indicate that the FABPs do not contain RNase
activity. Rnase A and M-FABP have about the same IC
50
 value and the IC
50
 values of I-FABP and
H-FABP are only 10-fold lower (Fig. 1), indicating that the inhibitory effect of the FABPs can not be
due to RNase contamination. These findings show that FABPs inhibit protein synthesis in the
rabbit reticulocyte cell-free lysate system in a different manner from RNase A. The same findings
were reported for rat liver- and heart-derived perchloric acid-soluble protein (PSP) [12-13]. It was
also shown that these PSPs stimulated the disaggragation of polyribosomes in the lysate,
indicating that they inhibit the initiation stage of the protein synthesis [12]. It remains to be
investigated whether this is the same for FABPs.
There seems to be no clear relation between protein synthesis inhibition and FABP structure,
isoelectric point, fatty acid-binding activity or the presence of a ligand in the FABP molecule. M-
FABP and A-FABP with similar isoelectric points and structure show a different action. Delipidation
has no effect. H-FABP mutants F16E and R106T which have low affinity for oleic acid show the
same inhibitory effect on protein synthesis as wildtype human H-FABP. However, mutants with
high affinity for oleic acid have either no effect (F4S, F4E and G67S), or the same effect as wildtype
H-FABP (F57S). Furthermore, delipidation of FABPs does not alter their inhibitory effect. Thus, it
appears that the inhibitory effect is established by the FABP itself and not by its bound ligand.
Interestingly, H-FABPs derived from different species did not show the same effect on protein
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synthesis. Both human and bovine recombinant H-FABP inhibited protein synthesis whereas
rat recombinant H-FABP had no effect. Surprisingly, tissue-derived rat H-FABP had an inhibitory
effect, whereas tissue-derived porcine H-FABP had not. We have no explanation for these
contrasting results.
Some members of the FABP family have been implicated in the regulation of growth and
differentiation. Yeast, mouse mammary epithelial cells and human breast cancer cell lines
showed a specific inhibition of growth and exhibited a differentiated morphology upon H-FABP
cDNA transfection [5,6]. In agreement with these data, recombinant human and bovine H-FABP
and tissue-derived rat H-FABP inhibited cell-free protein synthesis at physiological concentrations.
Studies on rat L6 muscle cells showed that A-FABP cDNA transfection resulted in an increased
growth but a decrease in differentiation [16], which may be in accordance with our observation
that A-FABP does not influence cell-free protein synthesis. Although L-FABP plays an important
role in the modulation of mitogenesis of liver and hepatoma cells [20], addition of L-FABP did
not affect cell-free protein synthesis in the system we used. In conclusion, some members of
the FABP family possibly regulate cell proliferation and differentiation by interaction with the
translation complex, although the mechanism of this interaction remains to be investigated.
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ABSTRACT
Intracellular accumulation of fatty acids (FA) is a well-described consequence of renal ischae-
mia and may lead to lethal cell injury. Fatty acid-binding proteins (FABPs) are small cytosolic
proteins with high affinity for FA. They may protect vital cellular functions by binding and pro-
moting metabolism of FA, thereby reducing their intracellular concentration. In this study we
investigated the putative cytoprotective role of FABP in a Madin-Darby canine kidney (MDCK)
cell model for renal damage. We studied the effects of transfection with cDNA encoding heart
FABP, adipocyte FABP or liver FABP on cytotoxicity induced by chemical anoxia or FA.
Transfection of MDCK type II cells with these cDNA types caused a 5-20 fold increase of FABP
content, but did not change the rate or extent of palmitate uptake. After 1 h incubation with KCN
all cell types showed a reduced cell viability and cellular ATP content and an intracellular accu-
mulation of non-esterified FA. High extracellular concentrations of oleate, but not palmitate,
caused a markedly decreased cell viability and cellular ATP content. Oleate accumulated in
non-esterified form in these cells. Simultaneous addition of glucose ameliorated the damaging
effects of KCN or oleate, indicating that glycolytic ATP could substitute for uncoupled oxidative
phosphorylation. No significant differences in the effects of chemical anoxia or oleate were
observed between non-transfected, mock-transfected and FABP cDNA-transfected cells. Non-
esterified FA accumulation was not reduced in any of the FABP cDNA-transfected cell lines. In
conclusion, our data do not provide evidence for a cytoprotective role of FABP in this kidney cell
model.
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INTRODUCTION
Ischaemia and hypoxia are major causes of renal failure. Intracellular accumulation of non-
esterified fatty acids (FA) is a well-described consequence of renal ischaemia [1] and ATP deple-
tion is induced by chemical anoxia [2]. Multiple phospholipases are probably activated by Ca2+
as a result of ATP depletion, but the large amounts of FA and lysophospholipids released after
ischaemia indicate that phospholipase A
2
 is responsible for most of the FA released [1,3].
Activation of this enzyme and the resulting release and accumulation of FA have been impli-
cated in the pathogenesis of cell injury after renal ischaemia [4,5]. In proximal tubule segments
from mouse, hypoxia caused an approximately 8-fold increment of FA [6]. Similarly, FA accumu-
lated when cultures of mouse proximal tubule cells and Madin Darby Canine Kidney (MDCK)
cells were subjected to chemical anoxia [7,8]. Extracellular albumin reduced accumulation of
FA and ameliorated injury, mitochondrial function and cell viability in renal tubules after ischaemia
[7]. It has also been proposed that accumulation of FA (especially arachidonic acid) can result in
a feedback inhibition of phospholipase A
2
, thereby protecting against hypoxic injury [6,9].
Fatty acid-binding proteins (FABPs) are 14-16 kDa cytosolic proteins, involved in the intracel-
lular binding and transport of long-chain FA. They bind FA with K
d
 values between 2 and 1000
nM, depending on the type of FABP and the type of FA [10,11]. FABPs may modulate the role of FA
in cellular processes, like metabolism, signal transduction and gene expression, and the function
of ion channels, receptors and enzymes [12-15].
In addition to these functions FABPs may have cytoprotective effects e.g. in the cardiomyocyte
[12]. It has been hypothesized that FABPs protect vital cellular functions by binding intracellular
long-chain FA and their derivatives [12,14-16]. FABPs are suitable for this function since they are
present intracellularly in concentrations considerably higher than those of long-chain FA [14,17].
Vork et al. [18,19] suggested that heart (H-)FABP can bind the FA accumulating under patho-
physiological circumstances, and that initially the accumulating FA are released from the
cardiomyocyte in this form. Other mechanisms by which H-FABP could protect the heart include
the scavenging of free radicals [20] and the inhibition of a β-adrenergic response as observed
in cultured neonatal rat heart cells [21]. The presence of FABP would enable a more rapid
exchange of FA among subcellular and intercellular sites, so as to counteract a local FA accu-
mulation [22]. Another example of putative cytoprotection by FABP is the reversion of FA-mediated
inhibition of brain synaptosomal Na+-dependent amino acid uptake systems by liver (L-)FABP
[23]. Overexpression of epidermal FABP in chemoresistant pancreatic cancer cell lines was
suggested to be part of a mechanism of sequestration or removal of cytotoxic drugs [24]. Taken
together, the present data do not yet allow a definitive conclusion to be drawn about the
potentially protective effect of FABP.
In the present study we investigate the putative cytoprotective role of FABP against induced
cytotoxicity in a MDCK cell model for renal damage. In the human kidney H-FABP and L-FABP
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are present in different concentrations and with differing localizations [25]. H-FABP is present in
distal tubules, whereas L-FABP is identified only in proximal tubules [25]. MDCK type II epithelial
cells resemble nephron distal tubule segments [26] and were used previously to study suscep-
tibility to chemical anoxia [7,8]. Therefore we studied the effects of transfection of MDCK type II
cells with cDNA encoding three different FABP types, H-FABP, adipocyte (A-)FABP and L-FABP on
KCN-induced anoxia, FA-induced cytotoxicity and FA accumulation.
EXPERIMENTAL
Materials
Puromycin dihydrochloride was from Sigma (St. Louis, MO, USA); Dulbecco’s modified Eagle
medium (DMEM) was from Gibco (Hoofddorp, The Netherlands); fetal bovine serum was from
Integro (Zaandam, The Netherlands); [1-14C]oleic acid  (56 mCi/mmol) and [1-14C]palmitic acid
(57 mCi/mmol) were from Amersham Pharmacia Biotech  (Little Chalfont, Bucks., UK); Optifluor
was from Packard (Groningen, The Netherlands); trypsin was from Difco laboratories (Detroit,
Michigan, USA); TLC aluminium sheets with silica gel 60 F
254
 were from Merck (Darmstadt, Ger-
many). MDCK type II cells were a kind gift of Dr. P. Deen (Dept of Cell Physiology, University of
Nijmegen, The Netherlands). All other reagents were of analytical grade.
Culture media, buffers and cell culture
Dulbecco’s modified phosphate-buffered saline (D-PBS) contained 145 mM NaCl/5.4 mM
KCl/5 mM Na
2
HPO
4
/25 mM glucose/25 mM sucrose (pH 7.4). Growth medium was composed
of DMEM with 10 % fetal bovine serum.
MDCK II cells were proliferated in growth medium. At confluency the cells were washed with
D-PBS, treated with 2 mM EDTA in D-PBS during 1 min, and trypsinized (0.05% trypsin in D-PBS
for 7-10 min at 37°C), collected by centrifugation and seeded again in fresh growth medium.
Medium was changed every 3-4 days.
Preparation of FABP expression constructs
The constructs were based on the pSG5 expression plasmid [27]. Transcription of the cDNAs
was under the control of a simian virus 40 early promoter and the construct contained a rabbit
β-globin intron II and a simian virus 40 poly-A signal [27]. A modified pSG5 plasmid, with an
extended multiple cloning site and a 1,7 kb pac cassette (puromycin acetyltransferase) ligated
in the SalI site of the multiple cloning site was used as the expression construct.
Rat H-FABP and A-FABP cDNAs were cloned in the pSG5 expression plasmid as described
previously [28]. Human L-FABP cDNA in the prokaryotic expression plasmid pET3b was cloned
as described by Maatman et al. [29]. The EcoRI site in the L-FABP cDNA was removed by the
unique site elimination kit (Amersham Pharmacia Biotech) using the following primer: 5’-
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GTGATCCAAAACGAGTTCACGGTGGGGGAG-3’. Codon GAA encoding Glu62 was replaced by
GAG, which does not induce a change at the amino acid level. Human L-FABP was subsequently
amplified using primers with recognition sites for EcoRI, to facilitate cloning into the EcoRI site of
the pSG5-pac expression plasmid ’s multiple cloning site: forward primer 5 ’-
TAGGGCGAATTCGGCTTACATATGAGTTTC- 3’; reverse primer 5’- CCCATCGAATTCGGCTC
CGGATCCTGTTTA- 3’. The orientation of the FABP insert was verified by PstI/KpnI digestion and
automatic DNA sequencing.
Introduction of plasmids into MDCK II cells by Ca3(PO4)2 transfection
MDCK II cells were seeded at a density of 1x106 cells per 100 mm dish, and cultured for 18 h
to 40-50% confluency. Medium was refreshed and after 2 h transfection was started. Linearized
DNA (25-30 µg) was mixed with 125 mM CaCl
2
 in HBS buffer (140 mM NaCl/5 mM KCl/0.75 mM
Na
2
HPO
4
/6 mM dextrose/25 mM HEPES, pH 7.05). The DNA suspension was added dropwise
to the cells and incubated for 6 h at 37°C under 5% CO
2
. Cells were shocked by addition of 20%
glycerol in TBS buffer (137 mM NaCl/2.7 mM KCl/0.6 mM Na
2
HPO
4
/0.1 M Tris, 0.75 mM CaCl
2
,
0.75 mM MgCl
2
, pH 7.5) and incubated for 2 min at 22°C. Subsequently cells were washed with
TBS buffer and fresh growth medium was added to the cells. After 24 h incubation at 37°C with
5% CO
2
, cells were trypsinized and seeded in six well culture plates in growth medium containing
5 µg/ml puromycin. Medium was refreshed every 3 days. Then, 7-10 days after transfection,
separate colonies were picked and grown to check for clonal variation.
SDS-PAGE and immunoblotting
Cytoplasmic cell fractions were isolated by homogenization in SET buffer (250 mM sucrose/
2 mM EDTA/10 mM Tris, pH 7.4) and subsequent centrifugation for 15 min at 14000 g at 4°C.
Cytoplasmic fractions were analysed for FABP expression by separation of 10 µg of protein by
SDS/PAGE (15% gel) and Western blotting. Rat H- or A-FABP and human L-FABP were detected
with polyclonal rabbit antisera and the ECL detection system (Amersham Pharmacia Biotech).
FABP contents were determined by ELISA. Polyclonal antisera (1:500 dilutions) were used as first
antibodies. Peroxidase-conjugated goat anti-rabbit IgG (γ-chain specific, 1:5000 dilution) was
used as the second antibody. Extinction was measured at 490 nm. Purified recombinant rat A-
FABP and H-FABP, and human L-FABP with binding characteristics comparable with tissue-derived
or recombinant proteins were used as standards [28,29]
Assay of palmitic acid uptake
Palmitic acid uptake was determined as described previously for L6 myoblasts [28]. Incubation
with 75 µM [1-14C]palmitic acid bound to 15 µM albumin was performed during 1-30 min. At
each time point three plates were assayed. Values were corrected for a blank that was
determined by aspirating the FA-containing solution immediately after addition. The data were
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normalized for protein content, determined on three identical plates. Cells were washed three
times with PBS, lysed with 0.5 M NaOH, neutralised with 6 M HCl and used for protein determi-
nation according to Lowry et al. [30].
Methods to induce cytotoxicity
Chemical anoxia
Chemical anoxia was induced as previously described [7]. Triplicate cell monolayers were
incubated for 1 h with 10 mM KCN or 10 mM KCN/5 mM deoxyglucose (DOG) in Krebs-Henseleit
buffer (115 mM NaCl/3.6 mM KCl/1.3 mM KH
2
PO
4
/25 mM NaHCO
3
, pH 7.4), in the presence or
not of 10 mM glucose without metabolic inhibitors at 37°C under 5% CO
2
. Incubation in the
presence of 10 mM glucose only was used as a control.
Exogenous fatty acids
Oleic acid and palmitic acid were dissolved in 96% ethanol. A stock concentration of 50 mM
was divided into aliquots and frozen at –20°C. On the day of the experiment, aliquots were
diluted 1:10 or 1:4, respectively, in 96% ethanol, and further diluted in Krebs-Henseleit buffer to
50 or 125 µM for both oleic and palmitic acid. Cells were grown to confluence in 24-well culture
plates in growth medium and were subsequently incubated for 1 h at 37°C under 5% CO
2
 with
either 50 or 125 µM oleic or palmitic acid in Krebs-Henseleit buffer, in the presence or not of 10
mM glucose. The ethanol concentration during the experiment was 0.1%. Incubation in the
presence of 10 mM glucose only was used as a control.
Evaluation of cell injury
Cell viability
Cells from duplicate wells (grown in 24-well culture plates) were harvested at the end of
each period of induced injury. Cells were centrifuged at 185 g for 5 min and resuspended in 100
µl of growth medium. Trypan Blue (0.25%) in PBS was added, and the number of viable cells
(excluding Trypan Blue) was counted and expressed as percentage of total cells.
Cell ATP content
Cell ATP was extracted with 4% perchloric acid at 0°C. ATP levels were measured using a
luciferase assay with purified luciferin/luciferase (Promega, Madison, WI, USA). Cell ATP levels
were expressed in nmol/mg of cell protein.
Measurement of fatty acid accumulation
Cells were grown to confluence in 60 mm dishes in culture medium for 36 h in the presence
of 50 µM [1-14C]palmitic acid bound to 12.5 µM albumin and washed with PBS. After a subsequent
incubation for 1 h with 10 mM KCN in Krebs-Henseleit buffer at 37°C under 5% CO
2
, the cells
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were washed three times with 0.15 M NaCl, centrifuged for 5 min at 500 g, and resuspended in
the same medium (2-5 mg of protein/ml).
Alternatively, confluent cells were incubated for only 1 h with different concentrations of [1-
14C]oleic acid in Krebs-Henseleit buffer at 37°C under 5% CO
2
.  Cell extracts were prepared and
analysed for lipids by TLC as described by Mazière et al. [31]. Neutral lipids were separated in
hexane/diethylether/acetic acid (35:15:1, v/v). The incorporation and accumulation of [1-
14C]palmitic acid or [1-14C]oleic acid were determined by liquid scintillation counting of separated
spots.
RESULTS
Transfection of MDCK type II cells with cDNA encoding different FABP types
Endogenous H-FABP and L-FABP contents of MDCK type II cells were low (< 0.05% of cyto-
plasmic protein) or not detectable, respectively, as determined by semi-quantitative Western
blotting with specific antisera [28,32]. After stable Ca
3
(PO
4
) transfection of MDCK type II cells
with FABP cDNAs, separate colonies were picked and grown to check for clonal variation. Clonal
variation was monitored by SDS-PAGE and subsequent immunoblotting of cytosolic fractions
isolated from transfected cells (Figure 1). Among the seven isolated rat H-FABP-transfectants,
one clone (Figure 1A, lane 4) showed an eight-times higher expression of H-FABP than mock-
transfected cells.  After transfection with rat A-FABP cDNA, two of the seven isolated clones
showed expression of A-FABP, but in only one clone was the expression four times higher than
the mock-transfectant (Figure 1B, lane 3). Of 15 isolated clones transfected with human L-FABP
cDNA, six showed increased L-FABP expression (Figure 1C).
Figure 1.
FABP expression in non-transfected and transfected MDCK II clones.
Cytosolic protein (10 µg) was separated by 12.5% SDS-PAGE gel. After Western blotting on nitrocellulose,
detection was performed with polyclonal antisera (1:1000 dilution) directed against rat H-FABP (A), A-FABP
(B) or L-FABP (C). Recombinant H-, A-, or L-FABP (100 ng) were used as standards.  A, B: Lane 1, A-FABP;
lane 2, H-FABP; lane 3, A-FABP cDNA transfected clone 5; lane 4, H-FABP cDNA transfected clone 4; lane
5, mock-transfected clone 6; lane 6, non-transfected cells. C: Lanes 7-13, L-FABP cDNA transfected clones
1, 2, 4, 5, 6, 7, 9; lane 14, L-FABP.
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The FABP contents in transfected clones were also determined by ELISA (Table 1). The contents of
H-FABP, A-FABP and L-FABP in mock-transfected cells were in the same range as in non-
transfected MDCK type II cells. In rat H-FABP cDNA-transfected clone 4, H-FABP expression was
significantly increased compared with mock-transfected cells. The L-FABP content in all L-FABP
cDNA-transfected clones studied was significantly higher than in mock-transfected cells. A-
FABP cDNA-transfected clone 5 contained a significantly higher amount of A-FABP than the
mock-transfectants.
FABP contents were determined by ELISA, using purified recombinant H-, A-, or L-FABP as standards.
Polyclonal antisera (1:500 diluted) were used as first antibody. Peroxidase-conjugated goat anti-rabbit
IgG (γ-chain specific, 1:5000 diluted) was used as second antibody. Extinction was measured at 490 nm.
Values are means ± SD for at least three independent experiments.  -, not determined.
All transfected clones were morphologically similar to non-transfected MDCK type II cells,
and showed no differences in growth rate compared with mock-transfected or non-transfected
cells. Single representative clones with high expression of H-FABP (clone 4), A-FABP (clone 5) or
L-FABP (clone 5) and one mock clone (clone 6) were used in the following studies.
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Palmitic acid uptake
We did not observe significant differences in palmitic acid uptake of the different transfected
MDCK II cultures after 1-30 min (Table 2). H-FABP, A-FABP or L-FABP transfection and
overexpression did not have an effect on the palmitic acid uptake (after 1 min) or uptake together
with metabolism (longer periods).
Cells were used as confluent cultures on growth medium, and equilibrated for 1 h at 37°C and 5% CO2 on
DMEM without serum. The assay was started by the addition of 75 µM [1-14C]palmitic acid bound to 15 µM
albumin. Values (in nmol palmitic acid/mg protein) are the means ± SD of 3 independent experiments in
triplicate. No significant differences were detected between the different clone types.
Effects of chemical anoxia on cell viability and ATP content
Chemical anoxia, induced by 1 h incubation with 10 mM KCN, resulted in a decreased number
of viable cells for all cell types (Table 3). The same effect was observed when 10 mM KCN was
added in combination with 5 mM DOG. The decrease of cell viability induced by KCN could be
reduced by co-incubation with 10 mM glucose, although this effect was not significant for the
non-transfected and the A-FABP cDNA-transfected cells. No significant differences in the effect
of chemical anoxia were observed between non-transfected, mock-transfected and FABP cDNA-
transfected cells.
Cells treated for 1 h with 10 mM glucose (control) contained 6.4 ± 2.6 nmol of ATP/mg of
cytosolic protein (mean ± SD, n= 24). This value did not differ between mock-transfected, FABP
cDNA-transfected and non-transfected cells. Incubation of the clones with 10 mM KCN generally
resulted in a reduction of ATP content to 43-60 % of the control (Table 4). Addition of 10 mM KCN
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Cells were incubated for 1 h with 10 mM glucose (controls) or with the indicated agent. Glucose-treated
cells (controls) showed between 83 and 98% viable cells as determined by trypan blue staining. The
viability is given for all cell types in percentage of the appropriate control as mean ± SD of three independent
experiments. ‡p < 0.05 as compared with KCN/glucose; §p < 0.1 as compared with KCN/glucose; *p <
0.01 as compared with control; †p < 0.05 as compared with oleate alone.
together with 10 mM glucose had no effect compared with the control. Treatment with a combi-
nation of 10 mM KCN and 5 mM DOG led to a marked decrease of ATP content in all cell types
(7-25% of the control).
Cells were incubated for 1 h with 10 mM glucose (controls) or with the indicated agents. The ATP content of
glucose-incubated cells was 6.4 ± 2.6 nmol per mg cytosolic protein and did not differ for the various
transfected cells. The ATP content of treated cells is given in percentage of the appropriate control as
mean ± SD of three independent experiments. ‡p < 0.05 as compared with KCN/glucose; *p < 0.01 as
compared with control; †p < 0.05 as compared with oleate alone
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To establish the probable cause of the cellular injury, we studied the accumulation of labelled
non-esterified FA in cells cultured for 36 h with [1-14C]palmitate and subsequently incubated for
1 h with 10 mM KCN in Krebs-Henseleit buffer (Table 5). The palmitic acid release was taken as
representative for non-esterified FA. No marked differences were observed in FA incorporation
among the five different cell types after culturing (results not shown). In all KCN-treated cells the
content of labelled non-esterified palmitic acid became markedly higher than in non-treated
cells (Table 5).
Cells were cultured for 36 h on growth medium with 50 µM [1-14C]palmitic acid bound to 12.5 µM albumin,
washed and subsequently incubated for 1 h in Krebs-Henseleit buffer with or without 10 mM KCN. Cell
homogenates were analyzed by TLC. Fatty acid (FA) spots were isolated and counted by liquid scintillation.
Values (in pmol/mg cell protein) are means ± SD of three independent experiments.
Effect of oleic or palmitic acid on cell viability and ATP content
Exposure for 2 h of the cells to oleic acid (125 µM) completely eliminated cell viability, whereas
after 1 h exposure a reduction to 8% of the control (10 mM glucose) was achieved (Table 3). No
effect was observed after 1 h incubation with 10 µM oleic acid (results not shown). Incubation
with 50 µM oleic acid reduced cell viability of the non-transfected and transfected cells to 22-
44%. The effect of 125 µM oleic acid could be suppressed by co-incubation with 10 mM glucose.
In contrast to oleic acid, palmitic acid did not significantly affect cell viability of all cell types used,
independent of its concentration. No BSA was included during the incubations, so micelle for-
mation most assuredly took place. However, it did not result in cell-membrane disruption, as
observed by light microscopy.
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Treatment of cells with 50 µM oleic acid for 1 h resulted in a decreased ATP content, varying
between 12 and 48 % of the control (Table 4). After treatment with 125 µM oleic acid no ATP
could be detected. The ATP content could be recovered to 66-94 % of control levels by co-
incubation with 10 mM glucose. In contrast to oleic acid, palmitic acid did not affect or only to a
slight extent affected ATP content in all cell types used (Table 4).
Comparison of non-transfected cells with FABP cDNA-transfected cells showed no signifi-
cant differences in cell viability and ATP content after incubation with 50 or 125 µM oleic acid
(Table 3 and 4). These results indicate that transfection of MDCK type II cells with FABP-encoding
cDNA has no effect on oleic acid-induced cytotoxicity.
To establish the intracellular accumulation of FA, incorporation of [1-14C]oleic acid was meas-
ured after 1 h of incubation with concentrations between 0-125 µM in Krebs-Henseleit buffer.
Intracellular non-esterified oleic acid was significantly higher in MDCK cells treated with 125 µM
oleate than in those treated with 10 or 50 µM oleate (Table 6). Incorporation of oleate into
diacylglycerols/cholesterol and triacylglycerols was however lower at 125 µM than at 50 µM,
presumably by ATP deficiency. The radioactivity of the cholesterol + diacylglycerol spot was
mainly in diacylglycerol, which migrated together with cholesterol on TLC. No differences were
observed between mock-transfected, FABP cDNA-transfected and non-transfected cells (results
not shown). These observations indicate uptake and accumulation of non-esterified oleate in
all cell types. The intracellular non-esterified oleate concentration was related to the extracellular
concentration. The presence of FABP did not cause a lower intracellular concentration of non-
esterified oleic acid.
Cells were incubated for 1 h with 10, 50 or 125 µM [1-14C]oleic acid in Krebs-Henseleit buffer at 37°C and 5%
CO2. Cell homogenates were analyzed by TLC. Cholesterol (C) + diacylglycerol (DG), triacylglycerol (TG)
and fatty acid (FA) spots were isolated and counted by liquid scintillation. Values are expressed in pmol/
mg cell protein and are means ± range of two independent experiments. Similar values were obtained
for FABP cDNA-transfected and mock-transfected cells.
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DISCUSSION
Although previous studies have suggested a protective role of FABP against high intracellu-
lar FA concentrations [12,14-16,18,19], free radicals [20] or cytotoxic drugs [24], evidence for such
a role is lacking. In this study we investigated the putative cytoprotective role of FABPs in a
kidney cell model.
The kidney contains two types of FABP: the heart- and liver-types. L-FABP is twice as abun-
dant in the human kidney than H-FABP, but is predominantly localized in cells of the proximal
tubules. H-FABP is mainly present in the distal tubule cells [25]. In rat kidney the H-FABP content
is 10 times higher than the L-FABP content [25,33]. Like in humans, H-FABP is only present in the
distal tubules, but L-FABP is present in proximal and distal tubules [33]. In agreement with these
findings, we detected a higher content of endogenous H-FABP than of L-FABP in MDCK type II
cells, which are epithelial cells originating from the distal tubule. Transfection of MDCK type II
cells with H-FABP, A-FABP or L-FABP cDNA caused a 5-20 fold increase in cytoplasmic FABP
content, as shown by Western blot analysis and ELISA. The concentration of H-FABP in transfected
MDCK cells is about equal to that in rat and human kidney (10 and 5 µg/mg, respectively [33]).
The L-FABP concentration is higher after transfection than in human and rat kidney (9 and 0.9
µg/mg, respectively [33]).
The increase of the H-FABP, A-FABP or L-FABP content in MDCK type II cells did not cause a
difference in the rate or extent of palmitate uptake after 1-30 min. Comparable results were
obtained with L6 myoblasts overexpressing H-FABP or A-FABP [28]. Expression of L-FABP in
mouse L-cell fibroblasts increased the initial rate and extent of cis-parinaric acid uptake by 50
%, whereas expression of  intestinal FABP did not affect FA uptake [34,35]. However, in L-cells
expressing larger amounts of  intestinal FABP, FA uptake decreased [36]. In a differentiated
enterocyte model high levels of intestinal FABP also inhibited FA incorporation [37]. A direct
correlation between L-FABP content and FA uptake was observed in HepG2 cells either transfected
with antisense L-FABP mRNA or treated with a peroxisome proliferator [38]. In a human breast
cancer cell line transfected with H-FABP cDNA a modest increase in palmitic and oleic acid
uptake was observed, but there was no increase of the incorporation into phospholipids or
triacylglycerols [39]. Taken together, these observations suggest that the effect of FABP on FA
uptake and incorporation may differ according to the cell type used and the FABP type expressed.
We investigated the effect of FABP cDNA-transfection of MDCK cells on KCN-and FA-induced
cytotoxicity. CN inhibits oxidative phosphorylation in mitochondria and causes chemical anoxia.
We observed marked and similar decreases in cellular ATP content after KCN addition to FABP
cDNA-transfected and non-transfected cells (Table 4). The decrease in cell viability was modest
and was significant only for mock- and H-FABP cDNA-transfected cells (Table 3). These findings
are in agreement with a critical ATP level (5-15 % of control) above which cellular function and
integrity are maintained [2,7]. Addition of DOG together with KCN had an even stronger effect
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on the ATP content, since DOG inhibits the glycolysis as well. MDCK cells do demonstrate the
ability to generate ATP via a glycolytic metabolism, since the addition of glucose ameliorated
the severity of ATP depletion. Resistance of continuous cell lines to ischaemic injury by glycolytic
capacity has been reported previously [2,7].
We demonstrated that ATP depletion by KCN is accompanied by accumulation of non-es-
terified FA in MDCK cells (Table 5). After 1 h of incubation with KCN, the amount of intracellular
palmitate was increased by approx. 1.5-fold compared with the controls. Sheridan et al. [7]
reported a comparable accumulation of palmitate, and also of palmitoleate, stearate and oleate
in MDCK cells after KCN addition.
Cytotoxicity was also induced by extracellular addition of high concentrations of oleate (Tables
3 and 4). Oleate in combination with glucose resulted only in a modest decrease in cell viability
and no reduction of ATP levels, in agreement with previous experiments [8]. Our data show that
the intracellular concentration of non-esterified oleic acid was related to the extracellular con-
centration (Table 6). Intracellular accumulation of FA under pathophysiological conditions may
decrease the intracellular ATP content by uncoupling of oxidative phosphorylation by different
mechanisms. At high concentrations, FA probably irreversibly disrupt the membrane in a deter-
gent-like mode [40,41]. We found however that addition of glucose together with oleate resulted
in significant increases in cell viability and ATP content (Tables 3 and 4), indicating that glycolysis
occurs and that cell injury by oleate is not only due to a detergent effect. Other mechanisms of
FA-mediated uncoupling are their protonophoric action on the inner mitochondrial membrane
and their interference with the proton-pumping machinery of the respiratory chain [41]. At low
concentrations, FA may also act indirectly via uncoupling proteins which dissipate the proton
gradient across the mitochondrial membrane [42]. FA activate uncoupling protein 1 (UCP1) by
acting as second messengers [43]. Oleic acid also activates the UCP3 gene in C
2
C
12
 myoblasts
in a time- and dose-dependent manner [44].
Differences have been found in the effect of oleic and palmitic acid on cellular behaviour.
Oleate was reported to cause an intracellular release of Ca2+ in platelets, a phenomenon that
plays a role in the pathogenesis of ischaemic cell injury [45]. However, stearate and palmitate
had no effect on the cytosolic Ca2+ concentration. Furthermore it has been shown that unsaturated
FA, in contrast to saturated FA, could increase the membrane fluidity in cytotoxic T-lymphocytes
[46]. A role for oleate, but not palmitate, in respiratory control and enzyme activity was suggested
since oleate influences the membrane potential in cytochrome c oxidase-containing phospholipid
vesicles [47]. In agreement with abovementioned findings, we observed that exposure of MDCK
cells to oleate resulted in loss of cell viability and ATP content in a dose-dependent manner,
whereas palmitate had no effect (Tables 3 and 4).
Although FABPs were proposed to have a cytoprotective function by reducing high intracel-
lular FA levels, the FABP cDNA-transfected MDCK cells showed similar cytotoxicity, ATP deple-
tion, and FA uptake and accumulation to non-transfected and mock-transfected cells. These
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results indicate that FABPs do not substantially reduce intracellular levels of non-esterified FA in
these cells, in spite of their possible role in transfer and metabolism. In contrast, extracellular
albumin (3%) ameliorated cell injury in mouse proximal tubule cells at addition of cyanide and
DOG and reduced the amount of intracellular non-esterified FA found after ATP depletion [7].
Extraction of FA from cells by the large amount of albumin can explain the counteracting effect.
In conclusion, our data provide no evidence for a cytoprotective role of FABP in the kidney
cell model used. None of the FABP cDNA types used for transfection of MDCK type II cells were
able to decrease the deleterious effects of the intracellular accumulation of FA, caused by extra-
cellular addition of KCN and DOG or oleic acid.
REFERENCES
1. Matthys, E., Patel, Y., Kreisberg, J., Steward, J.H. and Venkatachalam, M. (1984) Lipid alterations induced by
renal ischaemia: pathogenetic factor in membrane damage. Kidney Int. 26, 153-161
2. Venkatachalam, M.A., Patel, Y.J., Kreisberg, J.I. and Weinberg, J.M. (1988) Energy thresholds that determine
membrane integrity and injury in a renal epithelial cell line (LLC-PK1). J. Clin. Invest. 81, 745-759
3. Weinberg, J.M. (1991) The cell biology of ischemic renal injury. Kidney Int. 39, 476-500
4. Humes, D.H., Nguyen, V.D., Cielinski, D.A. and Messana, J.M. (1989) The role of free fatty acids in hypoxia
induced injury to renal proximal tubule cells. Am. J. Physiol. 256, F688-F696
5. Bonventre, J.V. (1993) Mechanisms of ischemic acute renal failure. Kidney Int. 43, 1160-1178
6. Zager, R.A., Sacks, B.M., Burkhart, K.M. and Williams, A.C. (1999) Plasma membrane phospholipid integrity and
orientation during hypoxic and toxic proximal tubular attack. Kidney Int. 56, 104-107
7. Sheridan, A.M., Schwartz, J.H., Kroshian, V., Tercyak, A.M., Laraia, J., Masino, S. and Lieberthal, W. (1993)
Renal mouse proximal tubular cells are more susceptible than MDCK cells to chemical anoxia. Am. J. Physiol. 265,
F342-F350
8. Lieberthal, W., Sheridan, A.M. and Schwartz, J.H. (1997) Fatty acid-induced cytotoxicity: differences in suscepti-
bility between MDCK cells and primary cultures of proximal tubular cells. J. Lab. Clin. Med. 129, 260-265
9. Alkhunaizi, A.M., Yaqoob, M.M., Edelstein, C.L., Gengaro, P.E., Burke, T.J., Nemenoff, R.A. and Schrier, R.W.
(1996) Arachidonic acid protects against hypoxic injury in rat proximal tubules. Kidney Int. 49, 620-625
10. Richieri, G.V., Ogata, R.T. and Kleinfeld, A.M. (1994) Equilibrium constants for the binding of fatty acids with fatty
acid-binding proteins from adipocyte, intestine, heart, and liver measured with the fluorescent probe ADIFAB. J. Biol.
Chem. 269, 23918-23930
11. Richieri, G.V., Ogata, R.T., Zimmerman, A.W., Veerkamp, J.H. and Kleinfeld, A.M. (2000) Fatty acid binding
proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 39, 7197-7204
12. Glatz, J.F.C. and Van der Vusse, G.J. (1996) Cellular fatty acid-binding proteins: their function and physiological
significance. Prog. Lipid Res. 35, 243-282
13. Graber, R., Sumida, C. and Nunez, E.A. (1994) Fatty acids and signal transduction. J. Lipid Mediat. Cell Signal. 9,
91-116
14. Veerkamp, J.H., Peeters, R.A. and Maatman, R.G.H.J. (1991) Structural and functional features of different types
of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1081, 1-24
Chapter 7
146
15. Veerkamp, J.H., Van Kuppevelt, T.H.M.S.M., Maatman, R.G.H.J. and Prinsen, C.F.M. (1993) Structural and
functional aspects of cytosolic fatty acid-binding proteins. Prostaglandins Leukot Essent Fatty Acids 49, 887-906
16. Kaikaus, R.M., Bass, N.M. and Ockner, R.K. (1990) Functions of fatty acid binding proteins. Experientia 46, 617-
630
17. Bass, N.M., Kaikaus, R.M. and Ockner, R.K. (1993) Physiology and molecular biology of hepatic cytosolic fatty
acid-binding protein. In Hepatic transport and bile secretion: physiology and pathophysiology. (Tavoloni, N. and  Berk,
P.D., eds.), pp. 421-446, Raven Press Ltd., New York
18. Vork, M.M., Glatz, J.F.C. and Van der Vusse, G.J. (1993) Release of fatty acid-binding protein and long chain fatty
acids from isolated rat heart after ischemia and subsequent calcium paradox. Mol. Cell. Biochem. 123, 175-184
19. Vork, M.M., Glatz, J.F.C., Surtel, D.A. and Van der Vusse, G.J. (1993) Release of fatty acid binding protein and
lactate dehydrogenase from isolated rat heart during normoxia, low-flow ischemia, and reperfusion. Can. J. Physiol.
Pharmacol. 71, 952-958
20. Samanta, A., Das, D.K., Jones, R., George, A. and Prasad, M.R. (1989) Free radical scavenging by myocardial
fatty acid binding protein. Free Rad. Res. Comms. 7, 73-82
21. Wallukat, G., Böhmer, F.D., Engström, U., Langen, P., Hollenberg, M., Behlke, J., Kühn, H. and Grosse, R.
(1991) Modulation of the beta-adrenergic-response in cultured rat heart cells. II. Mammary-derived growth inhibitor
(MDGI) blocks induction of beta-adrenergic supersensitivity. Dissociation from lipid-binding activity of MDGI. Mol. Cell.
Biochem. 102, 49-60
22. Glatz, J.F.C., Vork, M.M. and Van der Vusse, G.J. (1993) Significance of cytoplasmic fatty acid-binding protein for
the ischemic heart. Mol. Cell. Biochem. 123, 167-173
23. Bass, N.M., Raghupathy, E., Rhoads, D.E., Manning, J.A. and Ockner, R.K. (1984) Partial purification of molecular
weight 12 000 fatty acid binding proteins from rat brain and their effect on synaptosomal Na+-dependent amino acid
uptake. Biochemistry 23, 6539-6544
24. Sinha, P., Hütter, G., Köttgen, E., Dietel, M., Schadendorf, D. and Lage, H. (1999) Increased expression of
epidermal fatty acid binding protein, cofilin, and 14-3-3-σ (stratifin) detected by two-dimensional gel electrophoresis,
mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis
20, 2952-2960
25. Maatman, R.G.H.J., Van Kuppevelt, T.H.M.S.M. and Veerkamp, J.H. (1991) Two types of fatty acid-binding
protein in human kidney. Isolation, characterization and localization. Biochem. J. 273, 759-766
26. Richardson, J.C.W., Scalera, V. and Simmons, N.L. (1981) Identification of two strains of MDCK cells which resemble
separate nephron tubule segments. Biochim. Biophys. Acta 673, 26-36
27. Green, S., Isseman, I. and Sheer, E. (1988) A versatile in vivo and in vitro eukaryotic expression vector for protein
engineering. Nucleic Acids Res. 16, 369-369
28. Prinsen, C.F.M. and Veerkamp, J.H. (1998) Transfection of L6 myoblasts with adipocyte fatty acid-binding protein
cDNA does not affect fatty acid uptake but disturbs lipid metabolism and fusion. Biochem J. 329, 265-273
29. Maatman, R.G.H.J., Van Moerkerk, H.T.B., Nooren, I.M.A., Van Zoelen, E.J.J. and Veerkamp, J.H. (1994)
Expression of human liver fatty acid-binding protein in Escherichia coli and comparative analysis of its binding
characteristics with muscle fatty acid-binding protein. Biochim. Biophys. Acta 1214, 1-10
30. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) Protein measurement with a Folin phenol
reagent. J. Biol. Chem. 193, 265-275
31. Mazière, C., Mazière, J.C., Mora, L. and Polonowski, J. (1987) Rapid analysis of cellular lipids without extraction.
J. Biochem. Biophys. Methods 14, 267-272
32. Zimmerman, A.W., Van Moerkerk, H.T.B. and Veerkamp, J.H. (2001) Ligand specificity and conformational
                                 Cytoprotection by FABPs
147
stability of human fatty acid-binding proteins. Int. J. Biochem. Cell Biol. 33, 865-876
33. Maatman, R.G.H.J., Van de Westerlo, E.M., Van Kuppevelt, T.H. and  Veerkamp J.H. (1992) Molecular identification
of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase
polymerase chain reaction. Biochem. J. 288, 285-290
34. Prows, D.R., Murphy, E.J. and Schroeder, F. (1995) Intestinal and liver fatty acid binding proteins differentially
affect fatty acid uptake and esterification in L-cells. Lipids 30, 907-910
35. Murphy, E.J., Prows. D.R., Jefferson, J.R. and Schroeder, F. (1996) Liver fatty acid-binding protein expression in
transfected fibroblasts stimulates fatty acid uptake and metabolism. Biochim. Biophys. Acta 1301, 191-198
36. Prows, D.R. and Schroeder, F. (1997) Metallothionein-IIA promoter induction alters rat intestinal fatty acid-binding
protein expression, fatty acid uptake, and lipid metabolism in transfected L-cells. Arch. Biochem. Biophys. 340, 135-
143
37. Darimont, C., Gradoux, N., Persohn, E., Cumin, F. and De Pover, A. (2000) Effects of intestinal fatty acid-binding
protein overexpression on fatty acid metabolism in Caco-2 cells. J. Lipid Res. 41, 84-92
38. Wolfrum, C., Buhlmann, C., Rolf, B., Börchers, T. and Spener, F. (1999) Variation of liver-type fatty acid binding
protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the
rate of fatty acid uptake. Biochim. Biophys. Acta 1437, 194-201
39. Buhlmann, C., Börchers, T., Pollak, M. and Spener, F. (1999) Fatty acid metabolism in human breast cancer cells
(MCF7) transfected with heart-type faty acid binding protein. Mol. Cell. Biochem. 199, 41-48
40. De Villiers, M. and Lochner, A. (1986) Mitochondrial Ca2+ fluxes : role of free fatty acids, acyl-CoA and acylcarnitine.
Biochim. Biophys. Acta 876, 309-317
41. Wojtczak, L. and Schönfeld, P. (1993) Effect of fatty acids on energy coupling processes in mitochondria. Biochim.
Biophys. Acta 1183, 41-57
42. Ricquier, D. and Bouillaud, F. (2000) The uncoupling protein homologues: UCP1, UCP2, UCP3, StUCP and AtUCP.
Biochem. J. 345, 161-179
43. Gonzáles-Barroso, M.M., Fleury, C., Bouillaud, F., Nicholls, D.G. and Rial, E. (1998) The uncoupling protein UCP1
does not increase the proton conductance of the inner mitochondrial membrane by functioning as a fatty acid anion
transporter. J. Biol. Chem. 273, 15528-15532
44. Hwang, C. and Lane, M.D. (1999) Up-regulation of uncoupling protein-3 by fatty acid in C2C12 myotubes. Biochem.
Biophys. Res. Comm. 258, 464-469
45. Siafaka-Kapadai, A., Hanahan, D. and Javors, M.A. (1997) Oleic acid-induced Ca2+ mobilization in human
platelets: is oleic acid an intracellular messenger ? J. Lipid Mediators Cell Signalling 15, 215-232
46. Richieri, G.V., Mescher, M.F. and Kleinfeld, A.M. (1990) Short term exposure to cis unsaturated free fatty acids
inhibits degranulation of cytotoxic T lymphocytes. J. Immunol. 144, 671-677
47. Sharpe, M., Perin, I., Wrigglesworth, J. and Nicholls, P. (1996) Fatty acids as modulators of cytochrome c
oxidase in proteoliposomes. Biochem. J. 320, 557-561
Chapter 7
148
                                      Survey and summary
149
Survey and summary

Chapter 8
150
SURVEY AND SUMMARY
     Fatty acid-binding proteins (FABPs) are part of a superfamily of lipid-binding proteins, and
occur intracellularly in vertebrates as well as invertebrates. Chapter 1 gives an overview of the
diversity of these FABPs and their proposed roles in fatty acid (FA) metabolism and other cellular
processes. Special attention is paid to the structural features of the different FABP types and the
physiological role of these proteins in FA transport, cell growth and differentiation, cellular
signalling and cytoprotection. Additionally, the implication of FABP as diagnostic marker in
medicine is discussed.
     Occurrence, FA-binding characteristics and protein stability may be important parameters
with respect to the physiological role of FABPs in FA uptake and transfer and the regulation of
various cellular systems and processes in different tissues. We prepared recombinant proteins
of eight different types of human FABP. Differences in ligand binding, conformational stability
and surface properties were observed between the different FABP types, which may relate to
tissue-specific differences in FA metabolism and FABP function (Chapter 2). The occurrence of
FABP types with a lower affinity for FA could cause higher intracellular FA levels resulting in FA
export and vice versa. The differences in conformational stability may reflect a variable turnover
in the cellular environment. Due to a higher structural flexibility compared to other FABP types,
I-LBP and L-FABP are able to bind bile acids. The affinity of I-LBP for bile acids increased in the
order deoxycholic acid > cholic acid > chenodeoxycholic acid. Conjugation appeared to markedly
increase the binding affinity, which is important for reabsorption, since in the bowel mainly
conjugated bile acids are present. Differential binding of (non)conjugated bile acids and FA to I-
LBP and L-FABP implies distinct roles for both proteins, which is supported by their different
distribution in the intestine.
     Mutational analysis is a valuable tool to study the relationship between structure and function
of proteins. In a previous study, site-directed mutagenesis was used to construct mutant H-
FABP proteins with single amino acid substitutions in order to establish the importance of amino
acids located in the binding cavity for FA-binding and the conformational stability of human H-
FABP. Using this knowledge and the information on the three-dimensional structure of FABP
provided by crystallographic and NMR studies, we extended the mutational analysis of human
H-FABP (Chapter 3). We tried to explore the regions that are possibly involved in the determination
of ligand specificity and affinity, and/or in the maintenance of the tertiary structure. A highly
conserved hydrophobic patch consisting of Phe-4, Trp-8 and Phe-64 is located near the bottom
of the gap between the βD and βE strands and may be related to protein stability. Trp-8 appeared
to be essential for structural stability and/or folding, whereas Phe-4 and Phe-64 played a minor
role in binding activity and stability of H-FABP. Phe-16 is located near the portal region and
makes Van der Waals contacts with the bound ligand. Mutation of Phe-16 showed that this
amino acid plays a role in FA binding and affinity, whereas it is not important for the structural
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integrity of H-FABP. Concludingly, our data showed distinct differences between the mutant H-
FABPs. No clear relationship was found between FA-binding activity and stability of mutant H-
FABP proteins.
     Although the members of the FABP family have highly comparable three-dimensional
structures, their ligand binding characteristics are different and their physiological functions will
not be identical. B-FABP shows a strong homology on the amino acid level with H-FABP, A-FABP,
E-FABP and M-FABP. Contrasting data exist on the FA-binding properties of B-FABP. Mouse B-
FABP was found by others to have a higher affinity for long chain polyunsaturated FA such as
docosahexaenoic acid, which is not bound by H-FABP. Human B-FABP however has a weaker
affinity for polyunsaturated FA than for saturated and monounsaturated FA. We used NMR
spectroscopy to obtain detailed structural data on human recombinant B-FABP in solution for
comparison with crystallographic data (Chapter 4). The NMR results were in good agreement
with crystallographic data and showed that the overall topology of B-FABP is similar to that of
other members of the FABP family, e.g. H-FABP, E-FABP and A-FABP. In the future, 15N relaxation
experiments may give information on the backbone dynamics of B-FABP for comparison with
those of other FABP types.
     FA transport has been extensively studied by using fluorescent FA such as anthroyloxy-labelled
FA (AOFA) or NBD-stearic acid. The fluorescent group may influence the interaction of FA with
FABP, which could explain the contrasting data obtained with AOFA and with NBD-stearic acid.
We used a system of liposomes fixed to nitrocellulose membranes, isolated heart or liver
mitochondria, recombinant FABP proteins and radioactive palmitic acid to study the effect of
membrane charge and of different FABP types on intermembrane transport (Chapter 5). Human
H-FABP and L-FABP were able to solubilize palmitate from fixed liposomes and increased the
palmitate level in the aqueous phase in a concentration-dependent and saturable manner. FA
oxidation could be used as a functional parameter for FA transfer from liposomes to mitochondria.
We showed that rat heart and liver mitochondria do not discriminate in FA uptake between the
different FABP types. The charge of the liposomes did not influence the solubilization and
mitochondrial oxidation of palmitate in the absence of FABP. The different FABP types were not
specific in their transfer activity from immobilized liposomes to heart or liver mitochondria, but
the release from liposomes to FABP seems to be dependent on the charge of the liposomes.
Conservation of the binding activity was necessary to get stimulation of intermembrane FA
transfer by H-FABP mutants. In our system the Lys21Ile mutant of H-FABP generally showed the
same effect on FA transfer as the wild-type protein, whereas this lysine residue appeared to be
essential for effective AOFA transfer from H-FABP to neutral and especially anionic phospholipid
vesicles. Some mutations in H-FABP changed the transfer activity, without any effect on binding.
These data suggest that specific amino acids are involved in the interaction with the membrane
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or in the uptake and release of FA from and to membranes, respectively.
     In an attempt to gain more insight in the physiological role of FABPs, we tested the role of
FABP in cell growth. In Chapter 6, we measured the effect of FABPs on protein synthesis in a
reticulocyte lysate system. Interestingly, some FABP types (M-FABP, I-FABP, H-FABP and B-FABP)
showed a dose-dependent inhibition of in vitro mRNA translation, whereas other types (A-FABP,
L-FABP and E-FABP) had no effect. The inhibition was not influenced by delipidation of FABP and
was not related to the FA affinity of H-FABP mutants. Our results indicate that some FABPs may
modulate cell growth and/or differentiation by inhibition of protein synthesis. The mechanism
by which FABPs interact with the protein synthesis machinery is unclear up to now, but provides
an interesting subject for further research.
     Another putative function of FABPs is cytoprotection against high intracellular concentrations
of FA, which may occur e.g. during hypoxia or anoxia after ischaemia. FABPs may protect vital
cellular functions by binding and promoting metabolism of FA, thereby reducing their intracellular
concentration. In Chapter 7, we investigated a possible cytoprotective role of FABPs in a Madin
Darby Canine Kidney (MDCK) cell model. Transfection of MDCK type II cells with cDNA encoding
H-FABP, A-FABP or L-FABP caused a 5-20 fold increase of FABP content, but did not change the
rate and extent of palmitate uptake. Chemical anoxia, induced by KCN resulted in a reduced
cell viability and cellular ATP content and an intracellular accumulation of unesterified FA. High
extracellular concentrations of oleate, but not palmitate, caused a marked decrease of cell
viability and cellular ATP content. Oleate accumulated in unesterified form in these cells. No
significant differences in the effects of chemical anoxia or oleate were observed between non-
transfected, mock-transfected and FABP cDNA-transfected cells. The presence of FABP in the
cells did not result in a reduced accumulation of unesterified FA. Taken together, our data do not
provide evidence for a cytoprotective role of FABP in this kidney cell model. Future experiments
are needed to definitely exclude or confirm a role for FABPs in cytoprotection.
     In spite of the large amount of data on the three-dimensional structure, FA-binding
characteristics and tissue occurrence of FABPs, the physiological role of these proteins has not
been completely resolved. Their specific occurrence in certain tissues or cells possibly results
from adaptation to specific cellular needs. FABPs undoubtedly play an essential role in cellular
FA transport and utilization. It has become evident that FABPs are indirectly involved in FA-
mediated regulation of gene expression, either or not via peroxisome proliferator-activated
receptors. The work described in this thesis sheds light on some other functional aspects of
FABPs. More investigations are necessary on the interaction of FABPs with membrane lipids,
with FA transporters in the plasma membrane and acceptor proteins of FA in intracellular
membranes and with enzyme systems involved in FA metabolism. Extended studies on knockout
mice and transgenic cell lines transfected with FABP-encoding cDNAs, in combination with signal
transduction studies will certainly help to come towards a better understanding of the
physiological significance of FABPs.
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     Application of the knowledge about FABPs in medicine can be an interesting possibility.
Deficiency or malfunctioning of FABP may play a role in the pathology observed in diabetes,
obesity and atherosclerosis. FABPs may be suitable targets for intervention in these cases.
Since FABPs are released in the blood and/or urine after tissue damage, they may be used as
diagnostic markers e.g. in case of cardiac infarction, intestinal ischamia, or renal failure. The
release of specific FABP types may be indicative of the origin and severity of the damage.
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SAMENVATTING
     Vetzuurbindende eiwitten (FABPs) vormen onderdeel van een familie van vetzuur- en retinoid-
bindende eiwitten en komen voor in cellen van zowel gewervelde als ongewervelde organismen.
Sinds de ontdekking van de eerste FABPs in 1973 is er veel gedetailleerde informatie over deze
eiwitfamilie en hun eigenschappen ter beschikking gekomen. Oorspronkelijk werd aan deze
eiwitten slechts een functie bij de intracellulaire binding en transport van vetzuren toegekend,
maar de laatste jaren zijn ook andere functies beschreven. Hieronder vallen het reguleren van
de vrije vetzuurconcentratie en daardoor indirecte regulatie van door vetzuren beïnvloede
processen en het beschermen van de cel tegen te hoge vetzuurconcentraties (cytoprotectie).
Tot nu toe zijn er negen verschillende FABP typen beschreven, ieder met een specifieke verdeling
over weefsels en cellen.
     Hoofdstuk 1 geeft een overzicht van de diversiteit van FABPs en hun mogelijke rol bij vetzuur-
metabolisme en modulatie van cellulaire processen. Speciale aandacht wordt besteed aan
structurele kenmerken van de verschillende FABP typen en hun (indirecte) rol bij vetzuurtransport,
celgroei en -differentiatie, cellulaire signaaloverdracht en regulatie van gen expressie en
cytoprotectie. Ook de mogelijkheden voor het gebruik van FABPs bij medische diagnostiek ko-
men aan de orde.
     In Hoofdstuk 2 wordt de synthese beschreven van recombinant eiwitten van acht verschil-
lende humane FABP typen en worden hun eigenschappen met elkaar vergeleken. Er werden
verschillen gevonden tussen de verschillende FABP typen in vetzuurbinding, stabiliteit van de
conformatie en oppervlakte-eigenschappen, die verband kunnen houden met weefselspecifieke
verschillen in vetzuurmetabolisme en FABP functie. Een FABP type als adipocyt-FABP, met een
lagere affiniteit voor vetzuren, zou hogere intracellulaire vetzuurconcentraties kunnen toelaten
wat kan resulteren in cellulaire afgifte van vetzuren, zoals bij lipolyse in de vetcel. Verschillen in
eiwitstabiliteit zouden kunnen betekenen dat de FABPs in de cellulaire omgeving een verschil-
lende levensduur hebben. Ileal lipid-binding protein (I-LBP) en lever (L-)FABP bleken in staat om
galzuren te binden omdat zij een hogere mate van structurele flexibiliteit bezitten dan de ove-
rige FABP typen. De affiniteit van I-LBP voor galzuren nam toe in de volgorde deoxycholzuur >
cholzuur > chenodeoxycholzuur. Conjugatie van een galzuur met glycine of taurine verhoogde
de bindingsaffiniteit van I-LBP. Dit is een belangrijk aspect want in het ileum, de plaats voor
galzuurabsorptie, komen met name geconjugeerde galzuren voor. Verschillen in de binding
van (on)geconjugeerde galzuren en vetzuren aan I-LBP en L-FABP en in de lokalisatie van beide
eiwitten impliceren dat zij een verschillende rol vervullen binnen de darm.
     Mutatie analyse is een goede techniek om de relatie tussen structuur en functie van eiwitten
te bestuderen. In een vorige studie met gemuteerde moleculen van humaan H-FABP werd
onderzocht welke aminozuren direct betrokken zijn bij de vetzuurbinding. Op basis hiervan en
van informatie over de driedimensionale structuur hebben we de mutatie analyse van H-FABP
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uitgebreid tot de gebieden die mogelijk betrokken zijn bij het bepalen van de ligand-specificiteit
en -affiniteit, en/of bij het handhaven van de ruimtelijke eiwitstructuur (Hoofdstuk 3). Een sterk
geconserveerd hydrofoob gebied, bestaande uit Phe-4, Trp-8 en Phe-64 bevindt zich dichtbij
de opening tussen de β-strands D en E en zou van belang kunnen zijn voor de eiwitstabiliteit.
Trp-8 bleek inderdaad essentieel te zijn voor de structurele stabiliteit en/of de vouwing van H-
FABP, terwijl Phe-4 en Phe-64 hierbij een minder belangrijke rol spelen. Phe-16 ligt naast de
zogenaamde portaal-regio en maakt Van der Waals contact met de gebonden ligand. Mutatie
van dit aminozuur toonde aan dat het een rol speelt bij de affiniteit voor het vetzuur, maar niet
bij de structurele integriteit van H-FABP.  Er werd geen relatie gevonden tussen de vetzuur-
bindingsactiviteit en de stabiliteit van H-FABP mutanten.
     Hoewel de verschillende FABP typen een sterk vergelijkbare driedimensionale structuur heb-
ben, bestaan er verschillen in hun ligandbinding en hun fysiologische functies. Hersen (B-)FABP
vertoont op aminozuurniveau een sterke homologie met H-FABP, adipocyt (A-)FABP, epidermaal
FABP en myeline FABP. B-FABP van de muis bindt meervoudig onverzadigde vetzuren en speelt
mogelijk een belangrijke rol bij de ontwikkeling van het centrale zenuwstelsel. Het humane B-
FABP heeft echter een zwakkere affiniteit voor meervoudig onverzadigde vetzuren dan voor
verzadigde en enkelvoudig verzadigde vetzuren. Wij gebruikten NMR spectroscopie om gede-
tailleerde structurele gegevens over het humane B-FABP te verkrijgen, ter vergelijking met
kristallografische gegevens uit de literatuur (Hoofdstuk 4). De NMR resultaten kwamen hier
goed mee overeen en lieten zien dat de tertiaire structuur van B-FABP sterk lijkt op die van
bovengenoemde leden van de FABP familie. In de toekomst zullen 15N relaxatie experimenten
helpen om de dynamiek van de tertiaire structuur van B-FABP te bepalen en te vergelijken met
die van andere FABP typen.
     Vetzuurtransport is uitgebreid bestudeerd met behulp van fluorescerende vetzuren zoals
anthroyloxy-gelabeld vetzuur (AOFA) of NBD-stearinezuur. De tegenstrijdige resultaten die hier-
bij verkregen zijn zouden verklaard kunnen worden door de fluorescerende groep. Wij hebben
gebruik gemaakt van een systeem met gefixeerde liposomen, geïsoleerde hart of lever
mitochondriën, recombinant FABP eiwitten en radioactief gemerkt palmitinezuur om het effect
van de lading van de membraan en van verschillende FABP typen op het vetzuurtransport
tussen membranen te bestuderen (Hoofdstuk 5). Mitochondriële oxidatie van palmitinezuur
kon gebruikt worden als maat voor de hoeveelheid vetzuur die door FABP is getransporteerd.
Humaan H-FABP en L-FABP waren in staat om palmitinezuur vrij te maken vanuit gefixeerde
liposomen en verhoogden afhankelijk van hun concentratie het palmitinezuur niveau in de
waterfase. We hebben aangetoond dat hart en lever mitochondriën van de rat geen onder-
scheid maken tussen de verschillende FABP typen wat betreft vetzuur aanbod. De lading van
de liposomen had geen invloed op het vrijkomen in de waterfase en de mitochondriële oxidatie
van palmitinezuur in afwezigheid van FABP. De overdracht van palmitinezuur van liposomen
naar FABP bleek afhankelijk te zijn van de lading van de liposomen. Behoud van de bindings-
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activiteit bleek noodzakelijk voor het stimuleren van vetzuurtransport tussen membranen door
H-FABP mutanten. De Lys21Ile mutant van H-FABP vertoonde in ons systeem over het algemeen
hetzelfde effect op vetzuurtransport als het wild-type eiwit, terwijl Lys-21 wel essentieel bleek
voor effectief AOFA transport van H-FABP naar neutrale en met name negatief geladen fosfolipide
vesicles. De effecten van enkele gemuteerde H-FABP eiwitten op de transportactiviteit waren
onafhankelijk van hun bindingsactiviteit en suggereren dat specifieke aminozuren betrokken
zijn bij de opname en het vrijmaken van vetzuren van membranen.
     In een poging meer inzicht te verkrijgen in de fysiologische rol van FABPs testten we hun rol
bij celgroei. In Hoofdstuk 6 maakten we gebruik van een celvrij (reticulocyt lysaat) systeem om
het effect te meten van verschillende FABP typen en H-FABP mutanten op de eiwitsynthese. Het
was interessant dat sommige FABP typen (myeline FABP, darm FABP, H-FABP en B-FABP) afhan-
kelijk van hun dosis, de in vitro mRNA translatie onderdrukten, terwijl andere typen (A-FABP, L-
FABP en epidermaal FABP) geen effect hadden. De remming werd niet beïnvloed door verwijde-
ring van het vetzuur van de FABPs en was, wat betreft de H-FABP mutanten, niet gerelateerd
aan de vetzuuraffiniteit. Onze resultaten geven aan dat sommige FABP typen celgroei en/of -
differentiatie zouden kunnen sturen door middel van remming van de eiwitsynthese. Het me-
chanisme van deze interactie is onduidelijk, maar vormt een interessant uitgangspunt voor
vervolgonderzoek.
     Een andere mogelijke functie van FABPs is de bescherming van cellen tegen hoge
intracellulaire vetzuurconcentraties, die kunnen optreden als gevolg van een zuurstoftekort bij
ischemie. In Hoofdstuk 7 werd deze functie van FABPs onderzocht met behulp van een niercel-
model, bestaande uit Madin Darby Canine Kidney (MDCK) cellen. Transfectie van MDCK type II
cellen met cDNA coderend voor H-FABP, A-FABP of L-FABP veroorzaakte een 5- tot 20-voudige
toename van het FABP gehalte in de cel, maar leidde niet tot een verandering in de snelheid en
mate van palmitinezuur opname. Inductie van chemische anoxie (zuurstoftekort) door middel
van KCN resulteerde in een verlaagd aantal levende cellen, een gereduceerd ATP gehalte en
een opeenhoping van onveresterde vetzuren in de cel. Hoge extracellulaire concentraties van
oliezuur veroorzaakten een duidelijke afname van het aantal levende cellen en het ATP gehalte
in de cel, terwijl palmitinezuur geen effect had. Oliezuur accumuleerde in onveresterde vorm in
deze cellen. Er werden geen verschillen gevonden in de effecten van chemische anoxie of
oliezuur tussen niet-getransfecteerde, mock-getransfecteerde en FABP cDNA-getransfecteerde
cellen. De aanwezigheid van FABP in de cellen resulteerde niet in een verminderde opeen-
hoping van onveresterde vetzuren. Samengevat duiden onze data niet op een beschermende
rol van FABPs in dit niercelmodel. Verdere experimenten zijn nodig om een functie van FABPs bij
cytoprotectie definitief te kunnen uitsluiten of bevestigen.
     Ondanks de grote hoeveelheid data die gedurende de laatste dertig jaar verkregen zijn over
de driedimensionale structuur, bindingseigenschappen en weefseldistributie van de FABPs, is
de precieze rol van deze eiwitten nog steeds niet volledig opgehelderd. Hun specifieke aanwe-
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zigheid in bepaalde weefsels en cellen is mogelijk het gevolg van aanpassing aan de speci-
fieke behoeften van de cel. FABPs spelen ongetwijfeld een essentiële rol in vetzuurtransport en
–gebruik in de cel. Het is inmiddels duidelijk geworden dat FABPs eveneens indirect betrokken
zijn bij de regulatie van vetzuur-gemedieerde gen expressie, al dan niet via peroxisoom
proliferator-geactiveerde receptoren. Het werk dat beschreven is in dit proefschrift belicht en-
kele andere functionele aspecten van FABPs. Meer onderzoek is van belang naar de interactie
van FABPs met membraanlipiden, met vetzuurtransporters in de plasmamembraan, met
vetzuuracceptoreiwitten in intracellulaire membranen en met enzymsystemen die betrokken
zijn bij vetzuurmetabolisme. Uitbreiding van het onderzoek aan knockout muizen en met FABP
getransfecteerde cellijnen, in combinatie met signaal transductie studies zal ongetwijfeld bij-
dragen tot een beter inzicht in het fysiologische belang van de FABPs.
     Toepassing van de kennis over FABPs in de geneeskunde vormt een interessante mogelijk-
heid. Het ontbreken of disfunctioneren van FABPs zou een rol kunnen spelen bij ziekten als
diabetes, vetzucht en aderverkalking. Daarom zouden FABPs van belang kunnen worden voor
interventie in deze gevallen. Bij weefselschade, bijvoorbeeld in geval van een hartinfarct, darm-
ischemie of nierfalen kunnen FABPs vrijkomen in het bloed en/of urine. Het vrijkomen van spe-
cifieke FABP typen kan aanwijzingen geven over de oorsprong en ernst van de beschadiging,
wat FABPs mogelijk geschikt maakt voor gebruik als diagnostische marker.
159
Dankwoord
Na ruim 4 jaar werken aan het vetzuurbindend eiwit is hier dan het eindresultaat. Natuur-
lijk ben ik erg blij en trots op dit boekje, maar zonder de hulp van anderen was het nooit zover
gekomen. Op deze plaats wil ik dan ook graag iedereen die heeft bijgedragen aan mijn werk
van harte bedanken.
Als eerste wil ik natuurlijk mijn promotor en begeleider Prof. Jacques Veerkamp bedanken.
Beste Jacques, jouw betrokkenheid bij het FABP gebeuren is altijd zeer groot geweest, ook na je
emeritaat. Je kwam altijd met nieuwe ideeën en suggesties, maar je hebt me ook veel vrijheid
gegeven om zelf de richting van mijn onderzoek te bepalen. Jouw deur op het Trigon, maar
later ook aan de Proosdijweg, stond altijd open voor het bespreken van resultaten, nieuwe
experimenten en literatuur. Ongelooflijk hoe je uit die enorme stapels artikelen steeds in no
time die paper wist te trekken die ik op dat moment nodig had! Op het gebied van het schrijven
van artikelen heb ik veel geleerd van je suggesties en kritische opmerkingen, maar vooral de
snelheid waarmee je alles nakeek heb ik altijd bijzonder op prijs gesteld.
Toin, hoewel het FABP niet echt jouw “ding” was, kwam je tijdens werkbesprekingen toch
regelmatig met kritische vragen en suggesties waardoor ik op een andere manier tegen de
zaken aan ging kijken. Bedankt daarvoor.
Beste Herman, jij bent met name gedurende de eerste jaren erg belangrijk voor me geweest
door me wegwijs te maken in de praktische kant van het FABP. Ontelbare keren moest je komen
opdraven als er weer eens een kolom droogliep, de antieke beta-counter het begaf, of gewoon
om gelletjes en blotjes te bekijken. Negen van de tien keer was jij de eerste persoon die mocht
mee “genieten” van mislukte experimenten, maar ook van de goede resultaten. Ook bij
problemen op het gebied van PC’s en fietsbanden heb ik vaak van je hulp gebruik mogen
maken. Heel erg bedankt daarvoor. Ik vond het prettig om met jou samen te werken en ben blij
dat je me straks als paranimf wilt bijstaan.
Tinri Wilmsen en Joyce Knipping, jullie wil ik graag bedanken voor jullie bijdragen aan mijn
werk, ook al heeft dit niet direct tot publicaties geleid. Ik heb met veel plezier met jullie
samengewerkt en heb er in ieder geval zelf veel van geleerd.
Willeke en Guido, als promovendi onder elkaar hebben we de ups en downs van het AIO-
schap gedeeld. Met jullie was het altijd gezellig, zowel binnen als buiten het lab. Veel succes
met het afronden van jullie proefschriften. En Wil, ik vind het heel erg leuk dat je mijn andere
paranimf wilt zijn.
Theo, jouw hulp bij het lay-outen van het boekje en het ontwerpen van de omslag is voor mij
onmisbaar geweest. Het was een grotere klus dan ik verwacht had, maar met jouw ervaring en
handigheid zijn we tot een zeer geslaagd eindresultaat gekomen. Heel veel dank, je hebt
absoluut een extra borrel verdiend!
Al mijn andere ex-collega’s van de groep Veerkamp (of moet ik zeggen: “Matrix Biochemie”) wil
160
ik bedanken voor hun hulp en vooral voor de bijzonder goede sfeer in de groep. Nu ik maar een
paar deuren verderop zit, hoef ik jullie gelukkig niet echt te missen!
Carmem, it was a great pleasure to have you over in our lab for six months. I enjoyed our
cooperation, our discussions about FABPs and the better things in life, and your company in
and outside the lab. I think we learned a lot from each other. Good luck with finishing your
thesis, and see you in Brazil some time!
Herr Prof. Heinz Rüterjans, ich danke Ihnen herzlich für die Möglichkeit einige Wochen in Ihrem
Labor in Frankfurt zu verbringen. Mein Dank gilt auch Dr. Christian Lücke und Martin Rademacher.
Unsere Zusammenarbeit hat mir viel Freude gemacht, und ich habe viel über die komplizierte
NMR Technik gelernt.
Tenslotte natuurlijk mijn ouders. Lieve pa en ma, de afgelopen jaren hebben jullie altijd voor me
klaargestaan. Bedankt voor het aanhoren van alle verhalen en frustraties over het
(onderzoeks)leven in Nijmegen, voor het regelen van honderdduizend dingen waar ik geen tijd
voor had en vooral voor de nodige ontspanning. Het was (en is nog steeds) fijn om thuis te
komen in de Achterhoek!
                                                             
161
Publications
Zimmerman, A.W. and Veerkamp, J.H. (1998) Members of the fatty acid-binding protein family
inhibit cell-free protein synthesis. FEBS Lett. 437, 183-186
Zimmerman, A.W., Rademacher, M., Rüterjans, H., Lücke, C., and Veerkamp, J.H. (1999)
Functional and conformational characterization of new mutants of heart fatty acid-binding
protein. Biochem. J. 344, 494-501
Richieri, G.V., Ogata, R.T., Zimmerman, A.W., Veerkamp, J.H. and Kleinfeld, A.M. (2000)
Fatty acid-binding proteins from different tissues show distinct patterns of fatty acid interactions.
Biochemistry 39, 7197-7204
Veerkamp, J.H., Van Moerkerk, H.T.B. and Zimmerman, A.W. (2000) Effect of fatty acid-
binding proteins on intermembrane fatty acid transport. Studies on different types and mutant
proteins. Eur. J. Biochem. 267, 5959-5966
Lücke, C., Rademacher, R., Zimmerman, A.W., Van Moerkerk, H.T.B., Veerkamp, J.H. and
Rüterjans, H. (2001) Spin-system heterogeneities indicate a selected-fit mechanism in fatty
acid binding to heart-type fatty acid-binding protein (H-FABP). Biochem. J. 354, 259-266
Zimmerman, A.W., Van Moerkerk, H.T.B. and Veerkamp, J.H. (2001) Ligand specificity and
conformational stability of human fatty acid-binding proteins. Int. J. Biochem. Cell Biol. 33, 865-
876
Veerkamp, J.H. and Zimmerman, A.W. (2001) Fatty acid-binding proteins of nervous tissue. J.
Mol. Neurosci. 16, 133-142
Zimmerman, A.W. and Veerkamp, J.H. (2001) Fatty acid-binding proteins do not protect against
induced cytotoxicity in a kidney cell model. Biochem. J. 360, 159-165
Rademacher, M., Zimmerman, A.W., Rüterjans, H., Veerkamp, J.H. and Lücke, C. Solution
structure of fatty acid-binding protein from human brain. Mol. Cell. Biochem. in press
Zimmerman, A.W. and Veerkamp, J.H. New insights into structure and function of the different
types of fatty acid-binding protein. Cell. Mol. Life Sci. in press
162
Curriculum Vitae
Aukje Zimmerman werd op 30 november 1972 geboren te Doetinchem. Na het behalen van het
VWO diploma aan het Isala College te Silvolde in 1991 begon zij aan de opleiding Biologie aan
de Katholieke Universiteit Nijmegen. Ze volgde de studierichting Medische Biologie met
hoofdvakstages bij de afdeling Celbiologie (Katholieke Universiteit Nijmegen) onder leiding van
Prof. Dr. J. van Zoelen en bij de afdeling Hematologie (Academisch Ziekenhuis St. Radboud,
Nijmegen) onder leiding van Prof. Dr. T. de Witte en Dr. E. van de Wiel. Op laatstgenoemde
afdeling werd eveneens een bijvakstage gevolgd onder leiding van Dr. H. Dolstra.
Na het behalen van het doctoraalexamen in 1996 startte zij in januari 1997 als assistent in
opleiding bij de afdeling Biochemie van de Faculteit der Medische Wetenschappen aan de
Katholieke Universiteit Nijmegen. Het onderzoek dat aldaar werd verricht onder leiding van
Prof. Dr. J.H. Veerkamp staat beschreven in dit proefschrift. Tijdens haar promotieonderzoek
deed zij gedurende twee maanden NMR onderzoek aan FABP onder leiding van Prof. Dr. H.
Rüterjans en Dr. C. Lücke op het Institut für Biophysikalische Chemie van de J.W. Goethe Universiteit
te Frankfurt am Main. Verder was zij betrokken bij de begeleiding van studenten en stagiaires
en vervulde zij diverse onderwijstaken binnen de afdeling Biochemie. Tevens verzorgde zij
meerdere voordrachten en posterpresentaties op binnen- en buitenlandse congressen. Vanaf
september 2001 is werkzaam als postdoc bij de afdeling Tumor Immunologie van het Universitair
Medisch Centrum St. Radboud te Nijmegen.
163
164
165
166
167
168
169
170
171
172
173
174
175
176
